US20170166585A1 - Pesticidal compositions and uses thereof - Google Patents

Pesticidal compositions and uses thereof Download PDF

Info

Publication number
US20170166585A1
US20170166585A1 US15/359,531 US201615359531A US2017166585A1 US 20170166585 A1 US20170166585 A1 US 20170166585A1 US 201615359531 A US201615359531 A US 201615359531A US 2017166585 A1 US2017166585 A1 US 2017166585A1
Authority
US
United States
Prior art keywords
methyl
ethyl
och
dioxo
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/359,531
Inventor
Jennifer Lynn Bennett
Karen C. Fitzsimmons
Shomir Ghosh
Jeremy Robert Greenwood
William P. Haakenson, JR.
Geraldine C. Harriman
Silvana Marcel Leit de Moradei
Barry J. Shortt
Urszula J. Slomczynska
Jeffrey Michael Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monsanto Co
Schroedinger LLC
Gilead Apollo LLC
Nimbus Discovery Inc
Original Assignee
Monsanto Co
Gilead Apollo LLC
Nimbus Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co, Gilead Apollo LLC, Nimbus Discovery Inc filed Critical Monsanto Co
Priority to US15/359,531 priority Critical patent/US20170166585A1/en
Publication of US20170166585A1 publication Critical patent/US20170166585A1/en
Priority to US16/030,722 priority patent/US10941157B2/en
Assigned to Nimbus Apollo, Inc. reassignment Nimbus Apollo, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NIMBUS DISCOVERY, INC.
Assigned to MONSANTO COMPANY reassignment MONSANTO COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STEIN, JEFFREY M.
Assigned to Nimbus Apollo, Inc. reassignment Nimbus Apollo, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GHOSH, SHOMIR
Assigned to MONSANTO COMPANY reassignment MONSANTO COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAAKENSON, WILLIAM P., JR.
Assigned to Nimbus Apollo, Inc. reassignment Nimbus Apollo, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MONSANTO COMPANY
Assigned to Nimbus Apollo, Inc. reassignment Nimbus Apollo, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MORADEI, SILVANA MARCEL LEIT DE
Assigned to MONSANTO COMPANY reassignment MONSANTO COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Bennett, Jennifer L.
Assigned to MONSANTO COMPANY reassignment MONSANTO COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHORTT, BARRY J.
Assigned to MONSANTO COMPANY reassignment MONSANTO COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SLOMCZYNSKA, URSZULA J.
Assigned to MONSANTO COMPANY reassignment MONSANTO COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FITZSIMMONS, Karen C.
Assigned to SCHRÖDINGER, INC. reassignment SCHRÖDINGER, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GREENWOOD, JEREMY ROBERT
Assigned to SCHRÖDINGER, L.L.C. reassignment SCHRÖDINGER, L.L.C. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHRÖDINGER, INC.
Assigned to NIMBUS DISCOVERY, INC. reassignment NIMBUS DISCOVERY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHRÖDINGER, L.L.C.
Assigned to NIMBUS DISCOVERY, INC. reassignment NIMBUS DISCOVERY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HARRIMAN, GERALDINE C.
Assigned to GILEAD APOLLO, INC. reassignment GILEAD APOLLO, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: Nimbus Apollo, Inc.
Assigned to GILEAD APOLLO, LLC reassignment GILEAD APOLLO, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: GILEAD APOLLO, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01C—PLANTING; SOWING; FERTILISING
    • A01C1/00—Apparatus, or methods of use thereof, for testing or treating seed, roots, or the like, prior to sowing or planting
    • A01C1/06—Coating or dressing seed
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G7/00—Botany in general
    • A01G7/06—Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A01N43/647—Triazoles; Hydrogenated triazoles
    • A01N43/653—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/88—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms six-membered rings with three ring hetero atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N2300/00—Combinations or mixtures of active ingredients covered by classes A01N27/00 - A01N65/48 with other active or formulation relevant ingredients, e.g. specific carrier materials or surfactants, covered by classes A01N25/00 - A01N65/48

Definitions

  • compositions that exhibit activity as pesticides are useful, for example, in methods for the control of fungal pathogens and diseases caused by fungal pathogens in plants.
  • Acetyl-CoA carboxylase (“ACCase”) is an essential catalyst for the rate-limiting step of fatty acid biosynthesis in both eukaryotes and prokaryotes.
  • Phytopathogenic fungi can infect crop plants either in the field or after harvesting, resulting in considerable economic losses to farmers and producers worldwide.
  • a number of debilitating diseases or death can occur.
  • Approximately 10,000 species of fungi are known to damage crops and affect quality and yield. Crop rotation, breeding of resistant cultivars, the application of agrochemicals and combinations of these strategies is commonly employed to stem the spread of fungal pathogens and the diseases they cause. Additional chemistry and methods of using such as a modulator for ACCase or to control fungi are important for, among other things, protection in agriculture.
  • R 1 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, or C 1 -C 4 haloalkoxy;
  • R 2 is heteroaryl, alkyl, cycloalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, oxo, or cyano; or R 2 is —C(O)R 21 , wherein R 21 is hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -C 6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, or cyano;
  • R 3 is —C(O)R 31 , —C(O)N(R 32 R 33 ), or —R 34 SO 2 N(R 32 R 33 ), wherein R 31 is hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -C 6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or 1-heterocycl-1-yl, each of which may be optionally independently substituted with one or more of hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, or cyano; R 32 and R 33 are each independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 3 -C 6 cycloalkyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C 1 -C 4 alkoxy, oxo, or cyano; and R 34 is
  • R 4 is hydrogen or —OR 6 , wherein R 6 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, C 4 -C 10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of an oxygen atom, hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, cyano, —N(R 61 R 62 ), —C(O)N(R 61 R 62 ), or —SO 2 R 63 , wherein R 61 and R 62 are each independently hydrogen or C 1 -C 6 alkyl, and R 63 is C 1 -C 6 alkyl;
  • R 4′ is hydrogen or C 1 -C 4 alkyl, which may be optionally substituted with one or more of hydroxyl, C 1 -C 4 alkoxy, or cyano;
  • R 5 and R 5′ are each independently hydrogen or C 1 -C 4 alkyl
  • R 7 is hydroxyl or C 1 -C 4 alkyl, which may be optionally substituted with one or more of hydroxyl, C 1 -C 4 alkoxy, oxo, or cyano; or R 7 is —OR 10 , wherein R 10 is C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkylmethyl, heterocyclyl, or aryl(C 1 -C 4 )alkyl, each of which may be optionally independently substituted with one or more of hydroxyl, an oxygen atom, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, or cyano; and
  • R 8 is hydrogen, halogen, or cyano.
  • a compound is provided, the compound having Formula Ia, or Ib:
  • R 1 is methyl
  • R 2 is oxazolyl, pyrazolyl, triazolyl, cyclobutyl, —CH 2 OH, —CH 2 O(C 1 -C 4 )alkyl, or —C(O)R 21 wherein R 21 is C 1 -C 4 alkoxy;
  • R 3 is —C(O)R 31 , —C(O)N(R 32 R 33 ), or R 34 SO 2 N(R 32 R 33 ), wherein R 31 is hydroxyl, ethoxy, benzoxy, 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 2,5-dihydro-1H-pyrrol-1-yl, or 3-hydroxyazetidin-1-yl, R 32 is hydrogen or methyl, and R 33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, 2-propenyl, or cyclobutyl; or R 34 is a bond, or C 1 -C 4 alkyl;
  • R 5 and R 5′ are each independently hydrogen or methyl
  • R 6 is hydrogen, C 1 -C 4 alkyl, which may be substituted with one or more of hydroxyl, methoxy, oxo, cyano, or —SO 2 CH 3 ;
  • R 6 is cyclohexyl or cyclohexylmethyl, which may be substituted with one or more of hydroxyl or oxo;
  • R 6 is 2-propenyl; or
  • R 6 is tetrahydropyranyl;
  • R 8 is hydrogen or F
  • R 9 is hydroxyl, methyl, ethyl, or —(CH 2 ) 3 CN;
  • R 10 is methyl or ethyl, each of which may be substituted with one or more of hydroxyl, methyl, methoxy, cyano, phenyl, oxo, or oxetan-3-yl; or R 10 is tetrahydropyranyl.
  • a compound is provided, wherein the compound is selected from the group consisting of:
  • composition wherein the composition comprises a compound as described herein.
  • a method of controlling fungal pathogens comprising administering to a plant, a seed or soil a composition comprising an effective amount of a compound as described herein.
  • a method for modulating ACCase in a biological organism comprising administering to the biological organism a composition comprising an effective amount of a compound as described herein.
  • a treated seed is provided, wherein the seed comprises a compound or a composition as described herein.
  • the compounds may be used, for example, in the preparation of compositions and in accordance with methods for control of fungal pathogens, as set forth in detail below.
  • R 1 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, or C 1 -C 4 haloalkoxy;
  • R 2 is heteroaryl, alkyl, cycloalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, oxo, or cyano; or R 2 is —C(O)R 21 , wherein R 21 is hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -C 6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, or cyano;
  • R 3 is —C(O)R 31 , —C(O)N(R 32 R 33 ), or —R 34 SO 2 N(R 32 R 33 ), wherein R 31 is hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -C 6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or 1-heterocycl-1-yl, each of which may be optionally independently substituted with one or more of hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, or cyano; R 32 and R 33 are each independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 3 -C 6 cycloalkyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C 1 -C 4 alkoxy, oxo, or cyano; and R 34 is
  • R 4 is hydrogen or —OR 6 , wherein R 6 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, C 4 -C 10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of an oxygen atom, hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, cyano, —N(R 61 R 62 ), —C(O)N(R 61 R 62 ), or —SO 2 R 63 , wherein R 61 and R 62 are each independently hydrogen or C 1 -C 6 alkyl, and R 63 is C 1 -C 6 alkyl;
  • R 4′ is hydrogen or C 1 -C 4 alkyl, which may be optionally substituted with one or more of hydroxyl, C 1 -C 4 alkoxy, or cyano;
  • R 5 and R 5′ are each independently hydrogen or C 1 -C 4 alkyl
  • R 7 is hydroxyl or C 1 -C 4 alkyl, which may be optionally substituted with one or more of hydroxyl, C 1 -C 4 alkoxy, oxo, or cyano; or R 7 is —OR 10 , wherein R 10 is C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkylmethyl, heterocyclyl, or aryl(C 1 -C 4 )alkyl, each of which may be optionally independently substituted with one or more of hydroxyl, an oxygen atom, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, or cyano; and R 8 is hydrogen, halogen, or cyano.
  • R 1 can be C 1 -C 4 alkyl. In some embodiments, for example, R 1 is methyl.
  • R 2 can be —C(O)R 21 , wherein R 21 is C 1 -C 4 alkoxy.
  • R 2 is —CH 2 OH.
  • R 2 is —CH 2 O(C 1 -C 4 )alkyl.
  • R 2 is cyclobutyl.
  • R 2 can be unsubstituted heteroaryl.
  • R 2 can be a 5-membered heteroaryl.
  • R 2 can be oxazolyl, pyrazolyl, triazolyl, isoxazolyl, or thienyl.
  • R 2 is selected from the group consisting of oxazolyl, pyrazolyl, and triazolyl.
  • R 2 is 2-oxazolyl.
  • R 2 is 1-pyrazolyl.
  • R 2 is 2H-1,2,3-triazol-2-yl.
  • R 3 can be —C(O)R 31 , wherein R 31 is hydroxyl, alkoxy, or an optionally independently substituted 1-heterocycl-1-yl.
  • R 31 can be hydroxyl or alkoxy (e.g., ethoxy or benzoxy).
  • R 31 can be 2,5-dihydro-1H-pyrrolyl, 1-piperidinyl, 1-pyrrolidinyl, 1-morpholinyl, or 1-azetidinyl, each of which may be optionally independently substituted with hydroxyl, methoxy, methyl, or cyano.
  • R 3 is —C(O)N(R 32 R 33 ), wherein R 32 and R 33 are independently selected from hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, and C 3 -C 6 cycloalkyl.
  • R 3 is —C(O)N(R 32 R 33 ), wherein R 32 is hydrogen or methyl, and R 33 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, 2-propenyl, or —CH 2 CN.
  • R 3 is —C(O)NHR 33 , wherein R 33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl, 2-propenyl, or —CH 2 CN. In other embodiments, R 3 is —C(O)N(CH 3 )(R 33 ), wherein R 33 is methyl, isopropyl, or 2-propenyl. In some embodiments, R 3 is —C(O)NH 2 . In other embodiments, R 3 is —C(O)N(CH 3 ) 2 .
  • R 3 can be —R 34 SO 2 NH 2 wherein R 34 is a bond or C 1 -C 4 alkyl. In some embodiments, R 3 is —CH 2 SO 2 NH 2 . In other embodiments, R 3 is —SO 2 NH 2 .
  • R 4 and R 4′ are both hydrogen.
  • R 4 is —OR 6 and R 4′ is hydrogen, wherein R 6 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, C 4 -C 10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, cyano, —N(CH 3 ) 2 , —C(O)NH 2 , or —SO 2 CH 3 .
  • R 6 is hydrogen.
  • R 6 can be C 1 -C 6 alkyl or C 2 -C 6 alkenyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, cyano, —N(CH 3 ) 2 , —C(O)NH 2 , or —SO 2 CH 3 .
  • R 6 can be ethyl, isopropyl, isobutyl, —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —(CH 2 ) 3 OCH 3 , —CH 2 CH(CH 3 )OH, CH 2 C(CH 3 ) 2 OH, —CH 2 CH ⁇ CH 2 , —C(O)CH 3 , —C(O)CH 2 OH, —CH 2 CN, —CH 2 CH 2 CN, —CH 2 CH(CH 3 )CN, —CH 2 C(CH 3 ) 2 CN, —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 C(O)NH 2 , or —CH 2 CH 2 SO 2 CH 3 .
  • R 6 is C 3 -C 6 cycloalkyl or C 4 -C 10 cycloalkylalkyl, which may be optionally independently substituted with hydroxyl or oxo.
  • R 6 can comprise an optionally substituted cyclohexyl moiety (e.g., R 6 can be 4-hydroxycyclohexyl, 4-oxycyclohexyl, (4-oxocyclohexyl)methyl, or (4-hydroxycyclohexyl)methyl).
  • R 6 is heterocyclyl (e.g., tetrahydropyranyl).
  • R 6 can be tetrahydro-2H-pyran-4-yl.
  • R 4 is hydroxyl or —OCH 2 CH 2 CN; and R 4 is methyl, —CH 2 OH, or —CH 2 CH 2 OH.
  • R 4 is —OH and R 4′ is —CH 2 OH; R 4 is —OH and R 4 is —CH 2 CH 2 OH; or R 4 is —OCH 2 CH 2 CN and R 4 is methyl.
  • R 5 and R 5′ can be independently selected from the group consisting of hydrogen and methyl. In some embodiments, R 5 and R 5′ are both methyl. In some embodiments, R 5 and R 5′ are both hydrogen. In other embodiments, R 5 is methyl and R 5′ is hydrogen.
  • R 7 is hydroxyl. In some embodiments, R 7 is C 1 -C 4 alkyl, which may be optionally substituted with cyano. For example, R 7 is methyl, ethyl, or —(CH 2 ) 3 CN. In other embodiments, R 7 is —OR 10 , wherein R 10 is C 1 -C 4 alkyl, heterocyclyl, or benzyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, oxetanyl, and cyano.
  • R 10 can be selected from the group consisting of methyl, —CH(CH 3 ) 2 , —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —C(O)CH 3 , —CH 2 (oxetan-3-yl), —CH 2 CN, and —CH 2 CH 2 CN.
  • R 10 is methyl.
  • R 10 is heterocyclyl (e.g., tetrahydropyranyl).
  • R 10 can be tetrahydro-2H-pyran-4-yl.
  • R 10 is benzyl.
  • R 8 can be selected from the group consisting of hydrogen and F.
  • the compound of Formula I can be a compound of Formula Ia, or Ib:
  • R 1 is methyl
  • R 2 is oxazolyl, pyrazolyl, triazolyl, cyclobutyl, —CH 2 OH, —CH 2 O(C 1 -C 4 )alkyl, or —C(O)R 21 wherein R 21 is C 1 -C 4 alkoxy;
  • R 3 is —C(O)R 31 , —C(O)N(R 32 R 33 ), or —R 34 SO 2 N(R 32 R 33 ), wherein R 31 is hydroxyl, ethoxy, benzoxy, 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 2,5-dihydro-1H-pyrrol-1-yl, 3-hydroxyazetidin-1-yl, R 32 is hydrogen or methyl, and R 33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, 2-propenyl, or cyclobutyl; or R 34 is a bond or C 1 -C 4 alkyl;
  • R 5 and R 5′ are each independently hydrogen or methyl
  • R 6 is hydrogen, C 1 -C 4 alkyl, which may be substituted with one or more of hydroxyl, methoxy, oxo, cyano, or —SO 2 CH 3 ;
  • R 6 is cyclohexyl or cyclohexylmethyl, which may be substituted with one or more of hydroxyl or oxo;
  • R 6 is 2-propenyl; or
  • R 6 is tetrahydropyranyl;
  • R 8 is hydrogen or F
  • R 9 is hydroxyl, methyl, ethyl, or —(CH 2 ) 3 CN;
  • R 10 is methyl or ethyl, each of which may be substituted with one or more of hydroxyl, methyl, methoxy, cyano, phenyl, oxo, or oxetan-3-yl; or R 10 is tetrahydropyranyl.
  • the compound of Formula I can be a compound of Formula Ia or a salt thereof.
  • R 2 can be 1-pyrazolyl, 2H-1,2,3-triazol-2-yl, 2-oxazolyl, or —C(O)OCH 2 CH 3 .
  • R 2 is 1-pyrazolyl, corresponding to a compound of Formula Ia-i:
  • R 1 , R 3 , R 5 , R 5′ , R 6 , R 8 , and R 10 is as defined above and described in embodiments herein, both singly and in combination.
  • R 2 is 2H-1,2,3-triazol-2-yl, corresponding to a compound of Formula Ia-ii:
  • R 1 , R 3 , R 5 , R 5′ , R 6 , R 8 , and R 10 is as defined above and described in embodiments herein, both singly and in combination.
  • R 2 is 2-oxazolyl, corresponding to a compound of Formula Ia-iii:
  • R 1 , R 3 , R 5 , R 5′ , R 6 , R 8 , and R 10 is as defined above and described in embodiments herein, both singly and in combination.
  • R 2 is —C(O)OCH 2 CH 3 , corresponding to a compound of Formula Ia-iv:
  • R 1 , R 3 , R 5 , R 5′ , R 6 , R 8 , and R 10 is as defined above and described in embodiments herein, both singly and in combination.
  • the compound of Formula I can be a compound of Formula Ib or a salt thereof.
  • R 2 can be 1-pyrazolyl, 2H-1,2,3-triazol-2-yl, 2-oxazolyl, or —C(O)OCH 2 CH 3 .
  • R 2 is 2H-1,2,3-triazol-2-yl, corresponding to a compound of Formula Ib-ii:
  • R 1 , R 3 , R 5 , R 5′ , R 6 , R 8 , and R 9 is as defined above and described in embodiments herein, both singly and in combination.
  • R 3 can be —C(O)N(R 32 R 33 ), wherein R 32 is hydrogen or methyl, and R 33 is ethyl, isopropyl, or cyclobutyl. In some embodiments, R 3 is —C(O)NHCH 2 CH 3 .
  • R 3 is —C(O)NHC(CH 3 ) 2 . In some embodiments, R 3 is —C(O)N(CH 3 )C(CH 3 ) 2 .
  • R 3 is —C(O)NH(cyclobutyl).
  • R 3 can be —C(O)R 31 wherein R 31 is 1-pyrrolidinyl or 1-piperidinyl. In some embodiments, R 3 is —C(O)R 31 wherein R 31 is 1-pyrrolidinyl.
  • R 5 and R 5′ are both methyl. In some embodiments, R 5 and R 5′ are both hydrogen. In other embodiments, R 5 is methyl and R 5′ is hydrogen.
  • R 6 can be hydrogen, isopropyl, —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —(CH 2 ) 3 OCH 3 , —C(O)CH 3 , —CH 2 CN, —CH 2 CH 2 CN, —CH 2 CH(CH 3 )CN, —CH 2 C(CH 3 ) 2 CN, —CH 2 CH 2 SO 2 CH 3 , or tetrahydro-2H-pyran-4-yl.
  • R 6 is hydrogen.
  • R 6 is isopropyl.
  • R 6 is —CH 2 CH 2 OH.
  • R 6 is —CH 2 CH 2 OCH 3 .
  • R 6 is —(CH 2 ) 3 OCH 3 . In some embodiments, R 6 is —C(O)CH 3 . In some embodiments, R 6 is —CH 2 CN. In some embodiments, R 6 is —CH 2 CH 2 CN. In some embodiments, R 6 is —CH 2 CH(CH 3 )CN. In some embodiments, R 6 is —CH 2 C(CH 3 ) 2 CN. In some embodiments, R 6 is —CH 2 CH(CH 3 )CN. In some embodiments, R 6 is —CH 2 CH 2 SO 2 CH 3 . In some embodiments, R 6 is tetrahydro-2H-pyran-4-yl.
  • R 8 is hydrogen. In other embodiments, R 8 is F.
  • R 9 is ethyl
  • R 10 is methyl
  • halo or halogen refers to any radical of fluorine, chlorine, bromine or iodine.
  • alkyl refers to both straight and branched chain radicals of up to ten carbons.
  • C 1 -C 10 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, 3-pentyl, hexyl and octyl groups.
  • alkyl as used herein, by itself or as part of another group, can refer to a straight or branched chain radical comprising from one to six carbon atoms.
  • alkenyl as employed herein, by itself or as part of another group, refers to both straight and branched chain radicals of up to ten carbons, and which comprise at least one carbon-carbon double bond.
  • hydroxyalkyl refers to both straight and branched chain alkyl radicals having a hydroxyl substituent.
  • the hydroxyl substituent can be bound to any carbon of the alkyl chain.
  • Non-limiting examples include —CH 2 OH, —CH 2 CH 2 OH, —CH 2 CH(OH)CH 3 and —CH 2 CH(OH)CH 2 CH 3 .
  • hydroxyalkyl as employed herein can refer to a straight or branched chain radical comprising from one to four carbon atoms and having one or more hydroxyl substituents.
  • haloalkyl as employed herein, by itself or as part of another group, refers to an alkyl group, as defined herein, substituted with at least one halogen.
  • Non-limiting examples of haloalkyl groups include trifluromethyl and 2,2,2-trifluoroethyl.
  • alkoxy refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • alkoxy groups include methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
  • haloalkoxy refers to an alkoxy group as defined herein, wherein the alkyl moiety of the alkoxy group is further substituted with at least one halogen.
  • Non-limiting example of haloalkoxy groups include trifluoromethoxy, and 2,2-dichloroethoxy.
  • cycloalkyl refers to an alkyl group comprising a closed ring comprising from 3 to 8 carbon atoms.
  • Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, (cyclohexyl)methyl, and (cyclohexyl)ethyl.
  • cycloalkylalkyl refers to an alkyl group, as defined herein, substituted with a cycloalkyl group, as defined herein.
  • Non-limiting examples of cycloalkylalkyl groups include (cyclobutyl)methyl, (cyclohexyl)methyl, and (cyclohexyl)ethyl.
  • heterocyclyl refers to a saturated or partially saturated 3 to 7 membered monocyclic, or 7 to 10 membered bicyclic ring system, which consists of carbon atoms and from one to four heteroatoms independently selected from the group consisting of O, N, and S, wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, the nitrogen can be optionally quaternized, and includes any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring, and wherein the heterocyclic ring can be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • Non-limiting examples of common saturated or partially saturated heterocyclic groups include azetinyl, oxetanyl, tetrahydrofuranyl, pyranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, isochromanyl, chromanyl, pyrazolidinyl, pyrazolinyl, tetronoyl and tetramoyl groups.
  • aryl as employed herein by itself or as part of another group refers to monocyclic, bicyclic or tricyclic aromatic groups containing from 6 to 14 carbons in the ring.
  • Common aryl groups include C 6-14 aryl, typically C 6-10 aryl.
  • Typical C 6-14 aryl groups include phenyl, naphthyl, phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl groups.
  • heteroaryl refers to groups having 5 to 14 ring atoms; 6, 10 or 14 ⁇ electrons shared in a cyclic array; and containing carbon atoms and 1, 2 or 3 oxygen, nitrogen or sulfur heteroatoms.
  • Example heteroaryl groups include thienyl (thiophenyl), benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl (furanyl), pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthiinyl, pyrrolyl, including without limitation 2H-pyrrolyl, imidazolyl, pyrazolyl, pyridyl (pyridinyl), including without limitation 2-pyridyl, 3-pyridyl, and 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalzinyl, naphthyrid
  • heteroaryl group contains a nitrogen atom in a ring
  • nitrogen atom may be in the form of an N-oxide, e.g., a pyridyl N-oxide, pyrazinyl N-oxide and pyrimidinyl N-oxide.
  • oxo refers to an oxygen atom joined by a double bond to a carbon atom.
  • an oxo substituent can be bound to any carbon of an alkyl chain.
  • Non-limiting examples include —CH 2 C(O)H, —C(O)CH 3 , —CH 2 C(O)CH 3 , —CH 2 CH 2 C(O)CH 3 , and —CH 2 C(O)CH 2 CH 3 .
  • Non-limiting examples of species encompassed by the present disclosure are disclosed in Table 1.
  • the compound of Formula I can be (R)-ethyl-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-003),
  • the compounds described herein can be present as a racemic mixture, as a mixture of two enantiomers at different ratios, or as a single enantiomer. In other stance, the compounds described herein can be present as a diastereoisomeric mixture, as a mixture of two or three isomers at different ratios (e.g., S,S-, S,R-, R,R-) or as a single isomer (e.g., R,R-).
  • compositions that are enriched with respect to one enantiomer or one diastereoisomer, or which comprise substantially a single enantiomer or a single diastereoisomer may be prepared using any technique known in the art, including chiral separation techniques known in the art (e.g., chiral chromatography or asymmetric synthesis).
  • the present disclosure is generally related to a composition
  • a composition comprising an effective amount of a compound (e.g., a compound of Formula I) as described herein having pesticidal activity, in particular fungicidal activity, for use in administration to a plant, a seed, or soil to control fungal pathogens.
  • a compound e.g., a compound of Formula I
  • pesticidal activity in particular fungicidal activity
  • the composition may be an aqueous composition.
  • compositions described herein can comprise any adjuvants, excipients, or other desirable components known in the art.
  • Non-limiting examples of additional ingredients include surfactants, co-surfactants, permeation enhancers, and co-solvents.
  • the composition may comprise as SPAN surfactants, TWEEN surfactants, TRITON surfactants, MAKON surfactants, IGEPAL surfactants, BRIJ surfactants, MORWET surfactants, PLURONIC surfactants, LANEXOL surfactants, ATLOX surfactants, ATLAS surfactants, SURFYNOL surfactants, TERGITOL surfactants, DOWFAX surfactants, TOXIMUL surfactants, SILWET surfactants, SYLGARD surfactants, BREAK THRU surfactants, PHYTOSAN, SOLUPLUS, cyclodextrans, polypropylene glycol, ethyl lactate, methyl soyate/ethyl lactate co-solvent blends (e.g., STEPOSOL), isopropanol, acetone, ethylene glycol
  • the composition may comprise a surfactant.
  • surfactants include SPAN 20, SPAN 40, SPAN 80, SPAN 85, TWEEN 20, TWEEN 40, TWEEN 80, TWEEN 85, TRITON X 100, MAKON 10, IGEPAL CO 630, BRIJ 35, BRIJ 97, TERGITOL TMN 6, DOWFAX 3B2, PHYSAN and TOXIMUL TA 15.
  • the composition may comprise a co-solvent.
  • co-solvents examples include ethyl lactate, methyl soyate/ethyl lactate co-solvent blends (e.g., STEPOSOL), isopropanol, acetone, 1,2-propanediol, n-alkylpyrrolidones (e.g., the AGSOLEX series), a petroleum based-oil (e.g., AROMATIC 200) or a mineral oil (e.g., paraffin oil)).
  • the composition may be formulated, mixed in a tank, combined on a seed by overcoating, or recommended for use with one or more additional active ingredients on a seed, plant, or soil.
  • the additional active ingredients may be, for example, one or more additional pesticides.
  • the composition may comprise one or more additional pesticides.
  • the pesticide may be, for example, an insecticide, a fungicide, an herbicide, or an additional nematicide.
  • Non-limiting examples of insecticides and nematicides include avermectins, carbamates, benzoylureas, butenolides, diacylhydrazines, diamides, macrocyclic lactones, mitochondrial complex I electron transport inhibitors, neonicotinoids, organophosphates, oxazoles, oxadiazoles, phenylpyrazoles, pyridine azomethine derivatives, pyrethrins, spinosyns, sulfoximines, synthetic pyrethroids, tetronic and tetramic acids.
  • insecticides and nematicides include abamectin, aldicarb, aldoxycarb, bifenthrin, broflanilide, carbofuran, chlorantraniliprole, clothianidin, cyantraniliprole, cyclaniliprole, cyfluthrin, cyhalothrin, cypermethrin, deltamethrin, dinotefuran, emamectin, ethiprole, fenamiphos, fipronil, flubendiamide, fosthiazate, imidacloprid, ivermectin, lambda-cyhalothrin, milbemectin, nitenpyram, oxamyl, permethrin, spinetoram, spinosad, spirodichlofen, spirotetramat, tefluthrin, thiacloprid, tetraniliprole,
  • the composition may comprise an insecticide and/or acaricide that inhibits ACCase activity.
  • insecticide and/or acaricide that inhibits ACCase activity.
  • Non-limiting examples include tetramic acids such as spirotetramat, and tetronic acids including spiromesifen and spirodiclofen.
  • composition may comprise one or more nematicidal compounds as described in U.S. Pub. Nos. 2009/0048311 A1 or 2011/028320 A1, or WO 2012/030887 A1, the contents of which are herein incorporated by reference.
  • composition may comprise 3-phenyl-5-(thiophen-2-yl)-1,2,4-oxadiazole.
  • Non-limiting examples of herbicides include ACCase inhibitors, acetanilides, ALS or AHAS modulators or inhibitors, auxin transport inhibitors, carotenoid biosynthesis inhibitors, cell division inhibitors, cellulose inhibitors, EPSPS modulators or inhibitors, fatty acid and lipid biosynthesis inhibitors, glutamine synthetase modulators or inhibitors, 4-hydroxyphenylpyruvate dioxygenase inhibitors (HPPD inhibitors, mitosis inhibitors, protoporphyrinogen oxidase (PPO) modulators or inhibitors, oxidative phosphorylation uncouplers, photosystem I (PS I) and photosystem II (PS II) modulators or inhibitors, and synthetic auxins.
  • HPPD inhibitors 4-hydroxyphenylpyruvate dioxygenase inhibitors
  • PPO protoporphyrinogen oxidase
  • oxidative phosphorylation uncouplers photosystem I (PS I) and photosystem II (PS II) modul
  • Non-limiting examples of herbicides include acetochlor, clethodim, dicamba, 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)-1,3,5-triazinane-2,4-dione (trifludimoxazin), ethyl 2-((3-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-(trifluoromethyl)-2,3-dihydropyrimidin-1(6H)-yl)phenoxy)pyridin-2-yl)oxy)acetate, flumioxazin, fomesafen, glyphosate, glufosinate, halauxifen, isoxaflutole, mesotrione, metolachlor, quizalofop, sa
  • the composition may comprise an herbicide that inhibits ACCase activity.
  • herbicidal aryloxyphenoxypropionates such as chlorazifop, clodinafop, clofop, cyhalofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, kuicaoxi, metamifop, propaquizafop, quizalofop, quizalofop-P, and trifop, herbicidal cyclohexanediones such as alloxydim, butroxydim, clethodim, cloproxydim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, and tralkoxydim, as well as
  • the herbicides cycloxydim and sethoxydim are known to exhibit moderate antifungal activity alone, and, without being bound to a particular theory, it is believed that the combination of these species with the compounds described herein may enhance fungal control by the additional suppression of ACCase.
  • the composition may comprise one or more additional fungicides.
  • additional fungicides include aromatic hydrocarbons, anilino-pyrimidines, benzamides, benzimidazoles, benzothiadiazole, carbamates, carboxamides, carboxylic acid amides, cinnamic acid amides, cyanoacetmide oximes, demethylation inhibitors, dicarboxamides, 2,6-dinitroanilines, dinitrophenyl crotonates, dithiocarbamates, mandelic acid amides, morpholines, phenylacetamides, phenylamides, phenyl benzamides, phenylpyrroles, phosphonates, phosphorothiolates, phthalimides, pyrazole carboxamides, pyridine carboxamides, pyridine ethyl benzamides, oxathiin carboxamides, quinine outside inhibitors (e.g.
  • strobilurins quinone inside inhibitors
  • thiadiazole carboxamides thiazolidines
  • thiocarbamates thiophanates
  • thiophene carboxamides triazoles
  • triazolinthiones quinone inside inhibitors
  • fungicides include acibenzolar-S-methyl, ametoctradin, amisulbrom, azaconazole, azoxystrobin, benalaxyl, bixafen, boscalid, captan, carbendazim, carboxin, coumoxystrobin, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, difenconazole, dimethomorph, dimoxystrobin, dinocap, enoxastrobin, epoxiconazole, ethaboxam, famoxadone, fenamidone, fenaminstrobin, fenpropimorph, fluazinam, fludioxonil, flufenoxystrobin, fluopicolide, fluopyram, fluoxastrobin, fluopyram, fluoxastrobin, fluquinconazole, fluoram
  • composition may comprise one or more additional fungicides that modulate or inhibit ACCase activity.
  • composition may also comprise one or more additional active substances, including biological control agents, microbial extracts, natural products, plant growth activators and/or plant defense agents.
  • biological control agents include bacteria, fungi, beneficial nematodes, and viruses.
  • the biological control agent can be a bacterium of the genus Actinomycetes, Agrobacterium, Arthrobacter, Alcaligenes, Aureobacterium, Azobacter, Bacillus, Beijerinckia, Bradyrhizobium, Brevibacillus, Burkholderia, Chromobacterium, Clostridium, Clavibacter, Comamonas, Corynebacterium, Curtobacterium, Enterobacter, Flavobacterium, Gluconobacter, Hydrogenophage, Klebsiella, Metarhizium, Methylobacterium, Paenibacillus, Pasteuria, Photorhabdus, Phyllobacterium, Pseudomonas, Rhizobium, Serratia, Sphingobacterium, Stenotrophomonas, Streptomyces, Variovax , and Xenorhabdus .
  • the bacteria may be Bacillus amyloliquefaciens, Bacillus cereus, Bacillus firmus, Bacillus lichenformis, Bacillus pumilus, Bacillus sphaericus, Bacillus subtilis, Bacillus thuringiensis, Bradyrhizobium japonicum, Chromobacterium subtsugae, Metarhizium anisopliae, Pasteuria nishizawae, Pasteuria penetrans, Pasteuria usage, Pseudomonas fluorescens , and Streptomyces lydicus.
  • the biological control agent can be a fungus of the genus Alternaria, Ampelomyces, Aspergillus, Aureobasidium, Beauveria, Colletotrichum, Coniothyrium, Gliocladium, Metarhizium, Muscodor, Paecilomyces, Penicillium, Trichoderma, Typhula, Ulocladium , and Verticillium .
  • the fungus may be Beauveria bassiana, Coniothyrium minitans, Gliocladium virens, Muscodor albus, Paecilomyces lilacinus, Trichoderma polysporum , or Trichoderma virens.
  • the biological control agents can be plant growth activators or plant defense agents including, but not limited to harpin, Reynoutria sachalinensis , jasmonate, lipochitooligosaccharides, salicylic acid and/or isoflavones.
  • the compounds described herein can be used in accordance with methods of controlling fungal pathogens.
  • compounds as described herein of Formula I are believed to exhibit control of phytopathogenic fungi as described herein.
  • the compounds disclosed herein can be administered to a plant, a seed, or soil in a composition as described herein to control fungal pathogens, including using the compounds as described herein with any adjuvants, excipients, or other desirable components as described herein or known in the art and formulating, mixing, or combining one or more additional active ingredients.
  • the additional active ingredient may be, for example, an additional pesticide.
  • the pesticide may be, for example, an insecticide, a fungicide, an herbicide, or an additional nematicide as described herein or otherwise known in the art.
  • compositions described herein can be administered to seeds, plants, or the environment of plants (e.g., soil) wherein the control of phytopathogenic fungi is desired.
  • a method of controlling fungal pathogens comprising administering to a plant, a seed or soil a composition comprising an effective amount of a compound as described herein.
  • Non-limiting examples of plants that may be protected from fungal pathogens in accordance with the methods described herein include monocotyledonous crops such as corn, wheat, barley, rye, rice, sorghum, oat; sugarcane and turf; and dicotyledonous crops such as cotton, sugar beet, peanut, potato, sweet potato, yam, sunflower, soybean, alfalfa, canola, grapes, tobacco; vegetables including Solanaceae vegetables such as eggplant, tomato, green pepper and pepper; Cucurbitaceae vegetables such as cucumber, pumpkin, zucchini, watermelon, melon and squash; Brassicaceae vegetables such as radish, turnip, horseradish, Chinese cabbage, cabbage, leaf mustard, broccoli and cauliflower; Asteraceae vegetables such as artichoke and lettuce; Liliaceae vegetables such as leek, onion, garlic and asparagus; Apiaceae vegetables such as carrot, parsley, celery and parsnip; Chenopodiaceae vegetables such as spinach and chard; Lamiace
  • Non-limiting examples of the plant diseases that may be controlled by the methods described herein include diseases caused by phytopathogenic fungi (in particular of the classes of Ascomycetes, Deuteromycetes, Oomycetes and Basidiomycetes) such as Magnaporthe grisea, Cochiobolus miyabeanus, Rhizoctonia solani and Gibberella fujikuroi on rice; Erysiphe graminis, Fusarium graminearum, F. avenacerum, F. culmorum, Microdochium nivale, Puccinia striiformis, P. graminis, P. recondita, P.
  • phytopathogenic fungi in particular of the classes of Ascomycetes, Deuteromycetes, Oomycetes and Basidiomycetes
  • Magnaporthe grisea Cochiobolus miyabeanus, Rhizoctonia solani and Gibberella fujikuroi on rice
  • hordei Typhula sp., Micronectriella nivalis, Ustilago tritici, U. nuda, Tilletia caries, Pseudocercosporella herpotrichoides, Rhynchosporium secalis, Septoria tritici, Leptosphaeria nodorum and Pyrenophora teres on wheat and barley; Diaporthe citri, Elsinoe fawcetti, Penicillium digitatum, P.
  • the methods described herein can be used to modulate, inhibit or eradicate fungal pathogens as described herein that cause disease on various parts of agricultural crop plants (e.g., fruit, blossoms, leaves, stems, tubers, roots) or other useful plants as described herein.
  • the methods described herein may be used to modulate, inhibit, and/or control any of the fungal pathogens and/or plant diseases listed above.
  • methods described herein may be used to modulate, inhibit or eradicate plant fungal pathogens in vegetable crops, row crops, trees, nuts, vines, turf, and ornamental plants.
  • a composition comprising a compound as described herein may be supplied to a plant exogenously.
  • the composition may be applied to the plant and/or the surrounding soil through sprays, drips, and/or other forms of liquid application.
  • the compounds described herein may penetrate the plant through the roots via the soil (systemic action); by drenching the locus of the plant with a liquid composition; or by applying the compounds in solid form to the soil, e.g. in granular form (soil application).
  • locus broadly encompasses the fields on which the treated plants are growing, or where the seeds of cultivated plants are sown, or the place where the seed will be placed into the soil.
  • composition as described herein may be applied to a plant, including plant leaves, shoots, roots, or seeds.
  • composition comprising a compound as described herein can be applied to a foliar surface of a plant.
  • Foliar applications may require 50 to 500 g per hectare of a compound as described herein.
  • foliar surface broadly refers to any green portion of a plant having surface that may permit absorption of silicon, including petioles, stipules, stems, bracts, flowerbuds, and leaves. Absorption commonly occurs at the site of application on a foliar surface, but in some cases, the applied composition may run down to other areas and be absorbed there.
  • compositions described herein can be applied to the foliar surfaces of the plant using any conventional system for applying liquids to a foliar surface.
  • application by spraying will be found most convenient.
  • Any conventional atomization method can be used to generate spray droplets, including hydraulic nozzles and rotating disk atomizers.
  • alternative application techniques including application by brush or by rope-wick, may be utilized.
  • a composition comprising a compound as described herein can be directly applied to the soil surrounding the root zone of a plant.
  • Soil applications may require 0.5 to 5 kg per hectare of a compound as described herein on a broadcast basis (rate per treated area if broadcast or banded).
  • a composition may be applied directly to the base of the plants or to the soil immediately adjacent to the plants.
  • a sufficient quantity of the composition is applied such that it drains through the soil to the root area of the plants.
  • compositions may be performed using any method or apparatus known in the art, including but not limited to hand sprayer, mechanical sprinkler, or irrigation, including drip irrigation.
  • a composition as provided herein can be applied to plants and/or soil using a drip irrigation technique.
  • the composition may be applied through existing drip irrigation systems.
  • this procedure can be used in connection with cotton, strawberries, tomatoes, potatoes, vegetables, and ornamental plants.
  • a composition can be applied to plants and/or soil using a drench application.
  • the drench application technique may be used in connection with crop plants and turf grasses.
  • a composition as provided herein may be applied to soil after planting.
  • a composition as provided herein may be applied to soil during planting, or may be applied to soil before planting.
  • composition as provided herein may be tilled into the soil or applied in furrow.
  • solid granulates comprising the compounds described herein may be applied to the flooded field or locus of the crop plants to be treated.
  • seed treatment methods described herein may be used to modulate, inhibit, and/or control any of the fungal pathogens and/or plant diseases described above.
  • the method may comprise treating a seed with a composition comprising a compound as described herein.
  • seed broadly encompasses plant propagating material such as, tubers cuttings, seedlings, seeds, and germinated or soaked seeds.
  • a method of administering to a seed a compound (e.g., a compound of Formula I) as described to control fungal pathogens in a composition as described herein including using the compounds as described herein with the any adjuvants, excipients, or other desirable components as described herein or known in the art and formulating, mixing, or combining one or more additional active ingredients.
  • the additional active ingredient may be, for example, an additional pesticide.
  • the pesticide may be, for example, an insecticide, a fungicide, an herbicide, or an additional nematicide as described herein or otherwise known in the art.
  • a compound as described herein may be applied to seeds or tubers by impregnating them with a liquid seed treatment composition comprising a compound described herein, or by coating them with a solid or liquid composition comprising a compound described herein.
  • Seed treatment methods described herein can be used in connection with any species of plant and/or the seeds thereof as described herein.
  • the methods are used in connection with seeds of plant species that are agronomically important.
  • the seeds can be of corn, peanut, canola/rapeseed, soybean, cucurbits, crucifers, cotton, beets, rice, sorghum, sugar beet, wheat, barley, rye, sunflower, tomato, sugarcane, tobacco, oats, as well as other vegetable and leaf crops.
  • the seed can be corn, soybean, or cotton seed.
  • the seed may be a transgenic seed from which a transgenic plant can grow and incorporate a transgenic event that confers, for example, tolerance to a particular herbicide or combination of herbicides, insect resistance, increased disease resistance, enhanced tolerance to stress and/or enhanced yield.
  • Transgenic seeds include, but are not limited to, seeds of corn, soybean and cotton.
  • a seed treatment method may comprise applying the seed treatment composition to the seed prior to sowing the seed, so that the sowing operation is simplified.
  • seeds can be treated, for example, at a central location and then dispersed for planting. This permits the person who plants the seeds to avoid the complexity and effort associated with handling and applying the compositions, and to merely handle and plant the treated seeds in a manner that is conventional for regular untreated seeds.
  • a composition can be applied to seeds by any standard seed treatment methodology, including but not limited to mixing in a container (e.g., a bottle or bag), mechanical application, tumbling, spraying, immersion, and solid matrix priming. Seed coating methods and apparatus for their application are disclosed in, for example, U.S. Pat. Nos. 5,918,413; 5,891,246; 5,554,445; 5,389,399; 5,107,787; 5,080,925; 4,759,945 and 4,465,017, among others. Any conventional active or inert material can be used for contacting seeds with the composition, such as conventional film-coating materials including but not limited to water-based film coating materials.
  • a composition can be introduced onto or into a seed by use of solid matrix priming.
  • a quantity of the composition can be mixed with a solid matrix material and then the seed can be placed into contact with the solid matrix material for a period to allow the composition to be introduced to the seed.
  • the seed can then optionally be separated from the solid matrix material and stored or used, or the mixture of solid matrix material plus seed can be stored or planted directly.
  • solid matrix materials which are useful include polyacrylamide, starch, clay, silica, alumina, soil, sand, polyurea, polyacrylate, or any other material capable of absorbing or adsorbing the composition for a time and releasing the active compound of the composition into or onto the seed. It is useful to make sure that the active compound and the solid matrix material are compatible with each other.
  • the solid matrix material should be chosen so that it can release the active compound at a reasonable rate, for example over a period of minutes, hours, days, or weeks.
  • Imbibition is another method of treating seed with the composition.
  • a plant seed can be directly immersed for a period of time in the composition. During the period that the seed is immersed, the seed takes up, or imbibes, a portion of the composition.
  • the mixture of plant seed and the composition can be agitated, for example by shaking, rolling, tumbling, or other means.
  • the seed can be separated from the composition and optionally dried, for example by patting or air drying.
  • a composition may be applied to the seeds using conventional coating techniques and machines, such as fluidized bed techniques, the roller mill method, rotostatic seed treaters, and drum coaters. Other methods, such as spouted beds may also be useful.
  • the seeds may be pre-sized before coating. After coating, the seeds may be dried and then transferred to a sizing machine for sizing. Such procedures are generally known in the art.
  • the seeds can be coated using a variety of methods known in the art.
  • the coating process can comprise spraying the composition onto the seed while agitating the seed in an appropriate piece of equipment such as a tumbler or a pan granulator.
  • the seed coating may be applied using a continuous process.
  • seed may be introduced into the treatment equipment (such as a tumbler, a mixer, or a pan granulator) either by weight or by flow rate.
  • the amount of treatment composition that is introduced into the treatment equipment can vary depending on the seed weight to be coated, surface area of the seed, the concentration of the fungicide and/or other active ingredients in a composition, the desired concentration on the finished seed, and the like.
  • a composition can be applied to the seed by a variety of means, for example by a spray nozzle or revolving disc.
  • the amount of liquid may be determined by the assay of the formulation and the required rate of active ingredient necessary for efficacy.
  • the seed can be treated (for example by misting or spraying with the composition) and passed through the treater under continual movement/tumbling where it can be coated evenly and dried before storage or use.
  • the seed coating may be applied using a batch process.
  • a known weight of seeds can be introduced into the treatment equipment (such as a tumbler, a mixer, or a pan granulator).
  • a known volume of the composition can be introduced into the treatment equipment at a rate that allows the composition to be applied evenly over the seeds.
  • the seed can be mixed, for example by spinning or tumbling.
  • the seed can optionally be dried or partially dried during the tumbling operation.
  • the treated sample can be removed to an area for further drying or additional processing, use, or storage.
  • the seed coating may be applied using a semi-batch process that incorporates features from each of the batch processes and continuous processes set forth above.
  • seeds can be coated in laboratory size commercial treatment equipment such as a tumbler, a mixer, or a pan granulator by introducing a known weight of seeds in the treater, adding the desired amount of the composition, tumbling or spinning the seed and placing it on a tray to thoroughly dry.
  • laboratory size commercial treatment equipment such as a tumbler, a mixer, or a pan granulator
  • Seeds can also be coated by placing the known amount of seed into a narrow neck bottle or receptacle with a lid. While tumbling, the desired amount of the composition can be added to the receptacle. The seed is tumbled until it is coated with the composition. After coating, the seed can optionally be dried, for example on a tray.
  • the treated seeds may also be enveloped with a film overcoating to protect the fungicidal coating.
  • a film overcoating to protect the fungicidal coating.
  • Such overcoatings are known in the art and may be applied using conventional fluidized bed and drum film coating techniques.
  • the overcoatings may be applied to seeds that have been treated with any of the seed treatment techniques described above, including but not limited to solid matrix priming, imbibition, coating, and spraying, or by any other seed treatment technique known in the art.
  • a seed that has been treated with a composition as described herein comprising a compound (e.g., a compound of Formula I) as described herein.
  • the seed may have been treated with the composition using one of the seed treatment methods set forth above, including but not limited to solid matrix priming, imbibition, coating, and spraying.
  • the treated seed may be of any plant species, as described above.
  • a seed can be treated with a composition as described herein, including formulating, mixing in a seed treater tank, or combining on a seed by overcoating one or more additional active ingredients.
  • the additional active ingredient may be, for example, an additional pesticide.
  • the pesticide may be, for example, an insecticide, a fungicide, an herbicide, or an additional nematicide as described herein.
  • the treated seed comprises a compound of Formula I in an amount of at least about 0.005 mg/seed.
  • treated seeds can comprise a compound of Formula I in an amount of from about 0.005 to about 2 mg/seed, from about 0.005 to about 1 mg/seed, or from about 0.05 to about 0.5 mg/seed.
  • the compounds of this invention may be prepared or isolated in general by synthetic and/or semi-synthetic methods known to those skilled in the art for analogous compounds and by methods described in detail herein.
  • LG includes, but is not limited to, halogens (e.g. fluoride, chloride, bromide, iodide), sulfonates (e.g. mesylate, tosylate, benzenesulfonate, brosylate, nosylate, triflate), diazonium, and the like.
  • halogens e.g. fluoride, chloride, bromide, iodide
  • sulfonates e.g. mesylate, tosylate, benzenesulfonate, brosylate, nosylate, triflate
  • diazonium and the like.
  • Suitable amide coupling reagents include, but are not limited to, (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT), N,N′-dicyclohexylcarbodiimide (DCC), N,N′-Diisopropylcarbodiimide (DIC), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), 3-[Bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate (HBTU), 3-Hydroxytriazolo[4,5-b]pyridine (HOAt), (7-Azabenzotriazol-1-y
  • compounds of the present invention of formula I, where R 2 is 2-oxazolyl are generally prepared by procedures described in U.S. Pat. No. 8,969,557, the entirety of which is incorporated herein by reference. Exemplative compounds listed in Table 1 can be prepared according to Scheme 1 or Scheme 2 set forth below:
  • each of PG, LG, R 6 , R 8 , R 31 , R 32 , and R 33 is as defined above and below and in classes and subclasses as described herein.
  • the first step comprises alkylating a compound of Formula Br-1 with a compound of Formula B-1, thereby forming a compound of Formula Br-2.
  • the compound of Formula B-1 is a halide wherein LG is chloride or bromide.
  • the compound of Formula B-1 is an alcohol wherein LG is —OH and the alkylation is accomplished by Mitsunobu reaction.
  • the Mitsunobu reaction is accomplished by the use of diisopropyl azodicarboxylate and triphenylphosine.
  • R 6 of the compound of Formula B-1 is isopropyl, tetrahydro-2H-pyran-4-yl; cis-4-hydroxycyclohexyl; 4-oxocyclohexyl; (4-oxocyclohexyl)methyl; or cis-4-hydroxycyclohexylmethyl.
  • R 8 of the compound of Formula B-1 is hydrogen or F.
  • the oxazole moiety is installed by Stille coupling reaction to provide a compound of Formula O-2.
  • the Stille coupling reaction is accomplished by reacting the compound of Formula Br-2 with 2-(tributylstannyl)oxazole in the presence of a palladium complex, for example, tetrakis(triphenylphosphine)palladium(O).
  • the carboxylic acid protection group of the compound of Formula O-1 is t-butyl and the deproction step comprises an acid treatment (e.g., trifluroacetic acid in dichloromethane) to provide the carboxylic acid of Formula O-3.
  • the protection group of Formula O-2 is benzyl.
  • the protecting group is a silyl protecting group.
  • the protecting group is TBDPS and the deproction step comprises a fluoride treatment (e.g., tetrabutylammonium fluoride).
  • the last step comprises an amidation of the carboxylic acid group of a compound of Formula O-3 with an amine, thereby providing a compound of Formula O-4 or Formula O-5.
  • the amine is ammonia (e.g., R 32 and R 33 are both hydrogen).
  • the amine is a primary amine (e.g., R 32 is hydrogen and R 33 is ethyl, isopropyl, or cyclobutyl).
  • the amine is a secondary amine.
  • the amine is a heterocycle (e.g., R 31 is 1-pyrrolidinyl, 1-piperidinyl, or 1-morpholinyl).
  • the oxazole moiety is installed first by Stille coupling reaction to provide a compound of Formula O-1.
  • each of PG, LG, R 6 , R 8 , R 31 , R 32 , and R 33 is as defined and described above.
  • compounds of the present invention of formula I, where R 2 is cycloalkyl are generally prepared by procedures described in U.S. Pat. No. 8,969,557, the entirety of which is incorporated herein by reference. Exemplative compounds listed in Table 1 can be prepared according to Scheme 3 set forth below:
  • each of PG, LG, R 6 , R 8 , R 31 , R 32 , and R 33 is as defined above and below and in classes and subclasses as described herein.
  • the first step comprises alkylating a compound of Formula Br-1 with a compound of Formula B-1, thereby forming a compound of Formula Br-2, as described above.
  • R 6 of the compound of Formula B-1 is tetrahydro-2H-pyran-4-yl.
  • R 8 of the compound of Formula B-1 is F.
  • the oxazole moiety is installed by Negishi or Suzuki coupling reaction to provide a compound of Formula Cb-2.
  • the Negishi coupling reaction is accomplished by reacting the compound of Formula Br-2 with cycloalkylzinc(II) chloride in the presence of a palladium complex, for example, 1,1-Bis(diphenylphosphino)ferrocene]palladium(11) dichloride.
  • the Suzuki coupling reaction is accomplished by reacting the compound of Formula Br-2 with a cycloalkylboronic compound in the presence of a palladium complex, for example, tetrakis(triphenylphosphine)palladium(0) or palladium(II) acetate.
  • a palladium complex for example, tetrakis(triphenylphosphine)palladium(0) or palladium(II) acetate.
  • the carboxylic acid protection group of the compound of Formula Cb-2 is described above.
  • the last step comprises an amidation of the carboxylic acid group of a compound of Formula Cb-3 with an amine, thereby providing a compound of Formula Cb-4 or Formula Cb-5, as described above.
  • the amine is ammonia (e.g., R 32 and R 33 are both hydrogen).
  • the amine is a primary amine (e.g., R 32 is hydrogen and R 33 is ethyl or isopropyl).
  • the amine is a secondary amine.
  • the amine is a heterocycle (e.g., R 31 is 1-pyrrolidinyl, 1-piperidinyl, or 1-morpholinyl).
  • each of PG, LG, R 5 , R 5′ , R 6 , R 7 , R 8 , R 31 , R 32 , and R 33 is as defined above and below and in classes and subclasses as described herein.
  • the first step comprises alkylating a compound of Formula P-1 with a compound of Formula B-2, thereby forming a compound of Formula P-2.
  • the compound of Formula B-2 is a halide wherein LG is chloride or bromide.
  • the compound of Formula B-2 is an alcohol wherein LG is —OH and the alkylation is accomplished by Mitsunobu reaction.
  • the Mitsunobu reaction is accomplished by the use of diisopropyl azodicarboxylate and triphenylphosine.
  • R 5 and R 5′ of the compound of Formula P-1 or P-2 are both methyl.
  • R 5 of the compound of Formula P-1 or P-2 is methyl and R 5 of the compound of Formula P-1 or P-2 is hydrogen.
  • R 6 of the compound of Formula B-2 is H, —CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH(CH 3 ) 2 , —CH 2 CH ⁇ CH 2 , —CH 2 CH 2 OH, —CH 2 CH(R—CH 3 )OH, —CH 2 CH(S—CH 3 )OH, —CH 2 C(CH 3 ) 2 (OH), —CH 2 CH 2 OCH 3 , —CH 2 CH 2 CH 2 OCH 3 , —C(O)CH 2 OH, —C(O)CH 3 , —CH 2 CN, —(CH 2 ) 2 CN, —CH 2 CH(CH 3 )CN, —CH 2 C(CH 3 ) 2 CN, tetrahydro-2H-pyran-4-yl, cis-4
  • the carboxylic acid protection group of the compound of Formula P-3 is a silyl protecting group.
  • the protecting group is TBDPS and the deproction step comprises a fluoride treatment (e.g., tetrabutylammonium fluoride).
  • the last step comprises an amidation of the carboxylic acid group of a compound of Formula P-3 with an amine, thereby providing a compound of Formula P-4 or Formula P-5.
  • the amine is ammonia (e.g., R 32 and R 33 are both hydrogen).
  • the amine is a primary amine (e.g., R 32 is hydrogen and R 33 is methyl, ethyl, isopropyl, isobutyl, cycloropropyl, cyclobutyl, or cyclohexyl).
  • the amine is a secondary amine (e.g., R 32 is methyl and R 33 is methyl, isopropyl, or 2-propenyl).
  • the amine is a heterocycle (e.g., R 31 is 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, or 2,5-dihydro-1H-pyrrol-1-yl).
  • R 7 of the compound of Formula P-2 is —OPG
  • deprotection and O-alkylation provides R 7 as of —OCH 2 CH 2 OH, or —OCH 2 CH 2 CN in compounds of Formula P-4 or P-5.
  • compounds of formula P-4 or P-5 may contain one or more stereocenters, and may be present as a racemic or diastereomeric mixture.
  • One of skill in the art will also appreciate that there are many methods known in the art for the separation of isomers to obtain stereoenriched or stereopure isomers of those compounds, including but not limited to HPLC, chiral HPLC, fractional crystallization of diastereomeric salts, kinetic enzymatic resolution (e.g. by fungal-, bacterial-, or animal-derived lipases or esterases), and formation of covalent diastereomeric derivatives using an enantioenriched reagent.
  • each of PG, LG, R 5 , R 5′ , R 6 , R 7 , R 8 , R 31 , R 32 , and R 33 is as defined above and below and in classes and subclasses as described herein.
  • the first step comprises alkylating a compound of Formula E-1 with a compound of Formula B-2, thereby forming a compound of Formula E-2.
  • the compound of Formula B-2 is a halide wherein LG is chloride or bromide.
  • the compound of Formula B-2 is an alcohol wherein LG is —OH and the alkylation is accomplished by Mitsunobu reaction.
  • the Mitsunobu reaction is accomplished by the use of diisopropyl azodicarboxylate and triphenylphosine.
  • R 5 and R 5′ of the compound of Formula E-1 or E-2 are both methyl.
  • R 5 of the compound of Formula E-1 or E-2 is methyl and R 5 of the compound of Formula E-1 or E-2 is hydrogen.
  • R 6 of the compound of Formula B-2 is H, —CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH(CH 3 ) 2 , —CH 2 CH ⁇ CH 2 , —CH 2 CH 2 OH, —CH 2 CH(R—CH 3 )OH, —CH 2 CH(S—CH 3 )OH, —CH 2 C(CH 3 ) 2 (OH), —CH 2 CH 2 OCH 3 , —CH 2 CH 2 CH 2 OCH 3 , —C(O)CH 2 OH, —C(O)CH 3 , —CH 2 CN, —(CH 2 ) 2 CN, —CH 2 CH(CH 3 )CN, —CH 2 C(CH 3 ) 2 CN, tetrahydro-2H-pyran-4-yl, cis-4
  • the carboxylic acid protection group of the compound of Formula E-3 is a silyl protecting group.
  • the protecting group is TBDPS and the deproction step comprises a fluoride treatment (e.g., tetrabutylammonium fluoride).
  • the last step comprises an amidation of the carboxylic acid group of a compound of Formula E-3 with an amine, thereby providing a compound of Formula E-4 or Formula E-5.
  • the amine is ammonia (e.g., R 32 and R 33 are both hydrogen).
  • the amine is a primary amine (e.g., R 32 is hydrogen and R 33 is methyl, ethyl, isopropyl, isobutyl, cycloropropyl, cyclobutyl, or cyclohexyl).
  • the amine is a secondary amine (e.g., R 32 is methyl and R 33 is methyl, ethyl, isopropyl, or 2-propenyl).
  • the amine is a heterocycle (e.g., R 31 is 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, or 2,5-dihydro-1H-pyrrol-1-yl).
  • R 7 of the compound of Formula E-2 is —OPG
  • deprotection and O-alkylation provides R 7 as of —OCH 2 CH 2 CN in compounds of Formula E-4 or E-5.
  • the ester group (i.e., —C(O)OCH 2 CH 3 ) in compounds of Formula E-4 or E-5 is further reduced to —CH 2 OH as the R 2 in compounds of Formula I.
  • the —CH 2 OH group is further alkylated to —CH 2 OCH 2 CH 3 as the R 2 in compounds of Formula I.
  • compounds of formula E-4 or E-5 may contain one or more stereocenters, and may be present as a racemic or diastereomeric mixture.
  • One of skill in the art will also appreciate that there are many methods known in the art for the separation of isomers to obtain stereoenriched or stereopure isomers of those compounds, including but not limited to HPLC, chiral HPLC, fractional crystallization of diastereomeric salts, kinetic enzymatic resolution (e.g. by fungal-, bacterial-, or animal-derived lipases or esterases), and formation of covalent diastereomeric derivatives using an enantioenriched reagent.
  • each of PG, LG, R 5 , R 5′ , R 6 , R 7 , R 8 , R 31 , R 32 , and R 33 is as defined above and below and in classes and subclasses as described herein.
  • the first step comprises alkylating a compound of Formula T1-1 with a compound of Formula B-2, thereby forming a compound of Formula T1-2.
  • the compound of Formula B-2 is a halide wherein LG is chloride or bromide.
  • the compound of Formula B-2 is an alcohol wherein LG is —OH and the alkylation is accomplished by Mitsunobu reaction.
  • the Mitsunobu reaction is accomplished by the use of diisopropyl azodicarboxylate and triphenylphosine.
  • R 5 and R 5′ of the compound of Formula T1-1 or T1-2 are both methyl.
  • R 5 of the compound of Formula T1-1 or T1-2 is methyl and R 5 of the compound of Formula T1-1 or T1-2 is hydrogen. In some embodiments, R 5 and R 5′ of the compound of Formula T1-1 or T1-2 are both hydrogen.
  • R 6 of the compound of Formula B-2 is H, —CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH(CH 3 ) 2 , —CH 2 CH ⁇ CH 2 , —CH 2 CH 2 OH, —CH 2 CH(R—CH 3 )OH, —CH 2 CH(S—CH 3 )OH, —CH 2 C(CH 3 ) 2 (OH), —CH 2 CH 2 OCH 3 , —CH 2 CH 2 CH 2 OCH 3 , —C(O)CH 2 OH, —C(O)CH 3 , —CH 2 CN, —(CH 2 ) 2 CN, —CH 2 CH(CH 3 )CN, —CH 2 C(CH 3 ) 2 CN, tetrahydro-2H-pyran-4-yl, cis-4-hydroxycyclohexyl, 4-oxocyclohexyl, (4-oxocyclohexyl)methyl, c
  • R 7 of the compound of Formula B-2 or T1-2 is —OMe, methyl, ethyl, —(CH 2 ) 3 CN, or —OPG.
  • R 8 of the compound of Formula B-2 or T1-2 is hydrogen or F.
  • the carboxylic acid protection group of the compound of Formula T1-3 is a silyl protecting group.
  • the protecting group is TBDPS and the deproction step comprises a fluoride treatment (e.g., tetrabutylammonium fluoride).
  • the last step comprises an amidation of the carboxylic acid group of a compound of Formula T1-3 with an amine, thereby providing a compound of Formula T1-4 or Formula T1-5.
  • the amine is ammonia (e.g., R 32 and R 33 are both hydrogen).
  • the amine is a primary amine (e.g., R 32 is hydrogen and R 33 is methyl, ethyl, isopropyl, isobutyl, cycloropropyl, cyclobutyl, cyclohexyl, or —CH 2 CN).
  • the amine is a secondary amine (e.g., R 32 is methyl and R 33 is methyl, ethyl, isopropyl, or 2-propenyl).
  • the amine is a heterocycle (e.g., R 31 is 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 2,5-dihydro-1H-pyrrol-1-yl, or 3-hydroxyazetidin-1-y).
  • R 7 of the compound of Formula T1-2 is —OPG
  • deprotection and O-alkylation provides R 7 as of —OCH(CH 3 ) 2 , —OCH 2 CH 2 OH, —OCH 2 CH 2 OCH 3 , —OCH 2 CH(CH 2 ) 20 , —OCH 2 CN, —OCH 2 CH 2 CN, —OC(O)CH 3 ; O-tetrahydro-2H-pyran-4-yl, or O-benzyl in compounds of Formula T1-4 or T1-5.
  • compounds of formula T1-4 or T1-5 may contain one or more stereocenters, and may be present as a racemic or diastereomeric mixture.
  • One of skill in the art will also appreciate that there are many methods known in the art for the separation of isomers to obtain stereoenriched or stereopure isomers of those compounds, including but not limited to HPLC, chiral HPLC, fractional crystallization of diastereomeric salts, kinetic enzymatic resolution (e.g. by fungal-, bacterial-, or animal-derived lipases or esterases), and formation of covalent diastereomeric derivatives using an enantioenriched reagent.
  • exemplative triazolyl compounds in Table 1 of the present invention of Formula I where R 4 is —O(CH 2 ) 2 CN and R 4 is CH 3 (I-273, I-274), R 4 is —OH and R 4′ is —CH 2 CH 2 OH (I-275, I-276), or R 4 is —OH and R 4′ is —CH 2 OH (I-315) are prepared specifically with modified chemical steps.
  • R 4 of —O(CH 2 ) 2 CN and R 4′ of CH 3 in compounds I-273 and I-274 are installed at the benzylic position of the compound of 3-((2-(5-fluoro-2-methoxyphenyl)-1-hydroxypropan-2-yl)oxy)propanenitrile, shown in Scheme 7 below:
  • Compounds I-275 and I-276 are prepared by amidation, dihydroxylation of the double bond, oxidation of the diol to an aldehyde, reduction of the aldehyde to an alcohol, and chiral separation.
  • R 4 of —OH and R 4′ of —CH 2 OH in the compound I-315 are installed via a ketone intermediate, shown in Scheme 9 below:
  • exemplative triazolyl compounds in Table 1 of the present invention of Formula I, where R 2 is 1H-1,2,4-triazol-1-yl (I-317) or 1H-1,2,3-triazol-1-yl (I-341) are generally prepared according to Scheme 10, shown below:
  • the 1H-1,2,4-triazol-1-yl or 1H-1,2,3-triazol-1-yl moiety is installed by a metal-mediated coupling reaction.
  • a growth inhibition assay was conducted to determine the ability of compounds to control the growth of fungal pathogens, such as Botrtyis cinerea (Bc), Collectotrichum graminicola (Cg), Diplodia maydis (Dm), Fusarium moniliforme (Fm), Fusarium virguliforme (Fv), Phytophthora capsici (Pc), Rhizoctonia solani (Rs), and Septoria tritici (St).
  • fungal pathogens such as Botrtyis cinerea (Bc), Collectotrichum graminicola (Cg), Diplodia maydis (Dm), Fusarium moniliforme (Fm), Fusarium virguliforme (Fv), Phytophthora capsici (Pc), Rhizoctonia solani (Rs), and Septoria tritici (St).
  • a set of positive controls was also prepared, with various concentrations of Soraphen (2, 0.4, and 0.08 ppm), Metalaxyl (1.1, 0.22, and 0.04 ppm), and Metconazole (2, 0.4, and 0.08 ppm or 0.2, 0.04, and 0.008 ppm) after the five-fold dilutions.
  • Negative controls on each plate included 2% DMSO, water, and a blank (media +2% DMSO).
  • Fungal spores were isolated from previously sub-cultured plates of Botrtyis cinerea (Bc), Collectotrichum graminicola (Cg), Diplodia maydis (Dm), Fusarium moniliforme (Fm), Fusarium virguliforme (Fv), Phytophthora capsici (Pc), and Septoria tritici (St).
  • the isolated spores were diluted to individual concentrations with a 17% V8 liquid media.
  • Rhizoctonia solani (Rs) 1.5 mm mycelial plugs were used in place of spores and 1 ⁇ 4 Potato Dextrose Broth (PDB) was used for dilution.
  • the spore concentrations and plug sizes were based on growth curves generated at 48 hours for each pathogen.
  • spores or mycelial plugs, media, diluted compound solutions, and controls were combined. Once the compound was added, a true final concentration of compound in each well was measured by an OD600 reading, which adjusted for any compound precipitation that might have occurred in the well. Plate readings were repeated at both 24 and 48 hours. The blank negative control was used as a background subtraction. Additional visual ratings were performed at both 24 and 48 hours for checking on precipitation and confirming efficacy. Visual and OD600 ratings of the compounds at 48 hours were compared to the 2% DMSO negative control, and the percent of pathogen growth inhibition was determined based on those values.
  • a list of compounds that have an inhibition of ⁇ 90% of Fusarium moniliforme (Fm) at a compound concentration of 2 ppm or lower is included in Table 2 below. Additional compounds that have an inhibition of ⁇ 90% of Fusarium moniliforme (Fm) are included in Table 3 below. Both tables list the concentration of each compound that was sufficient to ⁇ 90% inhibition of growth for each of the fungal pathogens listed above. In addition, some of compounds were tested in a yeast growth inhibition assay for Saccharomyces cerevisiae (Sc). Table 2 lists the concentration of the tested compound that was sufficient to ⁇ 75% inhibition of Saccharomyces cerevisiae (Sc).
  • Plants Hordeum vulgare cv. Perry were grown for 6 days in 2-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained in a growth chamber at conditions of 20 to 21° C., 16 hour light cycle, 400 uM of light, 70% humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Blumeria graminis f sp. hordei , plants were kept at conditions of 20 to 22° C., 70% relative humidity, and 200 uM of light to facilitate infection and disease development.
  • test compounds were dissolved in a solution of 5% acetone and 0.005% Tween 80 surfactant. An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted.
  • the amount of the compound applied to the leaves was typically 200, 100, 50, 10, or 2 ppm, but it may vary.
  • the plants were moved to a cooler chamber and inoculated by shaking well-colonized, untreated stock plants above the treated plants. This allowed producing a settling cloud of spores and resulting in uniform infection.
  • Plants ( Cucumis sativus cv. Straight Eight) were grown for 10 days in 2.5-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained in a growth chamber at conditions of 23 to 27° C., 16 hour light cycle, ambient humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Sphaerotheca fuliginea , plants were kept at conditions of 23 to 27° C., 16 hour light cycle, 60% relative humidity, and with sub-irrigation as needed to facilitate infection and disease development.
  • test compounds were dissolved in 5% acetone and 0.05% Tween 20 surfactant.
  • An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted.
  • the amount of the compound applied to the leaves was typically 200, 100, 50, or 10 ppm, but it may vary.
  • the plants were moved to a cooler chamber and inoculated by shaking well-colonized, untreated stock plants above the treated plants. This allowed producing a settling cloud of spores and resulting in uniform infection. Inoculated plants were kept near other sporulating stock plants to allow for infection of newly emerging leaves.
  • Efficacy was evaluated in 7 days later by examining leaves for colonization and growth of mildew.
  • Table 5 lists the results of cucumber powdery mildew control at a compound concentration of 10 ppm or lower.
  • Compounds having an activity designated as “AA” provided a compound having >85% control of cucumber powdery mildew; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of cucumber powdery mildew; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of cucumber powdery mildew; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of cucumber powdery mildew; and compounds having an activity designated as “D” provided a compound having ⁇ 25% control of cucumber powdery mildew.
  • Plants Triticum aestivum cv. WinterHawk were grown for 14 days in 2-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained at in a growth chamber at conditions of 24 to 26° C., 16 hour light cycle, 400 uM of light, 60% humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Mycosphaerella graminicola (synthetic Septoria tritici ), plants were kept at conditions of 16 to 20° C., 75% relative humidity, and 200 uM of light to facilitate infection and disease development.
  • test compounds were dissolved in a solution of 5% acetone and 0.01% Tween 20 surfactant. An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted. The amount of the compound applied to the leaves was typically 100, or 25 ppm, but it may vary.
  • the plants were moved to a cooler chamber and inoculated by spraying the spore suspension until all leaf surfaces were wetted.
  • the inoculated plants were then incubated for 3 days in a misting tent covered with a thin shade cloth. After misting for 3 days, they were removed from the mist tent and grown for 16 days before rating.
  • Table 6 lists the results of wheat septoria leaf blotch control at a compound concentration of 25 ppm or lower.
  • Compounds having an activity designated as “AA” provided a compound having >85% control of wheat septoria leaf blotch; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of wheat septoria leaf blotch; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of wheat septoria leaf blotch; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of wheat septoria leaf blotch; and compounds having an activity designated as “D” provided a compound having ⁇ 25% control of wheat septoria leaf blotch.
  • Plants ( Triticum aestivum cv. Samson) were grown until flowing in 4.5-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained at in a growth chamber at conditions of 20 to 21° C., 16 hour light cycle, 400 uM of light, 70% humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Fusarium graminearum , plants were kept at the same conditions to facilitate disease development.
  • test compounds When wheat plants were flowering, the test compounds were dissolved in a solution of 5% acetone and 0.02% Tween 20 surfactant. An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted. The amount of the compound applied to the leaves was typically 100, or 25 ppm, but it may vary.
  • the plants were inoculated by spraying the conidial suspension until the heads were thoroughly wetted.
  • the inoculated plants were then placed for 3 days in a misting tent at 22° C. during the day and 17° C. during the night with 15 hours of light. After misting, they remained in these same growth conditions for further disease development
  • Table 7 lists the results of wheat fusarium head blight control at a compound concentration of 25 ppm or lower.
  • Compounds having an activity designated as “AA” provided a compound having >85% control of wheat fusarium head blight; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of wheat fusarium head blight; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of wheat fusarium head blight; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of wheat fusarium head blight; and compounds having an activity designated as “D” provided a compound having ⁇ 25% control of wheat fusarium head blight.
  • Plants Triticum aestivum cv. Winterhawk were grown for 11 days in 2.5-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained in a growth chamber at conditions of 20 to 21° C., 16 hour light cycle, 400 uM of light, 60% humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Puccinia triticina , plants were kept at conditions of 20 to 20° C. and 80% relative humidity to facilitate infection and disease development.
  • test compounds were dissolved in a solution of 5% acetone and 0.02% Tween 20 surfactant. An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted. The amount of the compound applied to the leaves was typically 25 or 10 ppm, but it may vary.
  • plants were inoculated by spraying the spore suspension on the underside of the leaves until they are wetted. Inoculated plants were then incubated for 24 hours in a misting tent at 20° C. After misting, they were grown at the same conditions as the incubation conditions with exception of having a 85% relative humidity.
  • Table 8 lists the results of wheat leaf rust control at a compound concentration of 10 ppm or lower.
  • Compounds having an activity designated as “AA” provided a compound having ⁇ 85% control of wheat leaf rust; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of wheat leaf rust; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of wheat leaf rust; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of wheat leaf rust; and compounds having an activity designated as “D” provided a compound having ⁇ 25% control of wheat leaf rust.
  • Plants ( Glycine max AG4832) were grown in 2.5-inch square pots containing Fafard germination mix amended with fertilizer. For propagation, plants were maintained in a growth chamber at conditions of 21 to 26° C., 16 hour light cycle, 600 uM of light, 65% humidity, and with sub-irrigation as needed. To maintain the pathogen stocks, plants are inoculated with the pathogen of Phakopsora pachyrhizi and placed in a mist tent for 24 hours. After inoculation with the pathogen, plants were grown at conditions of 20 to 24° C., 12 hour light cycle, 400 uE of light, and 80 to 85% relative humidity to facilitate infection and disease development. At 10 to 28 days after inoculation, spores were collected and stored at 4° C. before use.
  • test compounds were dissolved in a solution of 5% acetone and 0.02% Tween 20 surfactant.
  • An air brush sprayer was used for applying the solution to the plant. Because of plant stature and angle of the leaves, chemistry accumulated mainly on the top of the leaf; leaves were wet but not dripping. The amount of the compound applied to the leaves was typically 25 or 100 ppm, but it may vary.
  • the left lateral leaf from the first or second trifoliate (dependent upon the purpose of the experiment) was removed and placed in a petri dish with moist filter paper and inoculated.
  • Leaflets were inoculated by spraying the spore suspension in a solution of 0.1% water agar on the bottom/abaxial side of the leaflet until they were covered with a fine mist. Typically, approximately 1 ml/leaflet was applied.
  • Percent disease area was evaluated in 14 days later via a software program, and efficacy was calculated based on the control leaves that were treated with the formulation without a test compound.
  • Table 9 lists the results of Asian soybean rust control at a compound concentration of 25 ppm or lower.
  • Compounds having an activity designated as “AA” provided a compound having >85% control of Asian soybean rust; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of Asian soybean rust; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of Asian soybean rust; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of Asian soybean rust; and compounds having an activity designated as “D” provided a compound having ⁇ 25% control of Asian soybean rust.
  • Rhizoctonia solani inoculum was grown on sterile sorghum; and the pathogen of Pythium ultimum inoculum was grown on white millet.
  • Soybean seeds ( Glycine max cv.AG4832) were planted in 2.5-inch square pots containing Berger BM2 germination mix amended with fertilizer (e.g., 14-14-14). Pots with soil were inoculated with the pathogen of R. solani or P. ultimum at time of planting. A hole was pressed into the soil to a depth of about 2 to 3 cm; the inoculum was added to the hole, followed by the seed which was then covered with soil. Two seeds per pot were planted. Plants were grown in a growth chamber at conditions of 20 to 24° C., 14 hour light cycle, 500 uM of light, and 65% humidity. The pots inoculated with P. ultimum were sub-irrigated every day; and the pots inoculated with R. solani were sub-irrigated every other day.
  • Seedling emergence was captured at 7 and 14 days after seeding. At 14 days, the top of the plant was removed and fresh weight was recorded.
  • the plant weights from the seeds treated with test compounds were compared to the ones either from the inoculated non-treated seeds or non-inoculated non-treated seeds.
  • Table 10 lists the results of the R. solani control in soybean upon seed treatment with test compounds
  • Table 11 lists the results of the P. ultimum control in soybean upon seed treatment with test compounds, respectively.
  • the pathogen of Fusarium graminearum was cultured aseptically on whole sorghum using standard mycological techniques and air-dried. The sorghum inoculum was then coarsely ground using a coffee mill before use.
  • Two corn seeds ( Zea mays cv. DKC 36-34 or DKC 63-33) were planted in 2.5-inch square pots containing Berger BM6 15P germination mix amended with fertilizer (e.g., 19-6-12).
  • the soil pots were pre-drenched and two two-inch holes were pressed into the soil.
  • the sorghum inoculums ( 1/16 teaspoon) was added to each hole, followed by one corn seed (treated with or without test compounds).
  • the two seeds were sown in opposite corners of the pot. Plants were grown in a growth chamber at conditions of 20 to 24° C., 16 hour light cycle, 500 uM of light, 65% humidity, and with sub-irrigation twice daily.
  • Seedling emergence and total plant height (cm) were recorded at 7 and 14 days after planting.
  • test compounds e.g., in formulations
  • Tables 12 and 13 list the results of the F. graminearum control in corn upon seed treatment with test compounds.
  • Barley seeds Hordeum vulgare cv. Perry or Conlon were treated with a test compound dissolved in pure acetone, in which the acetone solution (1 mL) was used per 50 seeds in glass jars in a fume hood. The seeds were swirled in the glass jars by hand until no obvious presence of acetone remained and the seeds were mostly dry.
  • Plants were grown for 7 days in 2-inch square pots containing Metromix 200 medium amended with fertilizer.
  • plants were maintained in a growth chamber at conditions of 20 to 21° C., 16 hour light cycle, 400 uM of light, 50% humidity, and with sub-irrigation as needed.
  • plants were kept at conditions of 20 to 22° C., 200 uM of light, 70% humidity to facilitate infection and disease development.
  • embodiment 1 is a composition for agricultural use comprising an effective amount of a fungicidal compound of Formula I:
  • R 1 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, or C 1 -C 4 haloalkoxy;
  • R 2 is heteroaryl, alkyl, cycloalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, oxo, or cyano; or R 2 is —C(O)R 21 , wherein R 21 is hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -C 6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, or cyano;
  • R 3 is —C(O)R 31 , —C(O)N(R 32 R 33 ), or —R 34 SO 2 N(R 32 R 33 ), wherein R 31 is hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -C 6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or 1-heterocycl-1-yl, each of which may be optionally independently substituted with one or more of hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, or cyano; R 32 and R 33 are each independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 3 -C 6 cycloalkyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C 1 -C 4 alkoxy, oxo, or cyano; and R 34 is
  • R 4 is hydrogen or —OR 6 , wherein R 6 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, C 4 -C 10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of an oxygen atom, hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, cyano, —N(R 61 R 62 ), —C(O)N(R 61 R 62 ), or SO 2 R 63 , wherein R 61 and R 62 are each independently hydrogen or C 1 -C 6 alkyl, and R 63 is C 1 -C 6 alkyl;
  • R 4′ is hydrogen or C 1 -C 4 alkyl, which may be optionally substituted with one or more of hydroxyl, C 1 -C 4 alkoxy, or cyano;
  • R 5 and R 5′ are each independently hydrogen or C 1 -C 4 alkyl;
  • R 7 is hydroxyl or C 1 -C 4 alkyl, which may be optionally substituted with one or more of hydroxyl, C 1 -C 4 alkoxy, oxo, or cyano; or
  • R 7 is —OR 10 , wherein R 10 is C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkylmethyl, heterocyclyl, or aryl(C 1 -C 4 )alkyl, each of which may be optionally independently substituted with one or more of hydroxyl, an oxygen atom, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, oxo, or cyano; and
  • R 8 is hydrogen, halogen, or cyano.
  • Embodiment 2 is the composition of embodiment 1 wherein R 1 is C 1 -C 4 alkyl.
  • Embodiment 3 is the composition of embodiment 2 wherein R 1 is methyl.
  • Embodiment 4 is the composition of any one of embodiments 1 to 3 wherein R 2 is —C(O)R 21 , wherein R 21 is C 1 -C 4 alkoxy.
  • Embodiment 5 is the composition of any one of embodiments 1 to 3 wherein R 2 is —CH 2 OH.
  • Embodiment 6 is the composition of any one of embodiments 1 to 3 wherein R 2 is —CH 2 O(C 1 -C 4 )alkyl.
  • Embodiment 7 is the composition of any one of embodiments 1 to 3 wherein R 2 is cyclobutyl.
  • Embodiment 8 is the composition of any one of embodiments 1 to 3 wherein R 2 is unsubstituted heteroaryl.
  • Embodiment 9 is the composition of embodiment 8 wherein R 2 is a 5-membered heteroaryl.
  • Embodiment 10 is the composition of embodiment 9 wherein R 2 is oxazolyl, pyrazolyl, triazolyl, isoxazolyl, or thienyl.
  • Embodiment 11 is the composition of embodiment 10 wherein R 2 is oxazolyl, pyrazolyl, or triazolyl.
  • Embodiment 12 is the composition of embodiment 11 wherein R 2 is 2-oxazolyl.
  • Embodiment 13 is the composition of embodiment 11 wherein R 2 is 1-pyrazolyl.
  • Embodiment 14 is the composition of embodiment 11 wherein R 2 is 2H-1,2,3-triazol-2-yl.
  • Embodiment 15 is the composition of any one of embodiment s 1 to 14 wherein R 3 is —C(O)R 31 , wherein R 31 is hydroxyl, alkoxy, or an optionally independently substituted 1-heterocycl-1-yl.
  • Embodiment 16 is the composition of embodiment 15 wherein R 31 is hydroxyl.
  • Embodiment 17 is the composition of embodiment 15 wherein R 31 is ethoxy or benzoxy.
  • Embodiment 18 is the composition of embodiment 15 wherein R 31 is 2,5-dihydro-1H-pyrrolyl, 1-piperidinyl, 1-pyrrolidinyl, 1-morpholinyl, or 1-azetidinyl, each of which may be optionally independently substituted with hydroxyl, methoxy, or methyl.
  • Embodiment 19 is the composition of any one of embodiments 1 to 14 wherein R 3 is —C(O)N(R 32 R 33 ), wherein R 32 and R 33 are independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 3 -C 6 cycloalkyl.
  • Embodiment 20 is the composition of embodiment 19 wherein R 32 is hydrogen or methyl, and R 33 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, 2-propenyl, or —CH 2 CN.
  • Embodiment 21 is the composition of embodiment 20 wherein R 32 is hydrogen, and R 33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl, 2-propenyl, or —CH 2 CN.
  • Embodiment 22 is the composition of embodiment 20 wherein R 32 is methyl, and R 33 is methyl, isopropyl, or 2-propenyl.
  • Embodiment 23 is the composition of any one of embodiments 1 to 14 wherein R 3 is —R 34 SO 2 N(R 32 R 33 ), wherein R 34 is a bond or C 1 -C 4 alkyl, and R 32 and R 33 are each hydrogen.
  • Embodiment 24 is the composition of any one of embodiments 1 to 14 wherein R 3 is —CH 2 SO 2 NH 2 .
  • Embodiment 25 is the composition of any one of embodiments 1 to 24 wherein R 4 and R 4′ are both hydrogen.
  • Embodiment 26 is the composition of any one of embodiments 1 to 24 wherein R 4 is —OR 6 and R 4′ is hydrogen, wherein R 6 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, C 4 -C 10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, cyano, —N(CH 3 ) 2 , —C(O)NH 2 , or —SO 2 CH 3 .
  • Embodiment 27 is the composition of embodiment 26 wherein R 6 is hydrogen.
  • Embodiment 28 is the composition of embodiment 26 wherein R 6 is C 1 -C 6 alkyl or C 2 -C 6 alkenyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, cyano, —N(CH 3 ) 2 , —C(O)NH 2 , or —SO 2 CH 3 .
  • Embodiment 29 is the composition of embodiment 28 wherein R 6 is ethyl, isopropyl, isobutyl, —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —(CH 2 ) 3 OCH 3 , —CH 2 CH(CH 3 )OH, —CH 2 C(CH 3 ) 2 OH, —CH 2 CH ⁇ CH 2 , —C(O)CH 3 , —C(O)CH 2 OH, —CH 2 CN, —CH 2 CH 2 CN, —CH 2 CH(CH 3 )CN, —CH 2 C(CH 3 ) 2 CN, —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 C(O)NH 2 , or —CH 2 CH 2 SO 2 CH 3 .
  • Embodiment 30 is the composition of embodiment 26 wherein R 6 is C 3 -C 6 cycloalkyl or C 4 -C 10 cycloalkylalkyl, which may be optionally independently substituted with hydroxyl or oxo.
  • Embodiment 31 is the composition of embodiment 30 wherein R 6 is 4-hydroxycyclohexyl, 4-oxycyclohexyl, (4-oxocyclohexyl)methyl, or (4-hydroxycyclohexyl)methyl.
  • Embodiment 32 is the composition of embodiment 26 wherein R 6 is tetrahydro-2H-pyran-4-yl.
  • Embodiment 33 is the composition of any one of embodiments 1 to 24 wherein R 4 is —OH or —OCH 2 CH 2 CN, and R 4′ is methyl, —CH 2 OH, or —CH 2 CH 2 OH.
  • Embodiment 34 is the composition of embodiment 33 wherein R 4 is —OH and R 4 is —CH 2 OH.
  • Embodiment 35 is the composition of embodiment 33 wherein R 4 is —OH and R 4 is —CH 2 CH 2 OH.
  • Embodiment 36 is the composition of embodiment 33 wherein R 4 is —OCH 2 CH 2 CN and R 4′ is methyl.
  • Embodiment 37 is the composition of any one of embodiments 1 to 36 wherein R 5 and R 5′ are independently hydrogen or methyl.
  • Embodiment 38 is the composition of embodiment 37 wherein R 5 and R 5′ are both methyl.
  • Embodiment 39 is the composition of embodiment 37 wherein R 5 is methyl and R 5 is hydrogen.
  • Embodiment 40 is the composition of embodiment 37 wherein R 5 and R 5′ are both hydrogen.
  • Embodiment 41 is the composition of any one of embodiments 1 to 40 wherein R 7 is hydroxyl.
  • Embodiment 42 is the composition of any one of embodiments 1 to 40 wherein R 7 is C 1 -C 4 alkyl, which may be optionally independently substituted with cyano.
  • Embodiment 43 is the composition of embodiment 42 wherein R 7 is methyl, ethyl, or —(CH 2 ) 3 CN.
  • Embodiment 44 is the composition of any one of embodiments 1 to 40 wherein R 7 is —OR 10 , wherein R 10 is C 1 -C 4 alkyl, heterocyclyl, or benzyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, oxetanyl, or cyano.
  • Embodiment 45 is the composition of embodiment 44 wherein R 10 is methyl, —CH(CH 3 ) 2 , —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —C(O)CH 3 , —CH 2 (oxetan-3-yl), —CH 2 CN, or —CH 2 CH 2 CN.
  • Embodiment 46 is the composition of embodiment 45 wherein R 10 is methyl.
  • Embodiment 47 is the composition of embodiment 44 wherein R 10 is tetrahydro-2H-pyran-4-yl or benzyl.
  • Embodiment 48 is the composition of any one of embodiments 1 to 47 wherein R 8 is hydrogen or fluorine.
  • Embodiment 49 is a composition for agricultural use comprising an effective amount of a fungicidal compound of Formula Ia, or Ib:
  • R 1 is methyl
  • R 2 is oxazolyl, pyrazolyl, triazolyl, cyclobutyl, —CH 2 OH, —CH 2 O(C 1 -C 4 )alkyl, or —C(O)R 21 wherein R 21 is C 1 -C 4 alkoxy;
  • R 3 is —C(O)R 31 , —C(O)N(R 32 R 33 ), or —R 34 SO 2 N(R 32 R 33 ), wherein R 31 is hydroxyl, ethoxy, benzoxy, 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 2,5-dihydro-1H-pyrrol-1-yl, or 3-hydroxyazetidin-1-yl, R 32 is hydrogen or methyl, and R 33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, 2-propenyl, or cyclobutyl; or R 34 is a bond, or C 1 -C 4 alkyl;
  • R 5 and R 5′ are each independently hydrogen or methyl
  • R 6 is hydrogen, C 1 -C 4 alkyl, which may be substituted with one or more of hydroxyl, methoxy, oxo, cyano, or —SO 2 CH 3 ;
  • R 6 is cyclohexyl or cyclohexylmethyl, which may be substituted with one or more of hydroxyl or oxo;
  • R 6 is 2-propenyl; or
  • R 6 is tetrahydropyranyl;
  • R 8 is hydrogen or F
  • R 9 is hydroxyl, methyl, ethyl, or —(CH 2 ) 3 CN;
  • R 10 is methyl or ethyl, each of which may be substituted with one or more of hydroxyl, methyl, methoxy, cyano, phenyl, oxo, or oxetan-3-yl; or R 10 is tetrahydropyranyl.
  • Embodiment 50 is the composition of embodiment 49 wherein R 2 is 1-pyrazolyl, 2H-1,2,3-triazol-2-yl, 2-oxazolyl, or —C(O)OCH 2 CH 3 .
  • Embodiment 51 is the composition of embodiment 50 wherein R 2 is 1-pyrazolyl.
  • Embodiment 52 is the composition of embodiment 50 wherein R 2 is 2H-1,2,3-triazol-2-yl.
  • Embodiment 53 is the composition of embodiment 50 wherein R 2 is 2-oxazolyl.
  • Embodiment 54 is the composition of embodiment 50 wherein R 2 is —C(O)OCH 2 CH 3 .
  • Embodiment 55 is the composition of any one of embodiment 49 to 54 wherein R 3 is —C(O)R 31 , wherein R 31 is 1-pyrrolidinyl or 1-piperidinyl.
  • Embodiment 56 is the composition of embodiment 55 wherein R 3 is —C(O)R 31 , wherein R 31 is 1-pyrrolidinyl.
  • Embodiment 57 is the composition of any one of embodiment 49 to 54 wherein R 3 is —C(O)N(R 32 R 33 ), R 32 is hydrogen or methyl, and R 33 is ethyl, isopropyl, or cyclobutyl.
  • Embodiment 58 is the composition of embodiment 57 wherein R 32 is hydrogen, and R 33 is ethyl.
  • Embodiment 59 is the composition of embodiment 57 wherein R 32 is hydrogen, and R 33 is isopropyl.
  • Embodiment 60 is the composition of embodiment 57 wherein R 32 is methyl, and R 33 is isopropyl.
  • Embodiment 61 is the composition of embodiment 57 wherein R 32 is hydrogen, and R 33 is cyclobutyl.
  • Embodiment 62 is the composition of any one of embodiments 49 to 61 wherein R 5 and R 5′ are each methyl.
  • Embodiment 63 is the composition of any one of embodiments 49 to 61 wherein R 5 is methyl and R 5′ is hydrogen.
  • Embodiment 64 is the composition of any one of embodiments 49 to 63 wherein R 6 is hydrogen, isopropyl, —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —(CH 2 ) 3 OCH 3 , —C(O)CH 3 , —CH 2 CN, —CH 2 CH 2 CN, —CH 2 CH(CH 3 )CN, —CH 2 C(CH 3 ) 2 CN, —CH 2 CH 2 SO 2 CH 3 , or tetrahydro-2H-pyran-4-yl.
  • R 6 is hydrogen, isopropyl, —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —(CH 2 ) 3 OCH 3 , —C(O)CH 3 , —CH 2 CN, —CH 2 CH 2 CN, —CH 2 CH(CH 3 )CN, —CH 2 C(CH 3 ) 2 CN, —CH 2 CH 2 SO 2 CH 3
  • Embodiment 65 is the composition of any one of embodiments 49 to 64 wherein R 8 is hydrogen.
  • Embodiment 66 is the composition of any one of embodiments 49 to 64 wherein R 8 is F.
  • Embodiment 67 is the composition of any one of embodiments 49 to 66 wherein R 9 is ethyl.
  • Embodiment 68 is the composition of any one of embodiments 49 to 66 wherein R 10 is methyl.
  • Embodiment 69 is a composition for agricultural use comprising an effective amount of a fungicidal compound selected from the group consisting of:
  • Embodiment 70 is the composition of any one of embodiments 1 to 69 further comprising a surfactant.
  • Embodiment 71 is the composition of any one of embodiments 1 to 69 further comprising a co-solvent.
  • Embodiment 72 is the composition of any one of embodiments 1 to 69 further comprising a biological control agent, microbial extract, natural product, plant growth activator or plant defense agent or mixtures thereof.
  • Embodiment 73 is the composition of embodiment 72 wherein the biological control agent comprises a bacterium, a fungus, a beneficial nematode, or a virus.
  • Embodiment 74 is the composition of embodiment 73 wherein the biological control agent comprises a bacterium of the genus Actinomycetes, Agrobacterium, Arthrobacter, Alcaligenes, Aureobacterium, Azobacter, Bacillus, Beijerinckia, Bradyrhizobium, Brevibacillus, Burkholderia, Chromobacterium, Clostridium, Clavibacter, Comamonas, Corynebacterium, Curtobacterium, Enterobacter, Flavobacterium, Gluconobacter, Hydrogenophage, Klebsiella, Metarhizium, Methylobacterium, Paenibacillus, Pasteuria, Photorhabdus, Phyllobacterium, Pseudomonas, Rhizobium, Serratia, Sphingobacterium, Stenotrophomonas, Streptomyces, Variovax , or Xenorhabdus.
  • the biological control agent comprises a bacterium of the
  • Embodiment 75 is the composition of embodiment 73 wherein the biological control agent comprises a fungus of the genus Alternaria, Ampelomyces, Aspergillus, Aureobasidium, Beauveria, Colletotrichum, Coniothyrium, Gliocladium, Metarhizium, Muscodor, Paecilomyces, Penicillium, Trichoderma, Typhula, Ulocladium , and Verticillium.
  • the biological control agent comprises a fungus of the genus Alternaria, Ampelomyces, Aspergillus, Aureobasidium, Beauveria, Colletotrichum, Coniothyrium, Gliocladium, Metarhizium, Muscodor, Paecilomyces, Penicillium, Trichoderma, Typhula, Ulocladium , and Verticillium.
  • Embodiment 76 is the composition of embodiment 73 wherein the biological control agent is a plant growth activator or plant defense agent selected from the group consisting of harpin, Reynoutria sachalinensis , jasmonate, lipochitooligosaccharides, salicylic acid, and isoflavones.
  • the biological control agent is a plant growth activator or plant defense agent selected from the group consisting of harpin, Reynoutria sachalinensis , jasmonate, lipochitooligosaccharides, salicylic acid, and isoflavones.
  • Embodiment 77 is the composition of any one of embodiments 1 to 76 further comprising one or more additional pesticides, wherein the additional pesticide comprises a fungicide, an insecticide and a herbicide or a mixture thereof.
  • Embodiment 78 is the composition of embodiment 77 wherein the additional pesticide is a fungicide selected from the group consisting of acibenzolar-S-methyl, azoxystrobin, benalaxyl, benzovindiflupyr, bixafen, boscalid, carbendazim, cyproconazole, dimethomorph, epoxiconazole, fluindapyr, fluopyram, fluoxastrobin, flutianil, flutolanil, fluxapyroxad, fosetyl-A1, ipconazole, isopyrazam, kresoxim-methyl, mefenoxam, metalaxyl, metconazole, myclobutanil, orysastrobin, oxathiapiprolin, penflufen, penthiopyrad, picoxystrobin, propiconazole, prothioconazole, pyraclostrobin, pydiflumetofen,
  • Embodiment 79 is the composition of embodiment 77 wherein the additional pesticide is an insecticide or nematicide selected from the group consisting of abamectin, aldicarb, aldoxycarb, bifenthrin, broflanilide, carbofuran, chlorantraniliprole, clothianidin, cyantraniliprole, cyclaniliprole, cyfluthrin, cyhalothrin, cypermethrin, deltamethrin, dinotefuran, emamectin, ethiprole, fenamiphos, fipronil, flubendiamide, fosthiazate, imidacloprid, ivermectin, lambda-cyhalothrin, milbemectin, 3-phenyl-5-(2-thienyl)-1,2,4-oxadiazole, nitenpyram, oxamyl, permethrin, spine
  • Embodiment 80 is the composition of embodiment 77 wherein the additional pesticide is an herbicide selected from the group consisting of acetochlor, clethodim, dicamba, 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)-1,3,5-triazinane-2,4-dione (trifludimoxazin), ethyl 2-((3-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-(trifluoromethyl)-2,3-dihydropyrimidin-1(6H)-yl)phenoxy)pyridin-2-yl)oxy)acetate, flumioxazin, fomesafen, glyphosate, glufosinate, halauxifen, isoxaflutole, me
  • Embodiment 81 is the composition of embodiment 77 or 80 wherein the additional pesticide is an ACCase inhibitor.
  • Embodiment 82 is the composition of embodiment 81 wherein the additional pesticide is an ACCase inhibitor selected from the group consisting of chlorazifop, clodinafop, clofop, cyhalofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, kuicaoxi, metamifop, propaquizafop, quizalofop, quizalofop-P, trifop, alloxydim, butroxydim, clethodim, cloproxydim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, tralkoxydim, and pinoxaden.
  • an ACCase inhibitor selected from the group consisting of chloraz
  • Embodiment 83 is the composition of embodiment 77 wherein the additional pesticide is selected from the group consisting of fluoxastrobin, fluxapyroxad, ipconazole, mefenoxam, metalaxyl, penflufen, prothioconazole, pyraclostrobin, trifloxystrobin, abamectin, Bacillus firmus , clothianidin, imidacloprid, thiamethoxam and mixtures thereof.
  • the additional pesticide is selected from the group consisting of fluoxastrobin, fluxapyroxad, ipconazole, mefenoxam, metalaxyl, penflufen, prothioconazole, pyraclostrobin, trifloxystrobin, abamectin, Bacillus firmus , clothianidin, imidacloprid, thiamethoxam and mixtures thereof.
  • Embodiment 84 is the composition of embodiment 77 wherein the treatment composition comprises tioxazafen.
  • Embodiment 85 is a treated seed comprising a composition as set forth in any one of embodiments 1 to 84.
  • Embodiment 86 is the seed of embodiment 85, wherein the treated seed comprises: a seed and a coating comprising a composition as set forth in any one of embodiments 1 to 84.
  • Embodiment 87 is the seed of embodiment 86, wherein the coating comprises the fungicidal compound of Formula I, Formula Ia, or a salt thereof in an amount of at least about 0.005 mg/seed, from about 0.005 to about 1 mg/seed, or from about 0.05 to about 0.5 mg/seed.
  • Embodiment 88 is a method of controlling agricultural fungal pathogens, the method comprising administering to a plant, a seed or soil a composition as set forth in any one of embodiments 1 to 84.
  • Embodiment 89 is the method of embodiment 88 wherein the method comprises administering the composition to a seed.
  • Embodiment 90 is a treated seed prepared according to the method of embodiment 89.
  • Embodiment 91 is the method of embodiment 88 wherein the method comprises exogenously administering the composition to a plant.
  • Embodiment 92 is the method of embodiment 91 wherein the composition is applied to the foliage of a plant.
  • Embodiment 93 is the method of embodiment 91 wherein the method comprises applying the composition to the soil surrounding the root zone of a plant.
  • Embodiment 94 is the method of embodiment 91 wherein the composition is applied directly to the base of the plant or to the soil immediately adjacent to the plant.
  • Embodiment 95 is the method of embodiment 93 or 94 wherein the composition is applied such that it drains through the soil to the root area of the plant.
  • Embodiment 96 is the method of any one of embodiments 91 to 95 wherein the composition is applied using a sprayer, a mechanical sprinkler, a drench application, drip irrigation technique, or tilled into the soil or applied in furrow.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Ecology (AREA)
  • Forests & Forestry (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Soil Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)

Abstract

Provided herein are compounds that exhibit activity as fungicides and are useful, for example, in methods for the control of fungal pathogens in plants and can be applied to said plants in a variety of ways.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62/259,935, filed on Nov. 25, 2015, the entirety of which is incorporated herein by reference.
    • FIELD
  • Provided herein are compounds that exhibit activity as pesticides and are useful, for example, in methods for the control of fungal pathogens and diseases caused by fungal pathogens in plants.
    • BACKGROUND
  • Acetyl-CoA carboxylase (“ACCase”) is an essential catalyst for the rate-limiting step of fatty acid biosynthesis in both eukaryotes and prokaryotes. Phytopathogenic fungi can infect crop plants either in the field or after harvesting, resulting in considerable economic losses to farmers and producers worldwide. In addition to the agricultural impact, when food and feed contaminated with fungi or the toxins they produce are ingested by humans or livestock, a number of debilitating diseases or death can occur. Approximately 10,000 species of fungi are known to damage crops and affect quality and yield. Crop rotation, breeding of resistant cultivars, the application of agrochemicals and combinations of these strategies is commonly employed to stem the spread of fungal pathogens and the diseases they cause. Additional chemistry and methods of using such as a modulator for ACCase or to control fungi are important for, among other things, protection in agriculture.
  • For example, the rapid onset of resistance to chemical fungicides has often lowered the efficacy of some chemical fungicides. This threat, as well as emergence and spread of additional fungal diseases, accentuates the need for new means of fungal control.
    • SUMMARY
  • A compound is provided, the compound having Formula I:
  • Figure US20170166585A1-20170615-C00001
  • or a salt thereof, wherein:
  • R1 is hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy;
  • R2 is heteroaryl, alkyl, cycloalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, oxo, or cyano; or R2 is —C(O)R21, wherein R21 is hydroxyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano;
  • R3 is —C(O)R31, —C(O)N(R32R33), or —R34SO2N(R32R33), wherein R31 is hydroxyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or 1-heterocycl-1-yl, each of which may be optionally independently substituted with one or more of hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano; R32 and R33 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C3-C6 cycloalkyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C1-C4 alkoxy, oxo, or cyano; and R34 is a bond, C1-C4 alkyl, C1-C4 haloalkyl, or C2-C4 alkenyl;
  • R4 is hydrogen or —OR6, wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of an oxygen atom, hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, cyano, —N(R61R62), —C(O)N(R61R62), or —SO2R63, wherein R61 and R62 are each independently hydrogen or C1-C6 alkyl, and R63 is C1-C6 alkyl;
  • R4′ is hydrogen or C1-C4 alkyl, which may be optionally substituted with one or more of hydroxyl, C1-C4 alkoxy, or cyano;
  • R5 and R5′ are each independently hydrogen or C1-C4 alkyl;
  • R7 is hydroxyl or C1-C4 alkyl, which may be optionally substituted with one or more of hydroxyl, C1-C4 alkoxy, oxo, or cyano; or R7 is —OR10, wherein R10 is C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkylmethyl, heterocyclyl, or aryl(C1-C4)alkyl, each of which may be optionally independently substituted with one or more of hydroxyl, an oxygen atom, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano; and
  • R8 is hydrogen, halogen, or cyano.
  • A compound is provided, the compound having Formula Ia, or Ib:
  • Figure US20170166585A1-20170615-C00002
  • or a salt thereof, wherein:
  • R1 is methyl;
  • R2 is oxazolyl, pyrazolyl, triazolyl, cyclobutyl, —CH2OH, —CH2O(C1-C4)alkyl, or —C(O)R21 wherein R21 is C1-C4 alkoxy;
  • R3 is —C(O)R31, —C(O)N(R32R33), or R34SO2N(R32R33), wherein R31 is hydroxyl, ethoxy, benzoxy, 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 2,5-dihydro-1H-pyrrol-1-yl, or 3-hydroxyazetidin-1-yl, R32 is hydrogen or methyl, and R33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, 2-propenyl, or cyclobutyl; or R34 is a bond, or C1-C4 alkyl;
  • R5 and R5′ are each independently hydrogen or methyl;
  • R6 is hydrogen, C1-C4 alkyl, which may be substituted with one or more of hydroxyl, methoxy, oxo, cyano, or —SO2CH3; R6 is cyclohexyl or cyclohexylmethyl, which may be substituted with one or more of hydroxyl or oxo; R6 is 2-propenyl; or R6 is tetrahydropyranyl;
  • R8 is hydrogen or F;
  • R9 is hydroxyl, methyl, ethyl, or —(CH2)3CN; and
  • R10 is methyl or ethyl, each of which may be substituted with one or more of hydroxyl, methyl, methoxy, cyano, phenyl, oxo, or oxetan-3-yl; or R10 is tetrahydropyranyl.
  • A compound is provided, wherein the compound is selected from the group consisting of:
    • (R)-ethyl-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-2,4-di xo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-isopropoxyethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-isopropoxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6-(2H-1,2,3-triazol-2-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione;
    • (R)—N-ethyl-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-2-methylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(3-methoxypropoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)—N-cyclobutyl-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)propanamide;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(3-methoxypropoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropylpropanamide;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropylpropanamide;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropylpropanamide;
    • 3-((R)-1-(5-fluoro-2-methoxyphenyl)-2-(5-methyl-2,4-dioxo-3-((R)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6-(2H-1,2,3-triazol-2-yl)-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)ethoxy)propanenitrile;
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-ethyl-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-ethyl-2-methylpropanamide;
    • (R)-2-(1-(2-(cyanomethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyano-2-methylpropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-((R)-1-(isopropylamino)-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-((R)-1-(isopropyl(methyl)amino)-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(ethylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-3-(1-(ethylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (S)-2-(1-((R)-2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)-2-(1-(2-(2-ethyl-5-fluorophenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-ethyl-1-(2-(cyanomethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-((R)-2-(2-cyano-2-methylpropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropylpropanamide;
    • (R)-ethyl-1-(2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • 2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (S)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)propyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(2-ethyl-5-fluorophenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(2-ethyl-5-fluorophenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-(methylsulfonyl)ethoxy)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-(methylsulfonyl)ethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-ethylpropanamide;
    • (R)—N-ethyl-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-cyclobutyl-2-methylpropanamide;
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-cyclobutylpropanamide;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropylpropanamide;
    • (R)-2-(1-(2-hydroxy-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide; and
    • (R)-1-(5-fluoro-2-methoxyphenyl)-2-(3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)ethyl acetate.
  • A composition is provided, wherein the composition comprises a compound as described herein.
  • A method of controlling fungal pathogens is provided, the method comprising administering to a plant, a seed or soil a composition comprising an effective amount of a compound as described herein.
  • A method for modulating ACCase in a biological organism is provided, the method comprising administering to the biological organism a composition comprising an effective amount of a compound as described herein.
  • A treated seed is provided, wherein the seed comprises a compound or a composition as described herein.
  • Other objects and features will be in part apparent and in part pointed out hereinafter.
    • DETAILED DESCRIPTION
  • Provided herein are compounds that exhibit pesticidal activity, in particular fungicidal activity. The compounds may be used, for example, in the preparation of compositions and in accordance with methods for control of fungal pathogens, as set forth in detail below.
  • For example, provided herein are compounds of Formula I:
  • Figure US20170166585A1-20170615-C00003
  • or a salt thereof, wherein:
  • R1 is hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy;
  • R2 is heteroaryl, alkyl, cycloalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, oxo, or cyano; or R2 is —C(O)R21, wherein R21 is hydroxyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano;
  • R3 is —C(O)R31, —C(O)N(R32R33), or —R34SO2N(R32R33), wherein R31 is hydroxyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or 1-heterocycl-1-yl, each of which may be optionally independently substituted with one or more of hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano; R32 and R33 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C3-C6 cycloalkyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C1-C4 alkoxy, oxo, or cyano; and R34 is a bond, C1-C4 alkyl, C1-C4 haloalkyl, or C2-C4 alkenyl;
  • R4 is hydrogen or —OR6, wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of an oxygen atom, hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, cyano, —N(R61R62), —C(O)N(R61R62), or —SO2R63, wherein R61 and R62 are each independently hydrogen or C1-C6 alkyl, and R63 is C1-C6 alkyl;
  • R4′ is hydrogen or C1-C4 alkyl, which may be optionally substituted with one or more of hydroxyl, C1-C4 alkoxy, or cyano;
  • R5 and R5′ are each independently hydrogen or C1-C4 alkyl;
  • R7 is hydroxyl or C1-C4 alkyl, which may be optionally substituted with one or more of hydroxyl, C1-C4 alkoxy, oxo, or cyano; or R7 is —OR10, wherein R10 is C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkylmethyl, heterocyclyl, or aryl(C1-C4)alkyl, each of which may be optionally independently substituted with one or more of hydroxyl, an oxygen atom, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano; and R8 is hydrogen, halogen, or cyano.
  • In some embodiments, R1 can be C1-C4 alkyl. In some embodiments, for example, R1 is methyl.
  • In some embodiments, R2 can be —C(O)R21, wherein R21 is C1-C4 alkoxy. In some embodiments, R2 is —CH2OH. In some embodiments, R2 is —CH2O(C1-C4)alkyl. In some embodiments, R2 is cyclobutyl. In other embodiments, R2 can be unsubstituted heteroaryl. In some embodiments, R2 can be a 5-membered heteroaryl. For example, R2 can be oxazolyl, pyrazolyl, triazolyl, isoxazolyl, or thienyl. In some embodiments, for example, R2 is selected from the group consisting of oxazolyl, pyrazolyl, and triazolyl. In some embodiments, R2 is 2-oxazolyl. In some embodiments, R2 is 1-pyrazolyl. In other embodiments, R2 is 2H-1,2,3-triazol-2-yl.
  • In some embodiments, R3 can be —C(O)R31, wherein R31 is hydroxyl, alkoxy, or an optionally independently substituted 1-heterocycl-1-yl. For example, in some embodiments R31 can be hydroxyl or alkoxy (e.g., ethoxy or benzoxy). In other embodiments, R31 can be 2,5-dihydro-1H-pyrrolyl, 1-piperidinyl, 1-pyrrolidinyl, 1-morpholinyl, or 1-azetidinyl, each of which may be optionally independently substituted with hydroxyl, methoxy, methyl, or cyano. In other embodiments, R3 is —C(O)N(R32R33), wherein R32 and R33 are independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, and C3-C6 cycloalkyl. In some embodiments, R3 is —C(O)N(R32R33), wherein R32 is hydrogen or methyl, and R33 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, 2-propenyl, or —CH2CN. In some embodiments, R3 is —C(O)NHR33, wherein R33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl, 2-propenyl, or —CH2CN. In other embodiments, R3 is —C(O)N(CH3)(R33), wherein R33 is methyl, isopropyl, or 2-propenyl. In some embodiments, R3 is —C(O)NH2. In other embodiments, R3 is —C(O)N(CH3)2. In other embodiments, R3 can be —R34SO2NH2 wherein R34 is a bond or C1-C4 alkyl. In some embodiments, R3 is —CH2SO2NH2. In other embodiments, R3 is —SO2NH2.
  • In some embodiments, R4 and R4′ are both hydrogen. In some embodiments, R4 is —OR6 and R4′ is hydrogen, wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, cyano, —N(CH3)2, —C(O)NH2, or —SO2CH3. In some embodiments, R6 is hydrogen. In some embodiments, R6 can be C1-C6 alkyl or C2-C6 alkenyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, cyano, —N(CH3)2, —C(O)NH2, or —SO2CH3. For example, R6 can be ethyl, isopropyl, isobutyl, —CH2CH2OH, —CH2CH2OCH3, —(CH2)3OCH3, —CH2CH(CH3)OH, CH2C(CH3)2OH, —CH2CH═CH2, —C(O)CH3, —C(O)CH2OH, —CH2CN, —CH2CH2CN, —CH2CH(CH3)CN, —CH2C(CH3)2CN, —CH2CH2N(CH3)2, —CH2CH2C(O)NH2, or —CH2CH2SO2CH3. In some embodiments, R6 is C3-C6 cycloalkyl or C4-C10 cycloalkylalkyl, which may be optionally independently substituted with hydroxyl or oxo. For example, R6 can comprise an optionally substituted cyclohexyl moiety (e.g., R6 can be 4-hydroxycyclohexyl, 4-oxycyclohexyl, (4-oxocyclohexyl)methyl, or (4-hydroxycyclohexyl)methyl). In other embodiments, R6 is heterocyclyl (e.g., tetrahydropyranyl). For example, R6 can be tetrahydro-2H-pyran-4-yl. In other embodiments, R4 is hydroxyl or —OCH2CH2CN; and R4 is methyl, —CH2OH, or —CH2CH2OH. For example, R4 is —OH and R4′ is —CH2OH; R4 is —OH and R4 is —CH2CH2OH; or R4 is —OCH2CH2CN and R4 is methyl.
  • R5 and R5′ can be independently selected from the group consisting of hydrogen and methyl. In some embodiments, R5 and R5′ are both methyl. In some embodiments, R5 and R5′ are both hydrogen. In other embodiments, R5 is methyl and R5′ is hydrogen.
  • In some embodiments, R7 is hydroxyl. In some embodiments, R7 is C1-C4 alkyl, which may be optionally substituted with cyano. For example, R7 is methyl, ethyl, or —(CH2)3CN. In other embodiments, R7 is —OR10, wherein R10 is C1-C4 alkyl, heterocyclyl, or benzyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, oxetanyl, and cyano. For example, R10 can be selected from the group consisting of methyl, —CH(CH3)2, —CH2CH2OH, —CH2CH2OCH3, —C(O)CH3, —CH2 (oxetan-3-yl), —CH2CN, and —CH2CH2CN. In some embodiments, for example, R10 is methyl. In other embodiments, R10 is heterocyclyl (e.g., tetrahydropyranyl). For example, R10 can be tetrahydro-2H-pyran-4-yl. In other embodiments, R10 is benzyl.
  • R8 can be selected from the group consisting of hydrogen and F.
  • The compound of Formula I can be a compound of Formula Ia, or Ib:
  • Figure US20170166585A1-20170615-C00004
  • or a salt thereof, wherein:
  • R1 is methyl;
  • R2 is oxazolyl, pyrazolyl, triazolyl, cyclobutyl, —CH2OH, —CH2O(C1-C4)alkyl, or —C(O)R21 wherein R21 is C1-C4 alkoxy;
  • R3 is —C(O)R31, —C(O)N(R32R33), or —R34SO2N(R32R33), wherein R31 is hydroxyl, ethoxy, benzoxy, 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 2,5-dihydro-1H-pyrrol-1-yl, 3-hydroxyazetidin-1-yl, R32 is hydrogen or methyl, and R33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, 2-propenyl, or cyclobutyl; or R34 is a bond or C1-C4 alkyl;
  • R5 and R5′ are each independently hydrogen or methyl;
  • R6 is hydrogen, C1-C4 alkyl, which may be substituted with one or more of hydroxyl, methoxy, oxo, cyano, or —SO2CH3; R6 is cyclohexyl or cyclohexylmethyl, which may be substituted with one or more of hydroxyl or oxo; R6 is 2-propenyl; or R6 is tetrahydropyranyl;
  • R8 is hydrogen or F;
  • R9 is hydroxyl, methyl, ethyl, or —(CH2)3CN; and
  • R10 is methyl or ethyl, each of which may be substituted with one or more of hydroxyl, methyl, methoxy, cyano, phenyl, oxo, or oxetan-3-yl; or R10 is tetrahydropyranyl.
  • The compound of Formula I can be a compound of Formula Ia or a salt thereof. R2 can be 1-pyrazolyl, 2H-1,2,3-triazol-2-yl, 2-oxazolyl, or —C(O)OCH2CH3. In some embodiments, R2 is 1-pyrazolyl, corresponding to a compound of Formula Ia-i:
  • Figure US20170166585A1-20170615-C00005
  • or a salt thereof, wherein each of R1, R3, R5, R5′, R6, R8, and R10 is as defined above and described in embodiments herein, both singly and in combination. In some embodiments, R2 is 2H-1,2,3-triazol-2-yl, corresponding to a compound of Formula Ia-ii:
  • Figure US20170166585A1-20170615-C00006
  • or a salt thereof, wherein each of R1, R3, R5, R5′, R6, R8, and R10 is as defined above and described in embodiments herein, both singly and in combination. In some embodiments, R2 is 2-oxazolyl, corresponding to a compound of Formula Ia-iii:
  • Figure US20170166585A1-20170615-C00007
  • or a salt thereof, wherein each of R1, R3, R5, R5′, R6, R8, and R10 is as defined above and described in embodiments herein, both singly and in combination. In other embodiments, R2 is —C(O)OCH2CH3, corresponding to a compound of Formula Ia-iv:
  • Figure US20170166585A1-20170615-C00008
  • or a salt thereof, wherein each of R1, R3, R5, R5′, R6, R8, and R10 is as defined above and described in embodiments herein, both singly and in combination.
  • The compound of Formula I can be a compound of Formula Ib or a salt thereof. R2 can be 1-pyrazolyl, 2H-1,2,3-triazol-2-yl, 2-oxazolyl, or —C(O)OCH2CH3. In some embodiments, R2 is 2H-1,2,3-triazol-2-yl, corresponding to a compound of Formula Ib-ii:
  • Figure US20170166585A1-20170615-C00009
  • or a salt thereof, wherein each of R1, R3, R5, R5′, R6, R8, and R9 is as defined above and described in embodiments herein, both singly and in combination.
  • In some embodiments, R3 can be —C(O)N(R32R33), wherein R32 is hydrogen or methyl, and R33 is ethyl, isopropyl, or cyclobutyl. In some embodiments, R3 is —C(O)NHCH2CH3.
  • In some embodiments, R3 is —C(O)NHC(CH3)2. In some embodiments, R3 is —C(O)N(CH3)C(CH3)2.
  • In some embodiments, R3 is —C(O)NH(cyclobutyl).
  • In other embodiments, R3 can be —C(O)R31 wherein R31 is 1-pyrrolidinyl or 1-piperidinyl. In some embodiments, R3 is —C(O)R31 wherein R31 is 1-pyrrolidinyl.
  • In some embodiments, R5 and R5′ are both methyl. In some embodiments, R5 and R5′ are both hydrogen. In other embodiments, R5 is methyl and R5′ is hydrogen.
  • In some embodiments, R6 can be hydrogen, isopropyl, —CH2CH2OH, —CH2CH2OCH3, —(CH2)3OCH3, —C(O)CH3, —CH2CN, —CH2CH2CN, —CH2CH(CH3)CN, —CH2C(CH3)2CN, —CH2CH2SO2CH3, or tetrahydro-2H-pyran-4-yl. In some embodiments, R6 is hydrogen. In some embodiments, R6 is isopropyl. In some embodiments, R6 is —CH2CH2OH. In some embodiments, R6 is —CH2CH2OCH3. In some embodiments, R6 is —(CH2)3OCH3. In some embodiments, R6 is —C(O)CH3. In some embodiments, R6 is —CH2CN. In some embodiments, R6 is —CH2CH2CN. In some embodiments, R6 is —CH2CH(CH3)CN. In some embodiments, R6 is —CH2C(CH3)2CN. In some embodiments, R6 is —CH2CH(CH3)CN. In some embodiments, R6 is —CH2CH2SO2CH3. In some embodiments, R6 is tetrahydro-2H-pyran-4-yl.
  • In some embodiments, R8 is hydrogen. In other embodiments, R8 is F.
  • In some embodiments, R9 is ethyl.
  • In some embodiments, R10 is methyl.
  • As used herein, the term “halo” or “halogen” refers to any radical of fluorine, chlorine, bromine or iodine.
  • The term “alkyl” as employed herein, by itself or as part of another group, refers to both straight and branched chain radicals of up to ten carbons. Non-limiting examples of C1-C10 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, 3-pentyl, hexyl and octyl groups. For example, the term “alkyl” as used herein, by itself or as part of another group, can refer to a straight or branched chain radical comprising from one to six carbon atoms.
  • The term “alkenyl” as employed herein, by itself or as part of another group, refers to both straight and branched chain radicals of up to ten carbons, and which comprise at least one carbon-carbon double bond.
  • The term “hydroxyalkyl” as employed herein, refers to both straight and branched chain alkyl radicals having a hydroxyl substituent. The hydroxyl substituent can be bound to any carbon of the alkyl chain. Non-limiting examples include —CH2OH, —CH2CH2OH, —CH2CH(OH)CH3 and —CH2CH(OH)CH2CH3. For example, the term “hydroxyalkyl” as employed herein can refer to a straight or branched chain radical comprising from one to four carbon atoms and having one or more hydroxyl substituents.
  • The term “haloalkyl” as employed herein, by itself or as part of another group, refers to an alkyl group, as defined herein, substituted with at least one halogen. Non-limiting examples of haloalkyl groups include trifluromethyl and 2,2,2-trifluoroethyl.
  • The term “alkoxy” as employed herein, by itself or as part of another group, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
  • The term “haloalkoxy” as employed herein, by itself or as part of another group, refers to an alkoxy group as defined herein, wherein the alkyl moiety of the alkoxy group is further substituted with at least one halogen. Non-limiting example of haloalkoxy groups include trifluoromethoxy, and 2,2-dichloroethoxy.
  • The term “cycloalkyl” as used herein refers to an alkyl group comprising a closed ring comprising from 3 to 8 carbon atoms. Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, (cyclohexyl)methyl, and (cyclohexyl)ethyl.
  • The term “cycloalkylalkyl” as used herein refers to an alkyl group, as defined herein, substituted with a cycloalkyl group, as defined herein. Non-limiting examples of cycloalkylalkyl groups include (cyclobutyl)methyl, (cyclohexyl)methyl, and (cyclohexyl)ethyl.
  • As used herein, the term “heterocyclyl,” “heterocycloalkyl,” or “heterocycle” refers to a saturated or partially saturated 3 to 7 membered monocyclic, or 7 to 10 membered bicyclic ring system, which consists of carbon atoms and from one to four heteroatoms independently selected from the group consisting of O, N, and S, wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, the nitrogen can be optionally quaternized, and includes any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring, and wherein the heterocyclic ring can be substituted on carbon or on a nitrogen atom if the resulting compound is stable. Non-limiting examples of common saturated or partially saturated heterocyclic groups include azetinyl, oxetanyl, tetrahydrofuranyl, pyranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, isochromanyl, chromanyl, pyrazolidinyl, pyrazolinyl, tetronoyl and tetramoyl groups.
  • The term “aryl” as employed herein by itself or as part of another group refers to monocyclic, bicyclic or tricyclic aromatic groups containing from 6 to 14 carbons in the ring. Common aryl groups include C6-14 aryl, typically C6-10 aryl. Typical C6-14 aryl groups include phenyl, naphthyl, phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl groups.
  • The term “heteroaryl” as employed herein refers to groups having 5 to 14 ring atoms; 6, 10 or 14 π electrons shared in a cyclic array; and containing carbon atoms and 1, 2 or 3 oxygen, nitrogen or sulfur heteroatoms. Example heteroaryl groups include thienyl (thiophenyl), benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl (furanyl), pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthiinyl, pyrrolyl, including without limitation 2H-pyrrolyl, imidazolyl, pyrazolyl, pyridyl (pyridinyl), including without limitation 2-pyridyl, 3-pyridyl, and 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalzinyl, naphthyridinyl, quinozalinyl, cinnolinyl, pteridinyl, carbazolyl, β-carbolinyl, phenanthridinyl, acrindinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl, phenoxazinyl, 1,4-dihydroquinoxaline-2,3-dione, 7-aminoisocoumarin, pyrido[1,2-a]pyrimidin-4-one, pyrazolo[1,5-a]pyrimidinyl, including without limitation pyrazolo[1,5-a]pyrimidin-3-yl, 1,2-benzoisoxazol-3-yl, benzimidazolyl, 2-oxindolyl and 2-oxobenzimidazolyl. Where the heteroaryl group contains a nitrogen atom in a ring, such nitrogen atom may be in the form of an N-oxide, e.g., a pyridyl N-oxide, pyrazinyl N-oxide and pyrimidinyl N-oxide.
  • The term “oxo” as employed herein refers to an oxygen atom joined by a double bond to a carbon atom. For example, an oxo substituent can be bound to any carbon of an alkyl chain. Non-limiting examples include —CH2C(O)H, —C(O)CH3, —CH2C(O)CH3, —CH2CH2C(O)CH3, and —CH2C(O)CH2CH3.
  • Non-limiting examples of species encompassed by the present disclosure are disclosed in Table 1.
  • TABLE 1
    Compounds of Formula I
    Cmpd
    No. R Groups Substituent Compound Structure
    I-001 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00010
    I-002 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-piperidinyl) OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00011
    I-003 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-pyrrolidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00012
    I-004 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-piperidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00013
    I-005 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-pyrrolidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00014
    I-006 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-piperidinyl) OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00015
    I-007 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-pyrrolidinyl) OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00016
    I-008 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00017
    I-009 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00018
    I-010 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH2CH3 O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00019
    I-011 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00020
    I-012 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH(CH3)2 O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00021
    I-013 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH(CH3)2 O-4-oxocyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00022
    I-014 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00023
    I-015 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00024
    I-016 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-piperidinyl) OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00025
    I-017 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-pyrrolidinyl) OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00026
    I-018 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00027
    I-019 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00028
    I-020 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00029
    I-021 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-morpholinyl) OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00030
    I-022 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-piperidinyl) OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00031
    I-023 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00032
    I-024 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH(CH3)2 O-4-oxocyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00033
    I-025 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 O CH2CH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00034
    I-026 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 O CH2CH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00035
    I-027 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-piperidinyl) O CH2CH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00036
    I-028 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) O CH2CH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00037
    I-029 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00038
    I-030 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00039
    I-031 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00040
    I-032 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00041
    I-033 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-piperidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00042
    I-034 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00043
    I-035 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00044
    I-036 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-piperidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00045
    I-037 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00046
    I-038 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHC4H7 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00047
    I-039 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHC6H11 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00048
    I-040 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00049
    I-041 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00050
    I-042 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHC4H7 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00051
    I-043 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHC6H11 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00052
    I-044 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00053
    I-045 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00054
    I-046 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00055
    I-047 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-piperidinyl) OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00056
    I-048 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 O-4-oxocyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00057
    I-049 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00058
    I-050 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 O-4-oxocyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00059
    I-051 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) O-4-oxocyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00060
    I-052 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-piperidinyl) O-4-oxocyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00061
    I-053 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH2CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00062
    I-054 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00063
    I-055 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00064
    I-056 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH(CH3)2 H CH3, H CH3 F
    Figure US20170166585A1-20170615-C00065
    I-057 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH(CH3)2 H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00066
    I-058 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH(CH3)2 H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00067
    I-059 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH(CH3)2 H H, H OCH3 F
    Figure US20170166585A1-20170615-C00068
    I-060 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH(CH3)2 H H, H CH3 F
    Figure US20170166585A1-20170615-C00069
    I-061 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH(CH3)2 H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00070
    I-062 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH(CH3)2 H CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00071
    I-063 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH(CH3)2 H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00072
    I-064 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00073
    I-065 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH(R—CH3)OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00074
    I-066 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH(S—CH3)OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00075
    I-067 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(2,5-dihydro-1H-pyrrol-1-yl) OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00076
    I-068 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH2CH2OCH3 F
    Figure US20170166585A1-20170615-C00077
    I-069 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH2CH(CH2)2O F
    Figure US20170166585A1-20170615-C00078
    I-070 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH2CN F
    Figure US20170166585A1-20170615-C00079
    I-071 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH2CH2OH F
    Figure US20170166585A1-20170615-C00080
    I-072 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2C(CH3)2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00081
    I-073 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2C(CH3)2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00082
    I-074 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00083
    I-075 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(2,5-dihydro-1H-pyrrol-1-yl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00084
    I-076 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH2CH2OCH3 F
    Figure US20170166585A1-20170615-C00085
    I-077 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH═CH2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00086
    I-078 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHC3H5 OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00087
    I-079 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH CH2CH═CH2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00088
    I-080 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH2CH═CH2)(CH3) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00089
    I-081 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(2,5-dihydro-1H-pyrrol-1-yl) OCH2CH(R—CH3)OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00090
    I-082 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OCH3 H CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00091
    I-083 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00092
    I-084 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH(CH3)2 OCH2CH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00093
    I-085 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)OCH2CH3 OCH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00094
    I-086 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OCH3 H H, H OCH3 F
    Figure US20170166585A1-20170615-C00095
    I-087 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OH H H, H OCH3 F
    Figure US20170166585A1-20170615-C00096
    I-088 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2OH H H, H OCH3 F
    Figure US20170166585A1-20170615-C00097
    I-089 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH3)CH(CH3)2 OCH2CH2OH H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00098
    I-090 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH3)CH(CH3)2 OCH2CH2OH H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00099
    I-091 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHC4H7 OCH2CH2OH H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00100
    I-092 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHC4H7 OCH2CH2OH H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00101
    I-093 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CH2OCH3 H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00102
    I-094 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CH2OCH3 H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00103
    I-095 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00104
    I-096 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OH H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00105
    I-097 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OH H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00106
    I-098 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHC4H7 OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00107
    I-099 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHC4H7 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00108
    I-100 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NH2 O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00109
    I-101 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NH2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00110
    I-102 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00111
    I-103 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NH2 O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00112
    I-104 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NH2 O-cis-4-hydroxycyclohexylmethyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00113
    I-105 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH2CH3 O-4-oxocyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00114
    I-106 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-piperidinyl) O-4-oxocyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00115
    I-107 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)O-benzyl O-4-oxocyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00116
    I-108 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH2CH3 OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00117
    I-109 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-morpholinyl) OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00118
    I-110 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-piperidinyl) O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00119
    I-111 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-pyrrolidinyl) O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00120
    I-112 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-pyrrolidinyl) O-4-oxocyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00121
    I-113 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH2 OCH(CH3)2 H CH3, CH3 CH3 F
    Figure US20170166585A1-20170615-C00122
    I-114 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(3-hydroxyazetidin-1-yl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00123
    I-115 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00124
    I-116 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00125
    I-117 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-piperidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00126
    I-118 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00127
    I-119 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 O CH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00128
    I-120 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00129
    I-121 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pipieridinyl) OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00130
    I-122 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) O-4-oxocyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00131
    I-123 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00132
    I-124 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH2 O-4-oxocyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00133
    I-125 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00134
    I-126 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00135
    I-127 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH(CH3)2 H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00136
    I-128 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH(CH3)2 H H, H OCH3 F
    Figure US20170166585A1-20170615-C00137
    I-129 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00138
    I-130 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00139
    I-131 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH3)2 OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00140
    I-132 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH3 OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00141
    I-133 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH(S—CH3)OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00142
    I-134 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH(R—CH3)OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00143
    I-135 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH2CH(R—CH3)OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00144
    I-136 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH(S—CH3)OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00145
    I-137 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2C(CH3)2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00146
    I-138 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH2C(CH3)2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00147
    I-139 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2OCH3 H CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00148
    I-140 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2OCH3 H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00149
    I-141 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2OCH3 H H, H OCH3 F
    Figure US20170166585A1-20170615-C00150
    I-142 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2C(O)NH2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00151
    I-143 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-morpholinyl) OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00152
    I-144 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH2CH3 OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00153
    I-145 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH32-oxazolyl C(O)NH2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00154
    I-146 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NH2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00155
    I-147 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C4H7 C(O)NH2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00156
    I-148 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl CH2SO2NH2 O-tetrahydro-2H-pyran-4-yl H H, H OCH3 F
    Figure US20170166585A1-20170615-C00157
    I-149 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NH2 O(4-oxocyclohexyl)methyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00158
    I-150 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NH2 O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00159
    I-151 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-morpholinyl) OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00160
    I-152 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)(1-morpholinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00161
    I-153 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)OH OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00162
    I-154 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NH2 O-4-oxocyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00163
    I-155 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NH2 OCH(CH3)2 H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00164
    I-156 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(3-hydroxyazetidin-1-yl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00165
    I-157 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00166
    I-158 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)OH O-4-oxocyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00167
    I-159 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00168
    I-160 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CN OCH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00169
    I-161 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH2CH(S—CH3)OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00170
    I-162 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(2,5-dihydro-1H-pyrrol-1-yl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00171
    I-163 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00172
    I-164 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00173
    I-165 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH2 OCH2CH(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00174
    I-166 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-piperidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00175
    I-167 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH(R—CH3)OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00176
    I-168 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-piperidinyl) O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00177
    I-169 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2-oxazolyl C(O)NHCH2CH3 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00178
    I-170 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NH2 O-4-oxocyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00179
    I-171 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OCH3 H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00180
    I-172 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OCH3 H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00181
    I-173 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2N(CH3)2 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00182
    I-174 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NH2 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00183
    I-175 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH2CH3 O-tetrahydro-2H-pyran-4-yl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00184
    I-176 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NH2 OCH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00185
    I-177 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00186
    I-178 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-pyrrolidinyl) OCH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00187
    I-179 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-pyrrolidinyl) OCH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00188
    I-180 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NH2 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00189
    I-181 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00190
    I-182 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-pyrrolidinyl) OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00191
    I-183 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NH2 OCH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00192
    I-184 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00193
    I-185 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00194
    I-186 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00195
    I-187 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00196
    I-188 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH3)CH(CH3)2 OH H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00197
    I-189 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH3)CH(CH3)2 OH H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00198
    I-190 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NH2 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00199
    I-191 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00200
    I-192 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00201
    I-193 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00202
    I-194 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00203
    I-195 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00204
    I-196 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00205
    I-197 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00206
    I-198 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00207
    I-199 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2- C(O)NH2 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00208
    I-200 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH2 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00209
    I-201 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00210
    I-202 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00211
    I-203 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH2CH2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00212
    I-204 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH3)CH(CH3)2 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00213
    I-205 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH3)CH(CH3)2 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00214
    I-206 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00215
    I-207 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH3 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00216
    I-208 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 OCH2CH2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00217
    I-209 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH3 OCH2CH2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00218
    I-210 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00219
    I-211 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH(S—CH3)CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00220
    I-212 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-y C(O)NHCH(CH3)2 OCH2CH(R—CH3)CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00221
    I-213 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2C(CH3)2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00222
    I-214 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00223
    I-215 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OH H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00224
    I-218 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrroldiinyl) OH H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00225
    I-219 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00226
    I-220 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00227
    I-221 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH2 OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00228
    I-222 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrrolidinyl) OH H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00229
    I-224 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-pyrrolidinyl) OH H CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00230
    I-225 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-pyrrolidinyl) OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00231
    I-226 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)(1-pyrrolidinyl) OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00232
    I-227 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NH2 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00233
    I-228 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NH2 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00234
    I-229 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)N(CH3)CH(CH3)2 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00235
    I-230 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)N(CH3)CH(CH3)2 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00236
    I-231 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH2CH3 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00237
    I-232 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH2CH3 OCH2CH2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00238
    I-233 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00239
    I-234 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH2CH3 OCH2CH2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00240
    I-235 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH2CH3 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00241
    I-238 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH3)CH(CH3)2 OCH2CH2CN H R—CH3, H OCH3 H
    Figure US20170166585A1-20170615-C00242
    I-239 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)N(CH3)CH(CH3)2 OCH2CH2CN H S—CH3, H OCH3 H
    Figure US20170166585A1-20170615-C00243
    I-242 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)N(CH3)CH(CH3)2 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00244
    I-243 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)N(CH3)CH(CH3)2 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00245
    I-244 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)N(CH3)CH(CH3)2 OCH2CH2OH H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00246
    I-245 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OH H CH3, CH3 CH3 F
    Figure US20170166585A1-20170615-C00247
    I-246 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OH H CH3, CH3 CH2CH3 F
    Figure US20170166585A1-20170615-C00248
    I-247 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OCH3 H CH3, CH3 CH2CH3 F
    Figure US20170166585A1-20170615-C00249
    I-248 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OCH3 H CH3, CH3 CH3 F
    Figure US20170166585A1-20170615-C00250
    I-249 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)(1-pyrroldiinyl) OCH2CH2OCH3 H CH3, CH3 CH3 F
    Figure US20170166585A1-20170615-C00251
    I-250 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)N(CH3)CH(CH3)2 OCH2CH2OH H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00252
    I-251 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00253
    I-253 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2C(CH3)2CN H S—CH3, H CH3 F
    Figure US20170166585A1-20170615-C00254
    I-254 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2C(CH3)2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00255
    I-255 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH2 OCH2C(CH3)2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00256
    I-256 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NH2 OCH2C(CH3)2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00257
    I-257 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00258
    I-258 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH(S—CH3)CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00259
    I-259 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH(R—CH3)CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00260
    I-262 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH(S—CH3)CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00261
    I-263 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH(R—CH3)CN H CH3, CH3 CH3 F
    Figure US20170166585A1-20170615-C00262
    I-264 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00263
    I-265 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00264
    I-266 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2C(O)NHOH H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00265
    I-267 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHC4H7 OCH(CH3)2 H CH3, CH3 OCH2CN F
    Figure US20170166585A1-20170615-C00266
    I-268 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 O-cis-4-hydroxycyclohexyl H CH3, CH3 OCH2CN F
    Figure US20170166585A1-20170615-C00267
    I-269 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2C(CH3)2CN H CH3, CH3 OCH3 CN
    Figure US20170166585A1-20170615-C00268
    I-270 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-12,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2C(CH3)2CN H CH3, CH3 OCH3 Br
    Figure US20170166585A1-20170615-C00269
    I-271 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2OH H CH3, CH3 OH F
    Figure US20170166585A1-20170615-C00270
    I-272 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2C(CH3)CN H CH3, CH3 OCH3 Cl
    Figure US20170166585A1-20170615-C00271
    I-273 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CN CH3 CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00272
    I-274 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CN CH3 CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00273
    I-275 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OH CH2CH2OH CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00274
    I-276 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OH CH2CH2OH CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00275
    I-277 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH(CH3)2 H CH3, CH3 CH2CH2CN F
    Figure US20170166585A1-20170615-C00276
    I-278 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2C(CH3)2OH H CH3, CH3 OCH2CN F
    Figure US20170166585A1-20170615-C00277
    I-279 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2C(CH3)2CN H CH3, CH3 CH2CH3 F
    Figure US20170166585A1-20170615-C00278
    I-280 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 O-cis-3-hydroxycyclobutyl H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00279
    I-281 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH(S—CH3)CN H CH3, CH3 CH2CH3 F
    Figure US20170166585A1-20170615-C00280
    I-282 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OH F
    Figure US20170166585A1-20170615-C00281
    I-283 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OH F
    Figure US20170166585A1-20170615-C00282
    I-284 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH(R—CH3)CN H CH3, CH3 CH2CH3 F
    Figure US20170166585A1-20170615-C00283
    I-285 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH2SO2CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00284
    I-286 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH2SO2CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00285
    I-287 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2SO2CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00286
    I-289 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00287
    I-290 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00288
    I-291 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00289
    I-292 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00290
    I-293 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NH-cyclohexyl OCH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00291
    I-294 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00292
    I-295 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH2CH3 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00293
    I-296 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00294
    I-297 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH2CH3 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00295
    I-298 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 H H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00296
    I-299 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHC4H7 OCH2CH2OCH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00297
    I-300 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 CH2OCH2CH3 C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00298
    I-301 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OH H
    Figure US20170166585A1-20170615-C00299
    I-302 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH2CH3 OCH2CH2CN H CH3, CH3 OH F
    Figure US20170166585A1-20170615-C00300
    I-303 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2C(CH3)2CN H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00301
    I-304 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OC(O)CH3 H
    Figure US20170166585A1-20170615-C00302
    I-305 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH2CH3 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00303
    I-306 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH2CH3 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00304
    I-307 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHC4H7 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00305
    I-308 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHC4H7 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00306
    I-309 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OC(O)CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00307
    I-310 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH2OCH3 H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00308
    I-311 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH2OCH3 H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00309
    I-312 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHC4H7 OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00310
    I-313 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH2CH2CN H S—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00311
    I-314 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)(1-pyrrolidinyl) OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00312
    I-315 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OH CH2OH CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00313
    I-316 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OH H CH3, CH3 OCH3 H
    Figure US20170166585A1-20170615-C00314
    I-317 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1H-1,2,4-triazol-1-yl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00315
    I-318 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 OC(O)CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00316
    I-319 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00317
    I-320 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OCH2CH2CH2OH H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00318
    I-321 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH2CH3 OCH2C(CH3)2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00319
    I-322 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OC(O)CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00320
    I-323 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 OC(O)CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00321
    I-324 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH2CH3 OC(O)CH3 H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00322
    I-325 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 CH2OH C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00323
    I-326 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 CH2CH3 F
    Figure US20170166585A1-20170615-C00324
    I-328 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 CH2CH2CH2CN F
    Figure US20170166585A1-20170615-C00325
    I-329 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 H H CH3, CH3 OCH3 F
    Figure US20170166585A1-20170615-C00326
    I-330 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 OCH2CH2CN H R—CH3, H OCH3 F
    Figure US20170166585A1-20170615-C00327
    I-331 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 O-tetrahydro-2H-pyran-4-yl F
    Figure US20170166585A1-20170615-C00328
    I-332 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 O-benzyl F
    Figure US20170166585A1-20170615-C00329
    I-333 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 OCH2CH2CN H R—CH3, H OCH3 H
    Figure US20170166585A1-20170615-C00330
    I-334 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 OC(O)CH3 F
    Figure US20170166585A1-20170615-C00331
    I-335 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,4-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 C(O)OCH2CH3 F
    Figure US20170166585A1-20170615-C00332
    I-336 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 H H CH3, CH3 OCH2CH2CN F
    Figure US20170166585A1-20170615-C00333
    I-337 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1-pyrazolyl C(O)NHCH(CH3)2 H H CH3, CH3 OCH2CH2OH F
    Figure US20170166585A1-20170615-C00334
    I-338 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 O CH(CH3)2 F
    Figure US20170166585A1-20170615-C00335
    I-339 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 C(O)OCH2CH3 C(O)NHCH(CH3)2 H H CH3, CH3 OCH2CH2CN F
    Figure US20170166585A1-20170615-C00336
    I-340 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 2H-1,2,3-triazol-2-yl C(O)NHCH(CH3)2 H H CH3, CH3 OCH2CH2CN F
    Figure US20170166585A1-20170615-C00337
    I-341 R1 R2 R3 R4 R4′ R5, R5′ R7 R8 CH3 1H-1,2,3-triazol-1-yl C(O)NHCH(CH3)2 OCH2CH2CN H CH3, CH3 O CH3 F
    Figure US20170166585A1-20170615-C00338
  • The compound of Formula I can be (R)-ethyl-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-003),
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-isopropoxyethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-014),
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-isopropoxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-020),
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-030),
    • (R)-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6-(2H-1,2,3-triazol-2-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (Formula I-034),
    • (R)—N-ethyl-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-2-methylpropanamide (Formula I-035),
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-064),
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-074),
    • 2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide (Formula I-082),
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(3-methoxypropoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-084),
    • (S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide (Formula I-089),
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide (Formula I-090),
    • (R)—N-cyclobutyl-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)propanamide (Formula I-092),
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(3-methoxypropoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide (Formula I-094),
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-095),
    • (S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide (Formula I-096),
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide (Formula I-171).
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-181),
    • (R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-184),
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-185),
    • (R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-186),
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide (Formula I-188),
    • (S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide (Formula I-189),
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-191),
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-192),
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-193),
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide (Formula I-198),
    • 3-((R)-1-(5-fluoro-2-methoxyphenyl)-2-(5-methyl-2,4-dioxo-3-((R)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6-(2H-1,2,3-triazol-2-yl)-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)ethoxy)propanenitrile (Formula I-202),
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide (Formula I-205),
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-ethyl-2-methylpropanamide (Formula I-206),
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-ethyl-2-methylpropanamide (Formula I-208),
    • (R)-2-(1-(2-(cyanomethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-210),
    • 2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-211),
    • 2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-212),
    • (R)-2-(1-(2-(2-cyano-2-methylpropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-213),
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-((R)-1-(isopropylamino)-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-220),
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-((R)-1-(isopropyl(methyl)amino)-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-229),
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(ethylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-231),
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-233),
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-3-(1-(ethylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-234),
    • (S)-2-(1-((R)-2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide (Formula I-239),
    • (R)-2-(1-(2-(2-ethyl-5-fluorophenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-246),
    • (R)-ethyl-1-(2-(cyanomethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-251),
    • (R)-2-(1-((R)-2-(2-cyano-2-methylpropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide (Formula I-253),
    • (R)-ethyl-1-(2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-258),
    • (R)-ethyl-1-(2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-259),
    • 2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-262),
    • 2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-263),
    • (S)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)propyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-274),
    • 2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(2-ethyl-5-fluorophenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-281),
    • 2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(2-ethyl-5-fluorophenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-284),
    • (R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-(methylsulfonyl)ethoxy)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Formula I-285),
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-(methylsulfonyl)ethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-287),
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-ethylpropanamide (Formula I-289),
    • (R)—N-ethyl-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-2-methylpropanamide (Formula I-292),
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-cyclobutyl-2-methylpropanamide (Formula I-307),
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-cyclobutylpropanamide (Formula I-308),
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide (Formula I-310),
    • (R)-2-(1-(2-hydroxy-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide (Formula I-316),
    • or (R)-1-(5-fluoro-2-methoxyphenyl)-2-(3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)ethyl acetate (Formula I-323).
  • Enantiomers and Diastereoisomers
  • The compounds described herein can be present as a racemic mixture, as a mixture of two enantiomers at different ratios, or as a single enantiomer. In other stance, the compounds described herein can be present as a diastereoisomeric mixture, as a mixture of two or three isomers at different ratios (e.g., S,S-, S,R-, R,R-) or as a single isomer (e.g., R,R-). Compositions that are enriched with respect to one enantiomer or one diastereoisomer, or which comprise substantially a single enantiomer or a single diastereoisomer, may be prepared using any technique known in the art, including chiral separation techniques known in the art (e.g., chiral chromatography or asymmetric synthesis).
    • Compositions
  • In another aspect, the present disclosure is generally related to a composition comprising an effective amount of a compound (e.g., a compound of Formula I) as described herein having pesticidal activity, in particular fungicidal activity, for use in administration to a plant, a seed, or soil to control fungal pathogens.
  • For example, the composition may be an aqueous composition.
  • Generally, compositions described herein can comprise any adjuvants, excipients, or other desirable components known in the art.
  • Non-limiting examples of additional ingredients include surfactants, co-surfactants, permeation enhancers, and co-solvents. For example, the composition may comprise as SPAN surfactants, TWEEN surfactants, TRITON surfactants, MAKON surfactants, IGEPAL surfactants, BRIJ surfactants, MORWET surfactants, PLURONIC surfactants, LANEXOL surfactants, ATLOX surfactants, ATLAS surfactants, SURFYNOL surfactants, TERGITOL surfactants, DOWFAX surfactants, TOXIMUL surfactants, SILWET surfactants, SYLGARD surfactants, BREAK THRU surfactants, PHYTOSAN, SOLUPLUS, cyclodextrans, polypropylene glycol, ethyl lactate, methyl soyate/ethyl lactate co-solvent blends (e.g., STEPOSOL), isopropanol, acetone, ethylene glycol, propylene glycol, n-alkylpyrrolidones (e.g., the AGSOLEX series), a petroleum based-oil (e.g., AROMATIC 200) or a mineral oil (e.g., paraffin oil)).
  • The composition may comprise a surfactant. Non-limiting examples of surfactants include SPAN 20, SPAN 40, SPAN 80, SPAN 85, TWEEN 20, TWEEN 40, TWEEN 80, TWEEN 85, TRITON X 100, MAKON 10, IGEPAL CO 630, BRIJ 35, BRIJ 97, TERGITOL TMN 6, DOWFAX 3B2, PHYSAN and TOXIMUL TA 15.
  • The composition may comprise a co-solvent. Examples of co-solvents that can be used include ethyl lactate, methyl soyate/ethyl lactate co-solvent blends (e.g., STEPOSOL), isopropanol, acetone, 1,2-propanediol, n-alkylpyrrolidones (e.g., the AGSOLEX series), a petroleum based-oil (e.g., AROMATIC 200) or a mineral oil (e.g., paraffin oil)).
  • The composition may be formulated, mixed in a tank, combined on a seed by overcoating, or recommended for use with one or more additional active ingredients on a seed, plant, or soil. The additional active ingredients may be, for example, one or more additional pesticides. The composition may comprise one or more additional pesticides. The pesticide may be, for example, an insecticide, a fungicide, an herbicide, or an additional nematicide.
  • Non-limiting examples of insecticides and nematicides include avermectins, carbamates, benzoylureas, butenolides, diacylhydrazines, diamides, macrocyclic lactones, mitochondrial complex I electron transport inhibitors, neonicotinoids, organophosphates, oxazoles, oxadiazoles, phenylpyrazoles, pyridine azomethine derivatives, pyrethrins, spinosyns, sulfoximines, synthetic pyrethroids, tetronic and tetramic acids. For example, insecticides and nematicides include abamectin, aldicarb, aldoxycarb, bifenthrin, broflanilide, carbofuran, chlorantraniliprole, clothianidin, cyantraniliprole, cyclaniliprole, cyfluthrin, cyhalothrin, cypermethrin, deltamethrin, dinotefuran, emamectin, ethiprole, fenamiphos, fipronil, flubendiamide, fosthiazate, imidacloprid, ivermectin, lambda-cyhalothrin, milbemectin, nitenpyram, oxamyl, permethrin, spinetoram, spinosad, spirodichlofen, spirotetramat, tefluthrin, thiacloprid, tetraniliprole, thiamethoxam, tioxazafen, and thiodicarb.
  • The composition may comprise an insecticide and/or acaricide that inhibits ACCase activity. Non-limiting examples include tetramic acids such as spirotetramat, and tetronic acids including spiromesifen and spirodiclofen.
  • The composition may comprise one or more nematicidal compounds as described in U.S. Pub. Nos. 2009/0048311 A1 or 2011/028320 A1, or WO 2012/030887 A1, the contents of which are herein incorporated by reference.
  • For example, the composition may comprise 3-phenyl-5-(thiophen-2-yl)-1,2,4-oxadiazole.
  • Non-limiting examples of herbicides include ACCase inhibitors, acetanilides, ALS or AHAS modulators or inhibitors, auxin transport inhibitors, carotenoid biosynthesis inhibitors, cell division inhibitors, cellulose inhibitors, EPSPS modulators or inhibitors, fatty acid and lipid biosynthesis inhibitors, glutamine synthetase modulators or inhibitors, 4-hydroxyphenylpyruvate dioxygenase inhibitors (HPPD inhibitors, mitosis inhibitors, protoporphyrinogen oxidase (PPO) modulators or inhibitors, oxidative phosphorylation uncouplers, photosystem I (PS I) and photosystem II (PS II) modulators or inhibitors, and synthetic auxins. Non-limiting examples of herbicides include acetochlor, clethodim, dicamba, 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)-1,3,5-triazinane-2,4-dione (trifludimoxazin), ethyl 2-((3-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-(trifluoromethyl)-2,3-dihydropyrimidin-1(6H)-yl)phenoxy)pyridin-2-yl)oxy)acetate, flumioxazin, fomesafen, glyphosate, glufosinate, halauxifen, isoxaflutole, mesotrione, metolachlor, quizalofop, saflufenacil, sulcotrione, tembotrione, topramezone, and 2,4-D.
  • The composition may comprise an herbicide that inhibits ACCase activity. Non-limiting examples include herbicidal aryloxyphenoxypropionates such as chlorazifop, clodinafop, clofop, cyhalofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, kuicaoxi, metamifop, propaquizafop, quizalofop, quizalofop-P, and trifop, herbicidal cyclohexanediones such as alloxydim, butroxydim, clethodim, cloproxydim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, and tralkoxydim, as well as the herbicide pinoxaden.
  • The herbicides cycloxydim and sethoxydim are known to exhibit moderate antifungal activity alone, and, without being bound to a particular theory, it is believed that the combination of these species with the compounds described herein may enhance fungal control by the additional suppression of ACCase.
  • The composition may comprise one or more additional fungicides. Non-limiting examples of additional fungicides include aromatic hydrocarbons, anilino-pyrimidines, benzamides, benzimidazoles, benzothiadiazole, carbamates, carboxamides, carboxylic acid amides, cinnamic acid amides, cyanoacetmide oximes, demethylation inhibitors, dicarboxamides, 2,6-dinitroanilines, dinitrophenyl crotonates, dithiocarbamates, mandelic acid amides, morpholines, phenylacetamides, phenylamides, phenyl benzamides, phenylpyrroles, phosphonates, phosphorothiolates, phthalimides, pyrazole carboxamides, pyridine carboxamides, pyridine ethyl benzamides, oxathiin carboxamides, quinine outside inhibitors (e.g. strobilurins), quinone inside inhibitors, thiadiazole carboxamides, thiazolidines, thiocarbamates, thiophanates, thiophene carboxamides, triazoles, and triazolinthiones. Particular examples of fungicides include acibenzolar-S-methyl, ametoctradin, amisulbrom, azaconazole, azoxystrobin, benalaxyl, bixafen, boscalid, captan, carbendazim, carboxin, coumoxystrobin, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, difenconazole, dimethomorph, dimoxystrobin, dinocap, enoxastrobin, epoxiconazole, ethaboxam, famoxadone, fenamidone, fenaminstrobin, fenpropimorph, fluazinam, fludioxonil, flufenoxystrobin, fluopicolide, fluopyram, fluoxastrobin, fluopyram, fluoxastrobin, fluquinconazole, flutianil, flutolanil, flutriazole, fluxapyroxad, fosetyl-A1, furametpyr, hexaconazole, ipconazole, iprodione, iprovalicarb, isopyrazam, isotianil, kresoxim-methyl, mancozeb, mandestrobin, mandipropamid, mefenoxam, metalaxyl, metconazole, methasulfocarb, metominostrobin, myclobutanil, orysastrobin, oxycarboxin, penflufen, penthiopyrad, picoxystrobin, probenzole, propiconazole, prothiocarb, prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyrimethanil, sedaxane, silthiofam, simeconazole, tebuconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tolfenpyrad, tolclofos-methyl, triclopyricarb, tridemorph, trifloxystrobin, and triticonazole.
  • The composition may comprise one or more additional fungicides that modulate or inhibit ACCase activity.
  • The composition may also comprise one or more additional active substances, including biological control agents, microbial extracts, natural products, plant growth activators and/or plant defense agents. Non-limiting examples of biological control agents include bacteria, fungi, beneficial nematodes, and viruses.
  • For example, the biological control agent can be a bacterium of the genus Actinomycetes, Agrobacterium, Arthrobacter, Alcaligenes, Aureobacterium, Azobacter, Bacillus, Beijerinckia, Bradyrhizobium, Brevibacillus, Burkholderia, Chromobacterium, Clostridium, Clavibacter, Comamonas, Corynebacterium, Curtobacterium, Enterobacter, Flavobacterium, Gluconobacter, Hydrogenophage, Klebsiella, Metarhizium, Methylobacterium, Paenibacillus, Pasteuria, Photorhabdus, Phyllobacterium, Pseudomonas, Rhizobium, Serratia, Sphingobacterium, Stenotrophomonas, Streptomyces, Variovax, and Xenorhabdus. For example, the bacteria may be Bacillus amyloliquefaciens, Bacillus cereus, Bacillus firmus, Bacillus lichenformis, Bacillus pumilus, Bacillus sphaericus, Bacillus subtilis, Bacillus thuringiensis, Bradyrhizobium japonicum, Chromobacterium subtsugae, Metarhizium anisopliae, Pasteuria nishizawae, Pasteuria penetrans, Pasteuria usage, Pseudomonas fluorescens, and Streptomyces lydicus.
  • The biological control agent can be a fungus of the genus Alternaria, Ampelomyces, Aspergillus, Aureobasidium, Beauveria, Colletotrichum, Coniothyrium, Gliocladium, Metarhizium, Muscodor, Paecilomyces, Penicillium, Trichoderma, Typhula, Ulocladium, and Verticillium. For example, the fungus may be Beauveria bassiana, Coniothyrium minitans, Gliocladium virens, Muscodor albus, Paecilomyces lilacinus, Trichoderma polysporum, or Trichoderma virens.
  • The biological control agents can be plant growth activators or plant defense agents including, but not limited to harpin, Reynoutria sachalinensis, jasmonate, lipochitooligosaccharides, salicylic acid and/or isoflavones.
    • Methods of Use
  • The compounds described herein (e.g., compounds as described herein of Formula I) can be used in accordance with methods of controlling fungal pathogens. For example, compounds as described herein of Formula I are believed to exhibit control of phytopathogenic fungi as described herein.
  • The compounds disclosed herein can be administered to a plant, a seed, or soil in a composition as described herein to control fungal pathogens, including using the compounds as described herein with any adjuvants, excipients, or other desirable components as described herein or known in the art and formulating, mixing, or combining one or more additional active ingredients. The additional active ingredient may be, for example, an additional pesticide. The pesticide may be, for example, an insecticide, a fungicide, an herbicide, or an additional nematicide as described herein or otherwise known in the art.
  • Compounds and compositions described herein can be administered to seeds, plants, or the environment of plants (e.g., soil) wherein the control of phytopathogenic fungi is desired. For example, provided herein is a method of controlling fungal pathogens, the method comprising administering to a plant, a seed or soil a composition comprising an effective amount of a compound as described herein.
  • Non-limiting examples of plants that may be protected from fungal pathogens in accordance with the methods described herein include monocotyledonous crops such as corn, wheat, barley, rye, rice, sorghum, oat; sugarcane and turf; and dicotyledonous crops such as cotton, sugar beet, peanut, potato, sweet potato, yam, sunflower, soybean, alfalfa, canola, grapes, tobacco; vegetables including Solanaceae vegetables such as eggplant, tomato, green pepper and pepper; Cucurbitaceae vegetables such as cucumber, pumpkin, zucchini, watermelon, melon and squash; Brassicaceae vegetables such as radish, turnip, horseradish, Chinese cabbage, cabbage, leaf mustard, broccoli and cauliflower; Asteraceae vegetables such as artichoke and lettuce; Liliaceae vegetables such as leek, onion, garlic and asparagus; Apiaceae vegetables such as carrot, parsley, celery and parsnip; Chenopodiaceae vegetables such as spinach and chard; Lamiaceae vegetables such as mint and basil; flowers such as petunia, morning glory, carnation, chrysanthemum and rose; foliage plants; fruit trees such as pome fruits (e.g., apple, pear and Japanese pear), stone fruits (e.g., peach, plum, nectarine, cherry, apricot and prune), citrus (e.g., orange, lemon, lime and grapefruit), tree nuts (e.g., chestnut, pecan, walnut, hazel, almond, pistachio, cashew and macadamia), berries such as blueberry, cranberry, blackberry, strawberry and raspberry; persimmon; olive; loquat; banana; coffee; palm; coco; the other trees such tea, mulberry, flower trees, and landscape trees (e.g., ash, birch, dogwood, eucalyptus, ginkgo, lilac, maple, oak, poplar, Formosa sweetgum, sycamore, fir, hemlock fir, needle juniper, pine, spruce, yew).
  • Non-limiting examples of the plant diseases that may be controlled by the methods described herein include diseases caused by phytopathogenic fungi (in particular of the classes of Ascomycetes, Deuteromycetes, Oomycetes and Basidiomycetes) such as Magnaporthe grisea, Cochiobolus miyabeanus, Rhizoctonia solani and Gibberella fujikuroi on rice; Erysiphe graminis, Fusarium graminearum, F. avenacerum, F. culmorum, Microdochium nivale, Puccinia striiformis, P. graminis, P. recondita, P. hordei, Typhula sp., Micronectriella nivalis, Ustilago tritici, U. nuda, Tilletia caries, Pseudocercosporella herpotrichoides, Rhynchosporium secalis, Septoria tritici, Leptosphaeria nodorum and Pyrenophora teres on wheat and barley; Diaporthe citri, Elsinoe fawcetti, Penicillium digitatum, P. italicum, Phytophthora parasitica and Phytophthora citrophthora on citrus; Monilinia mali, Valsa ceratosperma, Podosphaera leucotricha, Alternaria alternata apple pathotype, Venturia inaequalis, Colletotrichum acutatum and Phytophtora cactorum on apple; Venturia nashicola, V. pirina, Alternaria alternata Japanese pear pathotype, Gymnosporangium haraeanum and Phytophthora cactorum on pear; Monilinia fucticola, Cladosporium carpophilum and Phomopsis sp. on peach; Elsinoe ampelina, Glomerella cingulata, Uncinula necator, Phakopsora ampelopsidis, Guignardia bidwellii and Plasmopara viticola on grape; Gloeosporium kaki, Cercospora kaki and Mycosphaerella nawae on persimmon; Colletotrichum lagenarium, Sphaerotheca fuliginea, Mycosphaerella melonis, Fusarium oxysporum, Pseudoperonospora cubensis and Phytophthora sp. on Cucurbitales vegetables; Alternaria solani, Cladosporium fulvum and Phytophthora infestans on tomato; Phomopsis vexans and Erysiphe cichoracearum on eggplant; Alternaria japonica, Cercosporella brassicae, Plasmodiophora brassicae and Peronospora parasitica on Brassicaceae vegetables; Puccinia allii and Peronospora destructor on leek; Cercospora kikuchii, Elsinoe glycines, Diaporthe phaseolorum var. sojae, Phakopsora pachyrhizi and Phytophthora sojae on soybean; Colletotrichum lindemuthianum of kidney bean; Cercospora personata, Cercospora arachidicola and Sclerotium rolfsii on peanut; Erysiphe pisi on pea; Alternaria solani, Phytophthora infestans, Phytophthora erythroseptica and Spongospora subterranean f sp. subterranean on potato; Sphaerotheca humuli and Glomerella cingulata on strawberry; Exobasidium reticulatum, Elsinoe leucospila, Pestalotiopsis sp. and Colletotrichum theae-sinensis on tea; Alternaria longipes, Erysiphe cichoracearum, Colletotrichum tabacum, Peronospora tabacina and Phytophthora nicotianae on tobacco; Cercospora beticola, Thanatephorus cucumeris, and Aphanidermatum cochlioides on sugar beet; Diplocarpon rosae, Sphaerotheca pannosa and Peronospora sparsa on rose; Bremia lactucae, Septoria chrysanthemi-indici and Puccinia horiana on chrysanthemum and Compositae vegetables; Alternaria brassicicola on radish; Sclerotinia homeocarpa and Rhizoctonia solani on turf; Mycosphaerella fijiensis and Mycosphaerella musicola on banana; Plasmopara halstedii on sunflower; and various diseases on crops caused by Aspergillus spp., Alternaria spp., Cephalosporium spp., Cercospora spp., Cochliobolus spp., Diaporthe spp., Phomopsis spp., Diplodia spp., Fusarium spp., Gibberella spp., Helminthosporium spp., Phakopsora spp., Phytophthora spp., Blumeria spp., Oidium spp., Erysiphe spp., Uncinula spp., Podosphaera spp., Microsphaera spp., Colletotrichum spp., Corynespora spp., Peronospora spp., Plasmopara spp., Pythium spp., Pyrenophora spp., Pythium spp., Rhizoctonia spp., Rhynchosporium spp., Botryotinia spp., Botrytis spp., Botryosphaeria spp., Sphaerotheca spp., Septoria spp., Thielaviopsis spp., Typhula spp., Pseudocercosporella spp., Cochliobolus spp., Gaeumannomyces spp., Mucor spp., Puccinia spp., Tilletia spp., Ustilago spp., Venturia spp., Gymnosporangium spp., Claviceps spp., Cladosporium spp., Physalospora spp., Pyricularia spp., Magnaporthe spp., Rhizopus spp., Monilinia spp., Cladosporium spp., Curvularia spp., Sclerotinia spp., Sclerotium sp., Corticum spp., Corticium spp., Phoma spp., Polymyxa spp., and Olpidium spp.
  • Application to Plants and/or Soil
  • Generally, the methods described herein can be used to modulate, inhibit or eradicate fungal pathogens as described herein that cause disease on various parts of agricultural crop plants (e.g., fruit, blossoms, leaves, stems, tubers, roots) or other useful plants as described herein. For example, the methods described herein may be used to modulate, inhibit, and/or control any of the fungal pathogens and/or plant diseases listed above.
  • For example, methods described herein may be used to modulate, inhibit or eradicate plant fungal pathogens in vegetable crops, row crops, trees, nuts, vines, turf, and ornamental plants.
  • A composition comprising a compound as described herein may be supplied to a plant exogenously. The composition may be applied to the plant and/or the surrounding soil through sprays, drips, and/or other forms of liquid application.
  • The compounds described herein may penetrate the plant through the roots via the soil (systemic action); by drenching the locus of the plant with a liquid composition; or by applying the compounds in solid form to the soil, e.g. in granular form (soil application).
  • As used herein, the term “locus” broadly encompasses the fields on which the treated plants are growing, or where the seeds of cultivated plants are sown, or the place where the seed will be placed into the soil.
  • A composition as described herein may be applied to a plant, including plant leaves, shoots, roots, or seeds. For example, composition comprising a compound as described herein can be applied to a foliar surface of a plant. Foliar applications may require 50 to 500 g per hectare of a compound as described herein.
  • As used herein, the term “foliar surface” broadly refers to any green portion of a plant having surface that may permit absorption of silicon, including petioles, stipules, stems, bracts, flowerbuds, and leaves. Absorption commonly occurs at the site of application on a foliar surface, but in some cases, the applied composition may run down to other areas and be absorbed there.
  • Compositions described herein can be applied to the foliar surfaces of the plant using any conventional system for applying liquids to a foliar surface. For example, application by spraying will be found most convenient. Any conventional atomization method can be used to generate spray droplets, including hydraulic nozzles and rotating disk atomizers. In other instances, alternative application techniques, including application by brush or by rope-wick, may be utilized.
  • A composition comprising a compound as described herein can be directly applied to the soil surrounding the root zone of a plant. Soil applications may require 0.5 to 5 kg per hectare of a compound as described herein on a broadcast basis (rate per treated area if broadcast or banded).
  • For example, a composition may be applied directly to the base of the plants or to the soil immediately adjacent to the plants.
  • In some embodiments, a sufficient quantity of the composition is applied such that it drains through the soil to the root area of the plants.
  • Generally, application of a composition may be performed using any method or apparatus known in the art, including but not limited to hand sprayer, mechanical sprinkler, or irrigation, including drip irrigation.
  • A composition as provided herein can be applied to plants and/or soil using a drip irrigation technique. For example, the composition may be applied through existing drip irrigation systems. For example, this procedure can be used in connection with cotton, strawberries, tomatoes, potatoes, vegetables, and ornamental plants.
  • In other embodiments, a composition can be applied to plants and/or soil using a drench application. For example, the drench application technique may be used in connection with crop plants and turf grasses.
  • A composition as provided herein may be applied to soil after planting. Alternatively, a composition as provided herein may be applied to soil during planting, or may be applied to soil before planting.
  • For example, a composition as provided herein may be tilled into the soil or applied in furrow.
  • In crops of water, such as rice, solid granulates comprising the compounds described herein may be applied to the flooded field or locus of the crop plants to be treated.
  • Application to Seeds
  • Provided herein is a method of protecting a seed, and/or the roots of a plant grown from the seed, against damage by phytopathogenic fungi. The seed treatment methods described herein may be used to modulate, inhibit, and/or control any of the fungal pathogens and/or plant diseases described above. For example, the method may comprise treating a seed with a composition comprising a compound as described herein. As used herein, the term “seed” broadly encompasses plant propagating material such as, tubers cuttings, seedlings, seeds, and germinated or soaked seeds.
  • Provided herein is a method of administering to a seed a compound (e.g., a compound of Formula I) as described to control fungal pathogens in a composition as described herein, including using the compounds as described herein with the any adjuvants, excipients, or other desirable components as described herein or known in the art and formulating, mixing, or combining one or more additional active ingredients. The additional active ingredient may be, for example, an additional pesticide. The pesticide may be, for example, an insecticide, a fungicide, an herbicide, or an additional nematicide as described herein or otherwise known in the art.
  • For example, a compound as described herein may be applied to seeds or tubers by impregnating them with a liquid seed treatment composition comprising a compound described herein, or by coating them with a solid or liquid composition comprising a compound described herein.
  • Seed treatment methods described herein can be used in connection with any species of plant and/or the seeds thereof as described herein. Typically, the methods are used in connection with seeds of plant species that are agronomically important. In particular, the seeds can be of corn, peanut, canola/rapeseed, soybean, cucurbits, crucifers, cotton, beets, rice, sorghum, sugar beet, wheat, barley, rye, sunflower, tomato, sugarcane, tobacco, oats, as well as other vegetable and leaf crops. For example, the seed can be corn, soybean, or cotton seed. The seed may be a transgenic seed from which a transgenic plant can grow and incorporate a transgenic event that confers, for example, tolerance to a particular herbicide or combination of herbicides, insect resistance, increased disease resistance, enhanced tolerance to stress and/or enhanced yield. Transgenic seeds include, but are not limited to, seeds of corn, soybean and cotton.
  • A seed treatment method may comprise applying the seed treatment composition to the seed prior to sowing the seed, so that the sowing operation is simplified. In this manner, seeds can be treated, for example, at a central location and then dispersed for planting. This permits the person who plants the seeds to avoid the complexity and effort associated with handling and applying the compositions, and to merely handle and plant the treated seeds in a manner that is conventional for regular untreated seeds.
  • A composition can be applied to seeds by any standard seed treatment methodology, including but not limited to mixing in a container (e.g., a bottle or bag), mechanical application, tumbling, spraying, immersion, and solid matrix priming. Seed coating methods and apparatus for their application are disclosed in, for example, U.S. Pat. Nos. 5,918,413; 5,891,246; 5,554,445; 5,389,399; 5,107,787; 5,080,925; 4,759,945 and 4,465,017, among others. Any conventional active or inert material can be used for contacting seeds with the composition, such as conventional film-coating materials including but not limited to water-based film coating materials.
  • For example, a composition can be introduced onto or into a seed by use of solid matrix priming. For example, a quantity of the composition can be mixed with a solid matrix material and then the seed can be placed into contact with the solid matrix material for a period to allow the composition to be introduced to the seed. The seed can then optionally be separated from the solid matrix material and stored or used, or the mixture of solid matrix material plus seed can be stored or planted directly. Non-limiting examples of solid matrix materials which are useful include polyacrylamide, starch, clay, silica, alumina, soil, sand, polyurea, polyacrylate, or any other material capable of absorbing or adsorbing the composition for a time and releasing the active compound of the composition into or onto the seed. It is useful to make sure that the active compound and the solid matrix material are compatible with each other. For example, the solid matrix material should be chosen so that it can release the active compound at a reasonable rate, for example over a period of minutes, hours, days, or weeks.
  • Imbibition is another method of treating seed with the composition. For example, a plant seed can be directly immersed for a period of time in the composition. During the period that the seed is immersed, the seed takes up, or imbibes, a portion of the composition. Optionally, the mixture of plant seed and the composition can be agitated, for example by shaking, rolling, tumbling, or other means. After imbibition, the seed can be separated from the composition and optionally dried, for example by patting or air drying.
  • A composition may be applied to the seeds using conventional coating techniques and machines, such as fluidized bed techniques, the roller mill method, rotostatic seed treaters, and drum coaters. Other methods, such as spouted beds may also be useful. The seeds may be pre-sized before coating. After coating, the seeds may be dried and then transferred to a sizing machine for sizing. Such procedures are generally known in the art.
  • If a composition is applied to the seed in the form of a coating, the seeds can be coated using a variety of methods known in the art. For example, the coating process can comprise spraying the composition onto the seed while agitating the seed in an appropriate piece of equipment such as a tumbler or a pan granulator.
  • When coating seed on a large scale (for example a commercial scale), the seed coating may be applied using a continuous process. For example, seed may be introduced into the treatment equipment (such as a tumbler, a mixer, or a pan granulator) either by weight or by flow rate. The amount of treatment composition that is introduced into the treatment equipment can vary depending on the seed weight to be coated, surface area of the seed, the concentration of the fungicide and/or other active ingredients in a composition, the desired concentration on the finished seed, and the like. A composition can be applied to the seed by a variety of means, for example by a spray nozzle or revolving disc. The amount of liquid may be determined by the assay of the formulation and the required rate of active ingredient necessary for efficacy. As the seed falls into the treatment equipment the seed can be treated (for example by misting or spraying with the composition) and passed through the treater under continual movement/tumbling where it can be coated evenly and dried before storage or use.
  • The seed coating may be applied using a batch process. For example, a known weight of seeds can be introduced into the treatment equipment (such as a tumbler, a mixer, or a pan granulator). A known volume of the composition can be introduced into the treatment equipment at a rate that allows the composition to be applied evenly over the seeds. During the application, the seed can be mixed, for example by spinning or tumbling. The seed can optionally be dried or partially dried during the tumbling operation. After complete coating, the treated sample can be removed to an area for further drying or additional processing, use, or storage.
  • The seed coating may be applied using a semi-batch process that incorporates features from each of the batch processes and continuous processes set forth above.
  • In other embodiments, seeds can be coated in laboratory size commercial treatment equipment such as a tumbler, a mixer, or a pan granulator by introducing a known weight of seeds in the treater, adding the desired amount of the composition, tumbling or spinning the seed and placing it on a tray to thoroughly dry.
  • Seeds can also be coated by placing the known amount of seed into a narrow neck bottle or receptacle with a lid. While tumbling, the desired amount of the composition can be added to the receptacle. The seed is tumbled until it is coated with the composition. After coating, the seed can optionally be dried, for example on a tray.
  • The treated seeds may also be enveloped with a film overcoating to protect the fungicidal coating. Such overcoatings are known in the art and may be applied using conventional fluidized bed and drum film coating techniques. The overcoatings may be applied to seeds that have been treated with any of the seed treatment techniques described above, including but not limited to solid matrix priming, imbibition, coating, and spraying, or by any other seed treatment technique known in the art.
    • Treated Seeds
  • Provided herein is a seed that has been treated with a composition as described herein comprising a compound (e.g., a compound of Formula I) as described herein. The seed may have been treated with the composition using one of the seed treatment methods set forth above, including but not limited to solid matrix priming, imbibition, coating, and spraying. The treated seed may be of any plant species, as described above.
  • A seed can be treated with a composition as described herein, including formulating, mixing in a seed treater tank, or combining on a seed by overcoating one or more additional active ingredients. The additional active ingredient may be, for example, an additional pesticide. The pesticide may be, for example, an insecticide, a fungicide, an herbicide, or an additional nematicide as described herein.
  • The amount of a compound present on a treated seed sufficient to protect the seed, and/or the roots of a plant grown from the seed, against damage by phytopathogenic fungi can be readily determined by one of ordinary skill in the art. In some embodiments, the treated seed comprises a compound of Formula I in an amount of at least about 0.005 mg/seed. For example, treated seeds can comprise a compound of Formula I in an amount of from about 0.005 to about 2 mg/seed, from about 0.005 to about 1 mg/seed, or from about 0.05 to about 0.5 mg/seed.
  • Having described the disclosure in detail, it will be apparent that modifications and variations are possible without departing from the scope of the claims.
    • General Methods for Providing the Present Compounds
  • The compounds of this invention may be prepared or isolated in general by synthetic and/or semi-synthetic methods known to those skilled in the art for analogous compounds and by methods described in detail herein.
  • In the Schemes below, where a particular protecting group (“PG”), leaving group (“LG”), or transformation condition is depicted, one of ordinary skill in the art will appreciate that other protecting groups, leaving groups, and transformation conditions are also suitable and are contemplated. Such groups and transformations are described in detail in March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 5th Edition, John Wiley & Sons, 2001, Comprehensive Organic Transformations, R. C. Larock, 2nd Edition, John Wiley & Sons, 1999, and Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of each of which is hereby incorporated herein by reference.
  • As used herein, the phrase “leaving group” (LG) includes, but is not limited to, halogens (e.g. fluoride, chloride, bromide, iodide), sulfonates (e.g. mesylate, tosylate, benzenesulfonate, brosylate, nosylate, triflate), diazonium, and the like.
  • The amidation of a carboxylic acid with an amine is well established and known in the art. The use of amide coupling reagents is one of common approaches to form amide bonds known in the art and included those described in detail in Handbook of Reagents for Organic Synthesis, Reagents for Glycoside, Nucleotide, and Peptide Synthesis, D. Crich, 1st edition, John Wiley & Sons, 2005, the entirety of which is incorporated herein by reference. Suitable amide coupling reagents include, but are not limited to, (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT), N,N′-dicyclohexylcarbodiimide (DCC), N,N′-Diisopropylcarbodiimide (DIC), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), 3-[Bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate (HBTU), 3-Hydroxytriazolo[4,5-b]pyridine (HOAt), (7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP), (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), and propylphosphonic anhydride (T3P). It is also well known in the art, amidation can be achieved by converting carboxylic acids to corresponding acyl halides (e.g., acyl chloride) and then reacting with amines.
  • Oxazolyl Compounds
  • In certain embodiments, compounds of the present invention of formula I, where R2 is 2-oxazolyl, are generally prepared by procedures described in U.S. Pat. No. 8,969,557, the entirety of which is incorporated herein by reference. Exemplative compounds listed in Table 1 can be prepared according to Scheme 1 or Scheme 2 set forth below:
  • Figure US20170166585A1-20170615-C00339
    Figure US20170166585A1-20170615-C00340
  • In Scheme 1 above, each of PG, LG, R6, R8, R31, R32, and R33 is as defined above and below and in classes and subclasses as described herein.
  • In some embodiments, the first step comprises alkylating a compound of Formula Br-1 with a compound of Formula B-1, thereby forming a compound of Formula Br-2. In some embodiments, the compound of Formula B-1 is a halide wherein LG is chloride or bromide. In some embodiments, the compound of Formula B-1 is an alcohol wherein LG is —OH and the alkylation is accomplished by Mitsunobu reaction. In some embodiments, the Mitsunobu reaction is accomplished by the use of diisopropyl azodicarboxylate and triphenylphosine. In some embodiments, R6 of the compound of Formula B-1 is isopropyl, tetrahydro-2H-pyran-4-yl; cis-4-hydroxycyclohexyl; 4-oxocyclohexyl; (4-oxocyclohexyl)methyl; or cis-4-hydroxycyclohexylmethyl. In some embodiments, R8 of the compound of Formula B-1 is hydrogen or F.
  • In some embodiments, the oxazole moiety is installed by Stille coupling reaction to provide a compound of Formula O-2. In some embodiments, the Stille coupling reaction is accomplished by reacting the compound of Formula Br-2 with 2-(tributylstannyl)oxazole in the presence of a palladium complex, for example, tetrakis(triphenylphosphine)palladium(O).
  • In some embodiments, the carboxylic acid protection group of the compound of Formula O-1 is t-butyl and the deproction step comprises an acid treatment (e.g., trifluroacetic acid in dichloromethane) to provide the carboxylic acid of Formula O-3. In some embodiment, the protection group of Formula O-2 is benzyl. In some embodiments, the protecting group is a silyl protecting group. In some embodiments, the protecting group is TBDPS and the deproction step comprises a fluoride treatment (e.g., tetrabutylammonium fluoride).
  • In some embodiments, the last step comprises an amidation of the carboxylic acid group of a compound of Formula O-3 with an amine, thereby providing a compound of Formula O-4 or Formula O-5. In some embodiments, the amine is ammonia (e.g., R32 and R33 are both hydrogen). In some embodiments, the amine is a primary amine (e.g., R32 is hydrogen and R33 is ethyl, isopropyl, or cyclobutyl). In some embodiments, the amine is a secondary amine. In some embodiments, the amine is a heterocycle (e.g., R31 is 1-pyrrolidinyl, 1-piperidinyl, or 1-morpholinyl).
  • Alternatively, in some embodiments, the oxazole moiety is installed first by Stille coupling reaction to provide a compound of Formula O-1. Alkylation of the compound of Formula 0-1 with a compound of Formula B-1, thereby forming a compound of Formula O-2, shown below:
  • Figure US20170166585A1-20170615-C00341
  • In Scheme 2 above, each of PG, LG, R6, R8, R31, R32, and R33 is as defined and described above.
  • Cycloalkyl Compounds
  • In certain embodiments, compounds of the present invention of formula I, where R2 is cycloalkyl, are generally prepared by procedures described in U.S. Pat. No. 8,969,557, the entirety of which is incorporated herein by reference. Exemplative compounds listed in Table 1 can be prepared according to Scheme 3 set forth below:
  • Figure US20170166585A1-20170615-C00342
    Figure US20170166585A1-20170615-C00343
  • In Scheme 3 above, each of PG, LG, R6, R8, R31, R32, and R33 is as defined above and below and in classes and subclasses as described herein.
  • In some embodiments, the first step comprises alkylating a compound of Formula Br-1 with a compound of Formula B-1, thereby forming a compound of Formula Br-2, as described above. In some embodiments, R6 of the compound of Formula B-1 is tetrahydro-2H-pyran-4-yl. In some embodiments, R8 of the compound of Formula B-1 is F.
  • In some embodiments, the oxazole moiety is installed by Negishi or Suzuki coupling reaction to provide a compound of Formula Cb-2. In some embodiments, the Negishi coupling reaction is accomplished by reacting the compound of Formula Br-2 with cycloalkylzinc(II) chloride in the presence of a palladium complex, for example, 1,1-Bis(diphenylphosphino)ferrocene]palladium(11) dichloride. In some embodiments, the Suzuki coupling reaction is accomplished by reacting the compound of Formula Br-2 with a cycloalkylboronic compound in the presence of a palladium complex, for example, tetrakis(triphenylphosphine)palladium(0) or palladium(II) acetate.
  • In some embodiments, the carboxylic acid protection group of the compound of Formula Cb-2 is described above.
  • In some embodiments, the last step comprises an amidation of the carboxylic acid group of a compound of Formula Cb-3 with an amine, thereby providing a compound of Formula Cb-4 or Formula Cb-5, as described above. In some embodiments, the amine is ammonia (e.g., R32 and R33 are both hydrogen). In some embodiments, the amine is a primary amine (e.g., R32 is hydrogen and R33 is ethyl or isopropyl). In some embodiments, the amine is a secondary amine. In some embodiments, the amine is a heterocycle (e.g., R31 is 1-pyrrolidinyl, 1-piperidinyl, or 1-morpholinyl).
  • Pyrazolyl Compounds
  • In certain embodiments, exemplative compounds in Table 1 of the present invention of formula I, where R2 is 1-pyrazolyl, are generally prepared according to Scheme 4 set forth below:
  • Figure US20170166585A1-20170615-C00344
  • In Scheme 4 above, each of PG, LG, R5, R5′, R6, R7, R8, R31, R32, and R33 is as defined above and below and in classes and subclasses as described herein.
  • In some embodiments, the first step comprises alkylating a compound of Formula P-1 with a compound of Formula B-2, thereby forming a compound of Formula P-2. In some embodiments, the compound of Formula B-2 is a halide wherein LG is chloride or bromide. In some embodiments, the compound of Formula B-2 is an alcohol wherein LG is —OH and the alkylation is accomplished by Mitsunobu reaction. In some embodiments, the Mitsunobu reaction is accomplished by the use of diisopropyl azodicarboxylate and triphenylphosine. In some embodiments, R5 and R5′ of the compound of Formula P-1 or P-2 are both methyl. In some embodiments, R5 of the compound of Formula P-1 or P-2 is methyl and R5 of the compound of Formula P-1 or P-2 is hydrogen. In some embodiments, R6 of the compound of Formula B-2 is H, —CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2CH═CH2, —CH2CH2OH, —CH2CH(R—CH3)OH, —CH2CH(S—CH3)OH, —CH2C(CH3)2(OH), —CH2CH2OCH3, —CH2CH2CH2OCH3, —C(O)CH2OH, —C(O)CH3, —CH2CN, —(CH2)2CN, —CH2CH(CH3)CN, —CH2C(CH3)2CN, tetrahydro-2H-pyran-4-yl, cis-4-hydroxycyclohexyl, 4-oxocyclohexyl, (4-oxocyclohexyl)methyl, cis-4-hydroxycyclohexylmethyl, —CH2CH2C(O)NH2, —CH2CH2N(CH3)2, or —CH2CH2SO2CH3. In some embodiments, R7 of the compound of Formula B-2 or P-2 is —OMe or —OPG. In some embodiments, R8 of the compound of Formula B-2 or P-2 is hydrogen or F.
  • In some embodiments, the carboxylic acid protection group of the compound of Formula P-3 is a silyl protecting group. In some embodiments, the protecting group is TBDPS and the deproction step comprises a fluoride treatment (e.g., tetrabutylammonium fluoride).
  • In some embodiments, the last step comprises an amidation of the carboxylic acid group of a compound of Formula P-3 with an amine, thereby providing a compound of Formula P-4 or Formula P-5. In some embodiments, the amine is ammonia (e.g., R32 and R33 are both hydrogen).
  • In some embodiments, the amine is a primary amine (e.g., R32 is hydrogen and R33 is methyl, ethyl, isopropyl, isobutyl, cycloropropyl, cyclobutyl, or cyclohexyl). In some embodiments, the amine is a secondary amine (e.g., R32 is methyl and R33 is methyl, isopropyl, or 2-propenyl). In some embodiments, the amine is a heterocycle (e.g., R31 is 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, or 2,5-dihydro-1H-pyrrol-1-yl).
  • In some embodiments, if R7 of the compound of Formula P-2 is —OPG, deprotection and O-alkylation provides R7 as of —OCH2CH2OH, or —OCH2CH2CN in compounds of Formula P-4 or P-5.
  • One of skill in the art will appreciate that compounds of formula P-4 or P-5 may contain one or more stereocenters, and may be present as a racemic or diastereomeric mixture. One of skill in the art will also appreciate that there are many methods known in the art for the separation of isomers to obtain stereoenriched or stereopure isomers of those compounds, including but not limited to HPLC, chiral HPLC, fractional crystallization of diastereomeric salts, kinetic enzymatic resolution (e.g. by fungal-, bacterial-, or animal-derived lipases or esterases), and formation of covalent diastereomeric derivatives using an enantioenriched reagent.
  • Ester Compounds
  • In certain embodiments, exemplative compounds in Table 1 of the present invention of Formula I, where R2 is —C(O)OCH2CH3, are generally prepared according to Scheme 5 set forth below:
  • Figure US20170166585A1-20170615-C00345
  • In Scheme 5 above, each of PG, LG, R5, R5′, R6, R7, R8, R31, R32, and R33 is as defined above and below and in classes and subclasses as described herein.
  • In some embodiments, the first step comprises alkylating a compound of Formula E-1 with a compound of Formula B-2, thereby forming a compound of Formula E-2. In some embodiments, the compound of Formula B-2 is a halide wherein LG is chloride or bromide. In some embodiments, the compound of Formula B-2 is an alcohol wherein LG is —OH and the alkylation is accomplished by Mitsunobu reaction. In some embodiments, the Mitsunobu reaction is accomplished by the use of diisopropyl azodicarboxylate and triphenylphosine. In some embodiments, R5 and R5′ of the compound of Formula E-1 or E-2 are both methyl. In some embodiments, R5 of the compound of Formula E-1 or E-2 is methyl and R5 of the compound of Formula E-1 or E-2 is hydrogen. In some embodiments, R6 of the compound of Formula B-2 is H, —CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2CH═CH2, —CH2CH2OH, —CH2CH(R—CH3)OH, —CH2CH(S—CH3)OH, —CH2C(CH3)2(OH), —CH2CH2OCH3, —CH2CH2CH2OCH3, —C(O)CH2OH, —C(O)CH3, —CH2CN, —(CH2)2CN, —CH2CH(CH3)CN, —CH2C(CH3)2CN, tetrahydro-2H-pyran-4-yl, cis-4-hydroxycyclohexyl, 4-oxocyclohexyl, (4-oxocyclohexyl)methyl, cis-4-hydroxycyclohexylmethyl, —CH2CH2C(O)NH2, —CH2CH2N(CH3)2, or —CH2CH2SO2CH3. In some embodiments, R7 of the compound of Formula B-2 or E-2 is —OMe or —OPG. In some embodiments, R8 of the compound of Formula B-2 or E-2 is hydrogen or F.
  • In some embodiments, the carboxylic acid protection group of the compound of Formula E-3 is a silyl protecting group. In some embodiments, the protecting group is TBDPS and the deproction step comprises a fluoride treatment (e.g., tetrabutylammonium fluoride).
  • In some embodiments, the last step comprises an amidation of the carboxylic acid group of a compound of Formula E-3 with an amine, thereby providing a compound of Formula E-4 or Formula E-5. In some embodiments, the amine is ammonia (e.g., R32 and R33 are both hydrogen). In some embodiments, the amine is a primary amine (e.g., R32 is hydrogen and R33 is methyl, ethyl, isopropyl, isobutyl, cycloropropyl, cyclobutyl, or cyclohexyl). In some embodiments, the amine is a secondary amine (e.g., R32 is methyl and R33 is methyl, ethyl, isopropyl, or 2-propenyl). In some embodiments, the amine is a heterocycle (e.g., R31 is 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, or 2,5-dihydro-1H-pyrrol-1-yl).
  • In some embodiments, if R7 of the compound of Formula E-2 is —OPG, deprotection and O-alkylation provides R7 as of —OCH2CH2CN in compounds of Formula E-4 or E-5.
  • In some embodiments, the ester group (i.e., —C(O)OCH2CH3) in compounds of Formula E-4 or E-5 is further reduced to —CH2OH as the R2 in compounds of Formula I. In some embodiments, the —CH2OH group is further alkylated to —CH2OCH2CH3 as the R2 in compounds of Formula I.
  • One of skill in the art will appreciate that compounds of formula E-4 or E-5 may contain one or more stereocenters, and may be present as a racemic or diastereomeric mixture. One of skill in the art will also appreciate that there are many methods known in the art for the separation of isomers to obtain stereoenriched or stereopure isomers of those compounds, including but not limited to HPLC, chiral HPLC, fractional crystallization of diastereomeric salts, kinetic enzymatic resolution (e.g. by fungal-, bacterial-, or animal-derived lipases or esterases), and formation of covalent diastereomeric derivatives using an enantioenriched reagent.
  • Triazolyl Compounds
  • In certain embodiments, exemplative compounds in Table 1 of the present invention of Formula I, where R2 is 2H-1,2,3-triazol-2-yl, are generally prepared according to Scheme 6 set forth below:
  • Figure US20170166585A1-20170615-C00346
  • In Scheme 6 above, each of PG, LG, R5, R5′, R6, R7, R8, R31, R32, and R33 is as defined above and below and in classes and subclasses as described herein.
  • In some embodiments, the first step comprises alkylating a compound of Formula T1-1 with a compound of Formula B-2, thereby forming a compound of Formula T1-2. In some embodiments, the compound of Formula B-2 is a halide wherein LG is chloride or bromide. In some embodiments, the compound of Formula B-2 is an alcohol wherein LG is —OH and the alkylation is accomplished by Mitsunobu reaction. In some embodiments, the Mitsunobu reaction is accomplished by the use of diisopropyl azodicarboxylate and triphenylphosine. In some embodiments, R5 and R5′ of the compound of Formula T1-1 or T1-2 are both methyl. In some embodiments, R5 of the compound of Formula T1-1 or T1-2 is methyl and R5 of the compound of Formula T1-1 or T1-2 is hydrogen. In some embodiments, R5 and R5′ of the compound of Formula T1-1 or T1-2 are both hydrogen. In some embodiments, R6 of the compound of Formula B-2 is H, —CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2CH═CH2, —CH2CH2OH, —CH2CH(R—CH3)OH, —CH2CH(S—CH3)OH, —CH2C(CH3)2(OH), —CH2CH2OCH3, —CH2CH2CH2OCH3, —C(O)CH2OH, —C(O)CH3, —CH2CN, —(CH2)2CN, —CH2CH(CH3)CN, —CH2C(CH3)2CN, tetrahydro-2H-pyran-4-yl, cis-4-hydroxycyclohexyl, 4-oxocyclohexyl, (4-oxocyclohexyl)methyl, cis-4-hydroxycyclohexylmethyl, —CH2CH2C(O)NH2, —CH2CH2N(CH3)2, or —CH2CH2SO2CH3. In some embodiments, R7 of the compound of Formula B-2 or T1-2 is —OMe, methyl, ethyl, —(CH2)3CN, or —OPG. In some embodiments, R8 of the compound of Formula B-2 or T1-2 is hydrogen or F.
  • In some embodiments, the carboxylic acid protection group of the compound of Formula T1-3 is a silyl protecting group. In some embodiments, the protecting group is TBDPS and the deproction step comprises a fluoride treatment (e.g., tetrabutylammonium fluoride).
  • In some embodiments, the last step comprises an amidation of the carboxylic acid group of a compound of Formula T1-3 with an amine, thereby providing a compound of Formula T1-4 or Formula T1-5. In some embodiments, the amine is ammonia (e.g., R32 and R33 are both hydrogen). In some embodiments, the amine is a primary amine (e.g., R32 is hydrogen and R33 is methyl, ethyl, isopropyl, isobutyl, cycloropropyl, cyclobutyl, cyclohexyl, or —CH2CN). In some embodiments, the amine is a secondary amine (e.g., R32 is methyl and R33 is methyl, ethyl, isopropyl, or 2-propenyl). In some embodiments, the amine is a heterocycle (e.g., R31 is 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 2,5-dihydro-1H-pyrrol-1-yl, or 3-hydroxyazetidin-1-y).
  • In some embodiments, if R7 of the compound of Formula T1-2 is —OPG, deprotection and O-alkylation provides R7 as of —OCH(CH3)2, —OCH2CH2OH, —OCH2CH2OCH3, —OCH2CH(CH2)20, —OCH2CN, —OCH2CH2CN, —OC(O)CH3; O-tetrahydro-2H-pyran-4-yl, or O-benzyl in compounds of Formula T1-4 or T1-5.
  • One of skill in the art will appreciate that compounds of formula T1-4 or T1-5 may contain one or more stereocenters, and may be present as a racemic or diastereomeric mixture. One of skill in the art will also appreciate that there are many methods known in the art for the separation of isomers to obtain stereoenriched or stereopure isomers of those compounds, including but not limited to HPLC, chiral HPLC, fractional crystallization of diastereomeric salts, kinetic enzymatic resolution (e.g. by fungal-, bacterial-, or animal-derived lipases or esterases), and formation of covalent diastereomeric derivatives using an enantioenriched reagent.
  • In certain embodiments, exemplative triazolyl compounds in Table 1 of the present invention of Formula I, where R4 is —O(CH2)2CN and R4 is CH3 (I-273, I-274), R4 is —OH and R4′ is —CH2CH2OH (I-275, I-276), or R4 is —OH and R4′ is —CH2OH (I-315) are prepared specifically with modified chemical steps. For example, R4 of —O(CH2)2CN and R4′ of CH3 in compounds I-273 and I-274 are installed at the benzylic position of the compound of 3-((2-(5-fluoro-2-methoxyphenyl)-1-hydroxypropan-2-yl)oxy)propanenitrile, shown in Scheme 7 below:
  • Figure US20170166585A1-20170615-C00347
  • Compounds I-273 and I-274 are prepared by alkylation, amidation, and chiral separation. For example, R4 of —OH and R4′ of —CH2CH2OH in compounds I-275 and I-276 are installed via a ketone intermediate, shown in Scheme 8 below:
  • Figure US20170166585A1-20170615-C00348
  • Compounds I-275 and I-276 are prepared by amidation, dihydroxylation of the double bond, oxidation of the diol to an aldehyde, reduction of the aldehyde to an alcohol, and chiral separation. For example, R4 of —OH and R4′ of —CH2OH in the compound I-315 are installed via a ketone intermediate, shown in Scheme 9 below:
  • Figure US20170166585A1-20170615-C00349
  • In certain embodiments, exemplative triazolyl compounds in Table 1 of the present invention of Formula I, where R2 is 1H-1,2,4-triazol-1-yl (I-317) or 1H-1,2,3-triazol-1-yl (I-341) are generally prepared according to Scheme 10, shown below:
  • Figure US20170166585A1-20170615-C00350
    Figure US20170166585A1-20170615-C00351
  • In some embodiments, the 1H-1,2,4-triazol-1-yl or 1H-1,2,3-triazol-1-yl moiety is installed by a metal-mediated coupling reaction.
  • One of skill in the art will appreciate that various functional groups present in compounds of the invention such as aliphatic groups, alcohols, carboxylic acids, esters, amides, aldehydes, halogens and nitriles can be interconverted by techniques well known in the art including, but not limited to reduction, oxidation, esterification, hydrolysis, partial oxidation, partial reduction, halogenation, dehydration, partial hydration, and hydration. See e.g. “March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entirety of which is incorporated herein by reference.
    • EXAMPLES
  • The following non-limiting examples are provided for further illustration.
    • Example 1: In Vitro Pathogen Growth Inhibition Assay
  • A growth inhibition assay was conducted to determine the ability of compounds to control the growth of fungal pathogens, such as Botrtyis cinerea (Bc), Collectotrichum graminicola (Cg), Diplodia maydis (Dm), Fusarium moniliforme (Fm), Fusarium virguliforme (Fv), Phytophthora capsici (Pc), Rhizoctonia solani (Rs), and Septoria tritici (St).
  • The compounds listed in Table 1 were each dissolved in DMSO at 2.5 mg/ml to produce compound stock solutions (“stocks”). Stocks were diluted with DMSO by a five-fold dilution in a 96-well stock plate, and two sets of final concentrations of 50, 10, and 2 ppm or 2, 0.4, and 0.08 ppm were obtained in vitro.
  • A set of positive controls was also prepared, with various concentrations of Soraphen (2, 0.4, and 0.08 ppm), Metalaxyl (1.1, 0.22, and 0.04 ppm), and Metconazole (2, 0.4, and 0.08 ppm or 0.2, 0.04, and 0.008 ppm) after the five-fold dilutions. Negative controls on each plate included 2% DMSO, water, and a blank (media +2% DMSO).
  • Fungal spores were isolated from previously sub-cultured plates of Botrtyis cinerea (Bc), Collectotrichum graminicola (Cg), Diplodia maydis (Dm), Fusarium moniliforme (Fm), Fusarium virguliforme (Fv), Phytophthora capsici (Pc), and Septoria tritici (St). The isolated spores were diluted to individual concentrations with a 17% V8 liquid media. For Rhizoctonia solani (Rs), 1.5 mm mycelial plugs were used in place of spores and ¼ Potato Dextrose Broth (PDB) was used for dilution. The spore concentrations and plug sizes were based on growth curves generated at 48 hours for each pathogen.
  • In a second 96-well plate, the spores or mycelial plugs, media, diluted compound solutions, and controls were combined. Once the compound was added, a true final concentration of compound in each well was measured by an OD600 reading, which adjusted for any compound precipitation that might have occurred in the well. Plate readings were repeated at both 24 and 48 hours. The blank negative control was used as a background subtraction. Additional visual ratings were performed at both 24 and 48 hours for checking on precipitation and confirming efficacy. Visual and OD600 ratings of the compounds at 48 hours were compared to the 2% DMSO negative control, and the percent of pathogen growth inhibition was determined based on those values.
  • A list of compounds that have an inhibition of ≧90% of Fusarium moniliforme (Fm) at a compound concentration of 2 ppm or lower is included in Table 2 below. Additional compounds that have an inhibition of ≧90% of Fusarium moniliforme (Fm) are included in Table 3 below. Both tables list the concentration of each compound that was sufficient to ≧90% inhibition of growth for each of the fungal pathogens listed above. In addition, some of compounds were tested in a yeast growth inhibition assay for Saccharomyces cerevisiae (Sc). Table 2 lists the concentration of the tested compound that was sufficient to ≧75% inhibition of Saccharomyces cerevisiae (Sc).
  • TABLE 2
    In Vitro Pathogen Growth Inhibition Assay Results
    Pathogens
    Bc Cg Dm Fm Fv Pc Rs St Sc
    Percentage of Inhibition
    Cmpd ≧90% ≧90% ≧90% ≧90% ≧90% ≧90% ≧90% ≧90% ≧75%
    No. Compound Concentration (ppm)
    I-001 ≧0.4 ≧2.0    2.0   0.080    0.40 >50.0   50.0 >10.0 1.2
    I-002 0.40 2.0    0.40   0.080    0.40 >50.0    0.40 >10.0 —
    I-003 2.0 0.40    2.0   0.080    0.40 >50.0    0.40 ≧10.0 0.40
    I-004 0.40 2.0    2.0   0.080    2.0 >50.0   10.0 >10.0 3.7
    I-005 2.0 2.0    2.0   0.080    2.0 >50.0    0.40 >10.0 0.40
    I-006 0.40 0.40    0.40   0.080    0.40 >50.0    0.40  ≧2.0 1.2
    I-007 0.40 0.40    0.40   0.080    0.40 >50.0    0.080  ≧2.0 0.40
    I-008 0.40 2.0    2.0   0.080    2.0 >50.0   10.0 >10.0 3.7
    I-009 0.40 2.0    0.40   0.080    0.40 >50.0   10.0 >50.0 3.7
    I-010 0.40 50.0  ≧2.0   0.080    2.0 >50.0   50.0 >50.0 0.40
    I-011 0.40 2.0    2.0   0.080    2.0 >50.0   10.0   50.0 1.2
    I-012 0.40 10.0    2.0   0.080    2.0 >50.0   50.0 ≧10.0 0.14
    I-013 0.40 10.0    0.40   0.080    2.0 >50.0   10.0 ≧10.0 0.14
    I-014 0.40 2.0    2.0   0.080    0.40 >50.0    2.0 >10.0 1.2
    I-015 0.40 2.0  ≧0.4   0.080    0.40 >50.0   10.0 >10.0 —
    I-016 0.40 2.0    0.40   0.080    0.40 >50.0    0.40 >10.0 —
    I-017 0.40 0.080  ≧0.08   0.080    0.40 >50.0    0.40 >10.0 —
    I-018 0.40 0.40    0.40   0.080    0.40 >50.0    0.080 >10.0 —
    I-019 ≧0.4 ≧0.4  ≧0.4   0.080    0.40 >50.0    0.080 >10.0 —
    I-020 ≧0.08 0.080    0.080   0.080    0.40 >50.0    0.080  ≧2.0 —
    I-021 0.40 2.0    2.0   0.080    0.40 >50.0    0.40 >10.0 —
    I-022 0.080 0.080    0.080   0.080  ≧0.08 >50.0    0.080  ≧2.0 —
    I-023 0.40 0.080    0.080   0.080  ≧0.08 >50.0    0.080 >10.0 —
    I-024 0.40 2.0  ≧2.0   0.080    2.0 >50.0    0.40 >50.0 —
    I-025 0.40 0.40    0.40   0.080    0.40 >50.0    0.40 >10.0 —
    I-026 0.40 0.080    0.080   0.080    0.40 >50.0    0.40  ≧2.0 —
    I-027 0.40 0.40    0.40   0.080    2.0 >50.0    0.40 >10.0 —
    I-028 0.40 0.080  ≧0.08   0.080    0.40 >50.0    0.080  ≧2.0 —
    I-029 0.40 ≧2.0  ≧2.0   0.080    0.40   50.0    0.40 >10.0 —
    I-030 0.40 0.40  ≧0.4   0.080    0.40   50.0    0.080  ≧2.0 —
    I-031 2.0 10.0   10.0   0.080   10.0 >50.0   10.0 >50.0 —
    I-032 0.40 ≧2.0   10.0   0.080   10.0 >50.0   10.0 >50.0 —
    I-033 0.40 ≧0.4  ≧0.4   0.080    0.40 >50.0    0.080 >10.0 —
    I-034 0.40 ≧0.4  ≧0.4   0.080    0.40 ≧10.0    0.080  ≧2.0 —
    I-035 2.0 ≧2.0    2.0   0.080    0.40 >50.0    0.40 >50.0 —
    I-036 0.40 0.080  ≧0.08   0.080    0.40 >50.0    0.080  ≧2.0 —
    I-037 ≧0.4 ≧0.08  ≧0.08   0.080    0.40   10.0    0.080  ≧2.0 —
    I-038 0.40 0.40    0.40   0.080    0.40   10.0    0.080  ≧2.0 —
    I-039 0.40 2.0    0.40   0.080    0.40 >50.0    0.40  ≧2.0 —
    I-040 0.40 ≧0.4  ≧0.4   0.080    0.40 >50.0    2.0 ≧10.0 —
    I-041 0.40 2.0  ≧2.0   0.080    2.0 >50.0    0.080 >10.0 —
    I-042 0.40 ≧0.4  ≧0.4   0.080    0.40 ≧10.0    0.080 ≧10.0 —
    I-043 0.40 ≧2.0    0.40   0.080    2.0 >10.0    0.40 >10.0 —
    I-044 0.40 0.40    2.0   0.080    0.40 >50.0    0.40 >50.0 —
    I-045 2.0 ≧0.4  ≧2.0   0.080   10.0 >50.0    2.0 >50.0 —
    I-046 2.0 2.0    2.0   0.080    0.40 >50.0    0.40 ≧50.0 —
    I-047 0.40 ≧2.0    2.0   0.080    0.40 >50.0    2.0 >50.0 —
    I-048 0.40 10.0    2.0   0.080    2.0 >50.0    2.0 >50.0 —
    I-049 0.40 50.0    2.0   0.080    2.0 >50.0    2.0 >50.0 —
    I-050 0.080 2.0  ≧0.08   0.080    0.40   50.0    0.080 >50.0 —
    I-051 0.40 0.40  ≧0.4   0.080    0.40 >50.0    0.40 >50.0 —
    I-052 0.40 ≧0.4    2.0   0.080    0.40 >50.0    2.0 >50.0 —
    I-053 0.40 2.0  ≧2.0   0.080    0.40 >50.0    2.0 ≧50.0 —
    I-054 0.40 0.40    0.40   0.080  ≧0.08 >50.0    0.40   10.0 —
    I-055 0.40 0.080  ≧0.4   0.080  ≧0.08 >50.0    0.40  ≧2.0 —
    I-056 0.40 0.080    0.080   0.080    0.24   30.0a    0.24   26.0a —
    I-057 0.40 0.080    0.40   0.080    0.40   50.0a    0.40   50.0a —
    I-058 0.40 0.080    0.080   0.080    0.080 ≧10.0    0.40 >50.0 —
    I-059 0.080 0.40    0.40   0.080  ≧0.08 >50.0    0.40   10.0 —
    I-060 0.40 >50.0    0.40   0.080    0.40 >50.0  ≧2.0 >50.0 —
    I-061 0.40 0.080    0.40   0.080    0.40 >50.0    0.40 >50.0 —
    I-062 0.40 0.40    1.2+   0.080    0.40   50.0a    2.0   50.0a —
    I-063 0.40 0.40  ≧0.4   0.080    0.40 >50.0    2.0 ≧50.0 —
    I-064 2.0 0.40    0.40   0.080    0.40  ≧2.0  ≧0.08  ≧2.0 —
    I-065 2.0 0.40    0.40   0.080    0.40  ≧2.0  ≧0.08  ≧2.0 —
    I-066 ≧0.4 ≧0.4  ≧0.4   0.080    0.40   50.0  ≧0.4 ≧10.0 —
    I-067 0.40 0.080    0.080   0.080    0.40 >50.0    0.40  ≧2.0 —
    I-068 0.40 0.40  ≧0.08   0.080    0.40 >50.0    0.40 ≧50.0 —
    I-069 0.40 0.40    0.40   0.080    0.40 >50.0  ≧0.4 ≧50.0 —
    I-070 0.40 2.0    0.40   0.080    0.080 >50.0    2.0 ≧10.0 —
    I-071 0.40 0.40    0.40   0.080    0.40 ≧50.0  ≧0.08 ≧50.0 —
    I-072 2.0 ≧0.08    0.40   0.080    0.40   10.0  ≧0.4  ≧2.0 —
    I-073 2.0 0.40    2.0   0.080    0.40 >50.0  ≧0.4 ≧10.0 —
    I-074 2.0 2.0    2.0   0.080    0.40 ≧50.0    0.40 >50.0 —
    I-075 2.0 0.40    0.40   0.080    0.40 >50.0    0.080 >50.0 —
    I-076 2.0 0.40    0.40   0.080    0.40 ≧50.0    0.080 ≧10.0 —
    I-077 2.0 2.0    2.0   0.080    0.40 >50.0    0.40 >50.0 —
    I-078 2.0 2.0    2.0   0.080    0.40 >50.0    0.40 >50.0 —
    I-079 2.0 2.0    2.0   0.080    0.40 >50.0    0.40 >50.0 —
    I-080 0.40 0.080    0.40   0.080    2.0 >50.0    0.080 >50.0 —
    I-081 2.0 0.40    2.0   0.080    0.40 ≧50.0    0.40 >50.0 —
    I-082 2.0 0.40    0.40   0.080    0.40   10.0a    0.24   30.0a —
    I-083 2.0 2.0    2.0   0.080    0.40 >50.0    0.40 ≧50.0 —
    I-084 0.40 0.40    0.080   0.080    0.080 >50.0    0.40 ≧10.0 —
    I-085 >0.08 0.40    0.40   0.080    0.40 >50.0    0.080 ≧10.0 —
    I-086 >50.0 >50.0 >50.0   0.080  ≧2.0 >50.0   10.0 >50.0 —
    I-087 2.0 2.0 >50.0   0.080    2.0 >50.0    2.0 >50.0 —
    I-088 0.080 2.0    2.0   0.080    0.40 >50.0    0.080 >50.0 —
    I-089 >0.4 >0.4    2.0   0.080  >0.4 ≧50.0    0.080 ≧10.0 —
    I-090 2.0 0.080  >0.08   0.080  >0.4    2.0    0.080  ≧2.0 —
    I-091 0.40 ≧2.0    2.0   0.080    0.40 >50.0    2.0 >50.0 —
    I-092 0.40 0.080    0.40   0.080  >0.40    2.0    0.080  ≧2.0 —
    I-093 0.40 10.0    2.0   0.080   10.0 >50.0    2.0 >50.0 —
    I-094 0.080 0.080  >0.4   0.080    0.080 >50.0    0.080 ≧10.0 —
    I-095 0.40 0.080    0.08   0.080    0.080  ≧2.0    0.080 >50 —
    I-096 2.0 0.080    0.40   0.080    2.0    2.0    0.080  ≧2.0 —
    I-097 0.40 50.0  ≧2.0   0.080    2.0 >50.0    2.0 >50.0 —
    I-098 2.0 10.0    2.0   0.40   10.0 >50.0   10.0 >50.0 11.0
    I-099 10.0 50.0   10.0   0.40   50.0 >50.0   50.0 >50.0 33.0
    I-100 2.0 50.0    2.0   0.40   10.0 >50.0   50.0 ≧50.0 1.2
    I-101 10.0 10.0   10.0   0.40   10.0   50.0   50.0 >50.0 3.7
    I-102 2.0 2.0    2.0   0.40    2.0   10.0  ≧2.0 ≧50.0 1.2
    I-103 2.0 50.0   10.0   0.40    2.0 >50.0   50.0 >10.0 1.2
    I-104 2.0 >50.0   10.0   0.40   10.0 >10.0   10.0 >50.0 11.0
    I-105 2.0 50.0   10.0   0.40   10.0 >50.0 >50.0 >50.0 1.2
    I-106 2.0 10.0    2.0   0.40    2.0 >50.0   50.0 >50.0 33.3
    I-107 0.40 >50.0  ≧0.4   0.40 >50.0 >50.0 >50.0 >50.0 >33.3
    I-108 2.0 10.0   10.0   0.40    2.0 >50.0   50.0 >50.0 11.1
    I-109 0.40 10.0    2.0   0.40   10.0 >50.0   50.0 >50.0 11.1
    I-110 2.0 >50.0   10.0   0.40    2.0 >50.0   50.0 >50.0 33.3
    I-111 2.0 10.0   10.0   0.40    2.0 >50.0   10.0   50.0 3.7
    I-112 2.0 ≧2.0   10.0   0.40   10.0 >50.0   50.0   50.0 3.7
    I-113 2.0 2.0    2.0   0.40    0.40 >50.0    0.080   50.0 —
    I-114 2.0 10.0   10.0   0.40    2.0 >50.0   10.0 >50.0 —
    I-115 2.0 ≧2.0  ≧2.0   0.40    2.0 >50.0   10.0 ≧50.0 —
    I-116 10.0 ≧2.0   10.0   0.40   10.0 >50.0    2.0 ≧50.0 —
    I-117 2.0 10.0   10.0   0.40   10.0 >50.0   10.0 >50.0 —
    I-118 2.0 10.0    2.0   0.40    0.40 >50.0   50.0 ≧50.0 —
    I-119 2.0 10.0  ≧2.0   0.40   10.0 >50.0    2.0 >50.0 —
    I-120 2.0 2.0    2.0   0.40   10.0 >50.0    2.0 >50.0 —
    I-121 2.0 10.0  ≧2.0   0.40 >50.0 >50.0   50.0 >50.0 —
    I-122 2.0 ≧2.0   10.0   0.40  ≧2.0 >50.0    2.0 >50.0 —
    I-123 2.0 ≧10.0   10.0   0.40    2.0 >50.0   10.0 >50.0 —
    I-124 ≧0.4 10.0  ≧2.0   0.40   10.0   50.0    2.0 >50.0 —
    I-125 2.0 ≧2.0 >50.0   0.40    0.40 >50.0  ≧2.0 >50.0 —
    I-126 2.0 2.0    2.0   0.40    1.2   50.0a    2.0   50.0a —
    I-127 2.0 2.0    2.0   0.40    0.40 >50.0    2.0 >50.0 —
    I-128 2.0 10.0 >10.0   0.40    2.0 >50.0  ≧2.0 >50.0 —
    I-129 2.0 2.0   10.0   0.40    2.0   50.0    2.0 >50.0 —
    I-130 2.0 2.0  ≧2.0   0.40  ≧0.4   50.0  ≧2.0 ≧50.0 —
    I-131 0.40 10.0    2.0   0.40    0.40 >50.0  ≧0.4 >50.0 —
    I-132 2.0 ≧2.0   10.0   0.40    0.40 >50.0  ≧2.0 >50.0 —
    I-133 2.0 0.40    2.0   0.40    0.40   50.0  ≧2.0 ≧50.0 —
    I-134 2.0 0.40  ≧2.0   0.40    2.0 ≧10.0  ≧0.4 ≧10.0 —
    I-135 2.0 10.0 ≧10.0   0.40    2.0 >50.0  ≧2.0   50.0 —
    I-136 2.0 10.0 ≧10.0   0.40    2.0 >50.0  ≧2.0 >50.0 —
    I-137 2.0 2.0  ≧2.0   0.40  ≧0.4 >50.0  ≧2.0 ≧10.0 —
    I-138 10.0 10.0 ≧10.0   0.40   10.0 >50.0  ≧2.0 >50.0 —
    I-139 2.0 10.0   10.0   0.40    0.40   50.0a    2.0   50.0a —
    I-140 2.0 10.0   10.0   0.40    0.40 >50.0    2.0 >50.0 —
    I-141 2.0 ≧2.0    2.0   0.40  ≧2.0 >50.0   10.0 >50.0 —
    I-142 2 10   50   0.4    0.4 ≧50    2 >50 —
    I-143 2.0 50.0   10.0   2.0 ≧10.0 >50.0 >50.0 >50.0 11.0
    I-144 10.0 50.0   10.0   2.0   10.0 >50.0 >50.0 >50.0 11.0
    I-145 50.0 50.0   50.0   2.0 >50.0 >50.0 >50.0 >50.0 >33.0
    I-146 2.0 10.0   50.0   2.0   50.0 >50.0   50.0 >50.0 —
    I-147 10.0 50.0 >50.0   2.0    2.0 >50.0   50.0 >50.0 33.0
    I-148 10.0 50.0 >10.0   2.0   50.0 >50.0   50.0 >50.0 33.0
    I-149 10.0 50.0   50.0   2.0    2.0 >50.0 >50.0 >50.0 11.0
    I-150 2.0 50.0 ≧10.0   2.0   10.0 >50.0   10.0 >50.0 —
    I-151 10.0 50.0   10.0   2.0    2.0 >50.0 >50.0 >50.0 11.0
    I-152 10.0 50.0   50.0   2.0 >50.0 >50.0 >50.0 >50.0 >33.0
    I-153 2.0 >50.0   50.0   2.0 >50.0 >50.0   50.0 >50.0 >33.3
    I-154 2.0 50.0   10.0   2.0   50.0 >50.0 >50.0 >50.0 3.7
    I-155 2.0 50.0   10.0   2.0   10.0 >50.0   50.0 >50.0 33.3
    I-156 10.0 50.0   50.0   2.0   10.0 >50.0   10.0 >50.0 —
    I-157 10.0 ≧10.0   10.0   2.0 ≧10.0 >50.0   50.0 ≧50.0 —
    I-158 10.0 >50.0   50.0   2.0 >50.0   50.0   10.0 >50.0 —
    I-159 10.0 ≧10.0 ≧50.0   2.0    2.0 >50.0 ≧10.0 >50.0 —
    I-160 2.0 ≧10.0   10.0   2.0    2.0 >50.0 ≧50.0 >50.0 —
    I-161 10.0 10.0   50.0   2.0   10.0 >50.0  ≧2.0 >50.0 —
    I-162 10.0 2.0   10.0   2.0   10.0 >50.0    2.0 >50.0 —
    I-163 10.0 50.0 ≧10.0   2.0    2.0 >50.0   10.0 >50.0 —
    I-164 50.0 10.0   10.0   2.0    2.0 >50.0   50.0 >50.0 —
    I-165 2.0 2.0    2.0 ≧0.08    2.0 >50.0    2.0 >50.0 —
    I-166 2.0 2.0  >2.0 ≧0.08    2.0 >50.0   10.0 ≧50.0 —
    I-167 2.0 ≧0.4    2.0 ≧0.08    2.0   50.0  ≧0.4 >50.0 —
    I-168 0.40 0.40    2.0 ≧0.4  ≧0.4 >50.0    2.0 ≧10.0 1.2
    I-169 10.0 50.0 ≧10.0 ≧0.4   50.0 >50.0 >50.0 >50.0 11.0
    I-170 10.0 ≧50.0   50.0 ≧2.0 >50.0 >50.0   50.0 >50.0 —
    I-171 0.08 0.08    0.08   0.08  ≧0.4 ≧10.0    0.08  ≧2.0 —
    I-172 2.0 50.0   10.0   2.0   50.0 >50.0   10.0 >50.0 —
    I-177 2.0 2.0    2.0   0.08    0.4 >50.0   10.0 >50.0 —
    I-178 2.0 ≧0.4    2.0   0.4    2.0 >50.0    0.4 ≧50.0 —
    I-179 2.0 ≧2.0   10.0   0.4  >2.0 >50.0   10.0 >50.0 —
    I-180 2.0 50.0 >50.0   0.4   10.0 >50.0   10.0 >50.0 —
    I-181 0.4 0.08  ≧0.08   0.08    0.4   10.0    0.08 ≧10.0 —
    I-182 2.0 2.0    2.0   0.08    2.0 >50.0    0.4 >50.0 —
    I-183 10.0 >50.0 >50.0   2.0   50.0 >50.0    2.0 >50.0 —
    I-184 2.0 0.4    0.4   0.08    2.0   50.0    0.08 >50.0 —
    I-185 0.4 0.4    0.4   0.08    0.08 ≧10    0.08 ≧50.0 —
    I-186 0.4 2    2   0.08    0.08 >50.0    0.4 >50.0 —
    I-187 2 10   10   0.4    0.4 ≧50.0    0.4 >50.0 —
    I-188 0.4 2    2   0.08    0.4 >50.0    0.4 >50.0 —
    I-189 0.4 0.4    0.4   0.08    0.4 >50.0    0.08   50.0 —
    I-191 0.4 ≧0.4  ≧0.4   0.08    0.4   50    0.08 ≧10 —
    I-192 0.4 ≧2    2   0.08    0.4   50    0.08 ≧50 —
    I-193 ≧0.08 ≧0.08    0.08   0.08    0.4    2    0.08  ≧2 —
    I-194 10 50   50   2 ≧10 >50   10 >50 —
    I-195 2 2  ≧2   2    2 >50    2 >50 —
    I-196 2 10   10   0.4    2 >50    2 >50 —
    I-197 0.4 10   10   0.4  ≧2 >50    0.4 >50 —
    I-198 0.4 0.08    0.08   0.08    0.4    2    0.08  ≧2 —
    I-200 2 >50 >50   2    2 >50    2 >50 —
    I-201 2 10  ≧2   0.4  ≧0.4 >50    0.08 >50 —
    I-202 ≧0.4 2    2   0.08    0.4 ≧50    0.4 >50 —
    I-204 2 10    2   0.4    2 >50    2 >50 —
    I-205 0.4 0.4  ≧0.08   0.4    0.4 >50    0.08 >50 —
    I-206 0.4 0.4    0.4   0.08    0.4 >50    0.08 >50 —
    I-207 2 10  ≧2   0.08    2 >50    0.08 >50 —
    I-208 0.4 2    2   0.4    0.4 >50    0.08 >50 —
    I-209 2 50 ≧10   0.08   10 >50    0.08 >50 —
    I-210 0.4 ≧0.4    0.4   2    0.4 >50    0.08 >50 —
    I-211 0.4 0.08    0.08   0.08    0.4 >50    0.08 >50 —
    I-212 0.4 0.08  ≧0.08   0.08    0.4 >50    0.08 >50 —
    I-213 0.4 0.4  ≧0.08   0.08    0.4 >50    0.08 >50 —
    I-214 2 2 ≧10   0.4    2 >50    0.08 >50 —
    I-218 10 10   50   2    2 ≧50    2 >50 —
    I-219 2 10 >10   0.4 ≧10 >50 >50 >50 —
    I-220 0.4 0.4    0.4   0.08    0.4 ≧10    0.08 >50 —
    I-222 2 2   10   0.40    0.4 >50    0.4   50 —
    I-224 2 10 >50   2    2 >50    0.08 >50 —
    I-225 10 >50 >10   2 ≧50 >50   10 >50 —
    I-226 2 2  ≧2   0.08    2 >50    0.08 >50 —
    I-229 2 2    2   0.08    0.4 >50    2 >50 —
    I-230 2 10 ≧10   0.4    0.4 >50    0.08 ≧10 —
    I-231 2 0.4    0.4   0.08    2 >50    0.08 ≧10 —
    I-232 10 10   50   2    0.4 >50    2 >50 —
    I-233 0.4 0.4    0.4   0.08    0.4  ≧2    2.0 ≧10 —
    I-234 2 2    2   0.08    2 >50    2 >10 —
    I-235 2 2  ≧2   0.4    2 >50    2 ≧50 —
    I-238 2 10   10   2   10 >50   10 >50 —
    I-239 2 2    2   0.08    0.08 ≧10    0.08 ≧10 —
    I-242 2 2    2   0.4    2 >50    2 ≧50 —
    I-243 10 2   10   2   50 >50    2 ≧50 —
    I-244 2 2   10   0.4    2   10    0.4 ≧50 —
    I-245 0.4 0.40    2.0   0.08    0.08   50    0.08  ≧2 —
    I-246 0.4 0.08    0.4   0.08    0.08   10    0.1  ≧2 —
    I-247 0.4 0.4    2.0   0.08    0.4 >50    2 ≧10 —
    I-248 2.0 2.0 ≧10   0.4    0.4 >50   10 ≧10 —
    I-249 2.0 2.0 ≧10   2.0    2.0 >50   10 >50 —
    I-250 2.0 10.0 >50   2.0    2.0 >50    2 >50 —
    I-251 0.4 2.0    2.0   0.08    0.4 >50    0.4 >10 —
    I-253 0.4 0.4    0.4   0.08    0.4 ≧50    0.08  ≧2 —
    I-254 2.0 >50 ≧10   2.00 >50 >50 >50 >50 —
    I-255 2.0 ≧10 ≧10   2.00 ≧10 >50    2 >50 —
    I-257 2.0 2.0   50.0   0.4    0.40 >50    2 >50 —
    I-258 0.4 0.08    0.4   0.08    0.40 ≧10    0.08  ≧2 —
    I-259 0.4 0.08    0.4   0.08    0.40 >50    0.08 >10 —
    I-262 0.4 0.08    2.0 ≧0.08    0.40 ≧10    0.08  ≧2 —
    I-263 0.4 0.4    2.0 ≧0.08    0.40 ≧50    0.4 >10 —
    I-264 0.4 2    2   0.08    0.4   50    0.08 >50 —
    I-265 0.4 2    2   0.08    0.4 ≧50    0.08 ≧50 —
    I-266 2 10   10   2    2 ≧50    2 >50 —
    I-267 0.4 2    2   0.08    0.4 >50    0.4 >50 —
    I-268 2 2  ≧2   0.08    2 >50    0.4 >50 —
    I-269 10 >50 >50   0.4   10 >50    2 >50 —
    I-270 0.4 2    2   0.08    0.4 >50 >50 >50 —
    I-271 10 ≧10   50   2.0   10   50    2 >50 —
    I-272 2 2    2   2.0    2 >50    2 >50 —
    I-273 0.4 2   50   0.08    0.4 >50    2 >50 —
    I-274 0.4 0.08    0.4   0.08    0.4    2    0.08 >50 —
    I-276 2 2    2   0.4    2   10    0.08 >50 —
    I-277 0.4 0.4    2   0.08    0.08 >50    0.08 >50 —
    I-278 2 0.4    2   0.4    2   10    0.4 >50 —
    I-279 0.08 0.08    2   0.08    0.08 >50    0.08 >50 —
    I-280 2 2    2   0.08    0.4   50    0.08 ≧50 —
    I-281 0.08 0.08    2   0.08    0.08 >50    0.08 >50 —
    I-282 2 2 ≧10   0.4    2   10    0.4 >50 —
    I-283 10 50 >50   2   10 >50    2 >50 —
    I-284 0.4 0.08    2   0.08    0.40 >50    0.08 >50 —
    I-285 2 0.4  ≧2   0.4    2   50    0.4 ≧50 —
    I-286 2 2 ≧50   2    2 ≧50    2 >50 —
    I-287 2 0.4    0.4   0.4    2   10    0.08 ≧50 —
    I-289 2 0.08    0.4   0.08    0.4 ≧10    0.08 >50 —
    I-290 2 10 ≧10   0.4   10 >50    2 >50 —
    I-292 2 2    2   0.08    0.4 >50    0.4 >50 —
    I-293 10 >50 >50   2   50 >50 >50 >50 —
    I-294 0.4 10   10   0.4    0.08 >50    2.0 >50 —
    I-295 2 2   10   0.4    2 >50    2.0 >50 —
    I-296 2 2   10   2    2 >50    2.0 >50 —
    I-297 10 10 >50   2 >50 >50 >50 >50 —
    I-298 2 10 ≧10   2    2 >50 >50 >50 —
    I-299 2 10   50   0.4    2 >50   50.0 >50 —
    I-300 2 2   50   0.08    0.4 >50    0.08 >50 —
    I-301 10 >50 >50   2  ≧2 >50   10.0 >50 —
    I-302 10 50   50 ≧2    2 >50    0.08 >50 —
    I-303 0.4 2  ≧2   0.08    2 >50    2.00 >50 —
    I-304 2 2 ≧10   0.08    0.4 >50    2.0 >50 —
    I-305 0.4 2    2   0.08    0.4 >50    0.4 >50 —
    I-307 ≧0.4 2    2   0.08    0.4 >50    0.08 >50 —
    I-308 0.4 2    2   0.4    2   50    0.08 >50 —
    I-310 2 2  ≧2   0.08    0 >50    0.08 >50 —
    I-313 >50 50 >50   2   50 >50   50.0 >50 —
    I-314 >50 50 >50   2   10 >50 >50 >50 —
    I-315 0.4 0.08    0.4   0.08    0.4    2    0.08 >50 —
    I-316 0.4 2    2   0.08    0.08 ≧10    0.08 >50 —
    I-319 50 >50 >50   2   10 >50 >50 >50 —
    I-321 0.4 0.4  ≧0.4   0.08    0.4 >50    2.0 >50 —
    I-323 0.4 0.4  ≧0.4   0.08    0.08 >50    0.08 >50 —
    I-324 2 10   10   0.4    2 >50    2.0 >50 —
    I-325 50 >50 >50   2   50 >50 >50 >50 —
    I-326 2 2    2   0.08    0.08 >50   10 >50 —
    I-328 2 10    2   0.4    0.4 >50   10 >50 —
    I-329 10 50   50   2    2 >50   50 >50 —
    I-330 2 10   10   0.08    0.4 >50    2 >50 —
    I-331 2 10 >50   0.08    0.08 >50   10 >50 —
    I-332 >50 >50 >50   2    2 >50 >50 >50 —
    I-333 2 2   10   0.4   10   50    2 >50 —
    I-335 10 50   50   2    2 >50   10 >50 —
    I-338 2 10    2   0.08    0.08 >50   10 >50 —
    I-339 10 >50 >50   2    2 >50   50 >50 —
    I-340 10 50   50   2    2 >50   50 >50 —
    aDenotes an average value derived from two experimental trials
  • TABLE 3
    In Vitro Pathogen Growth Inhibition Assay Results
    Pathogens
    Bc Cg Dm Fm Fv Pc Rs St Sc
    Percentage of Inhibition
    Cmpd. ≧90% ≧90% ≧90% ≧90% ≧90% ≧90% ≧90% ≧90% ≧75%
    No. Compound Concentration (ppm)
    I-173 50 ≧50 >50 50.0 >50 >50 10 >50 —
    I-174 10 50 10 10 10 >50 50 >50 —
    I-175 2 50 10 10 10 >50 >50 >50 —
    I-190 10 >50 >50 10 50 >50 10 >50 —
    I-199 10 50 50 10 10 >50 50 >50 —
    I-203 50 50 50 10 50 >50 10 >50 —
    I-215 10 50 >50 10 10 >50 0.08 >50 —
    I-221 10 50 >50 10 50 >50 >50 >50 —
    I-227 50 >50 >50 10 >50 >50 0.4 >50 —
    I-228 10 >50 >50 10 >50 >50 2 >50 —
    I-256 50.0 50.0 50.0 10.0 50.0 >50 50 >50 —
    I-275 50 50 >50 50 >50 >50 50 >50 —
    I-291 50 >50 50 10 50 >50 2 >50 —
    I-306 50 >50 >50 10 >50 >50 >50 >50 —
    I-309 50 >50 >50 10 10 >50 >50 >50 —
    I-311 50 >50 >50 50 >50 >50 >50 >50 —
    I-312 >50 >50 >50 10 >50 >50 2.0 >50 —
    I-317 50 50 >50 10 ≧10 >50 >50 >50 —
    I-318 50 >50 >50 10 >50 >50 >50 >50 —
    I-320 50 >50 >50 50 50 >50 >50 >50 —
    I-322 10 >50 >50 10 ≧10 >50 >50 >50 —
    I-334 >50 >50 >50 50 >50 >50 >50 >50 —
    I-336 50 >50 >50 10 10 >50 >50 >50 —
    I-337 50 >50 >50 10 10 >50 10 >50 —
    I-341 >50 >50 >50 >50 >50 >50 >50 >50 —
    • Example 2: Foliar Protection Test for Barley Powdery Mildew Control
  • Plants (Hordeum vulgare cv. Perry) were grown for 6 days in 2-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained in a growth chamber at conditions of 20 to 21° C., 16 hour light cycle, 400 uM of light, 70% humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Blumeria graminis f sp. hordei, plants were kept at conditions of 20 to 22° C., 70% relative humidity, and 200 uM of light to facilitate infection and disease development.
  • At 6 days after planting (1st true leaf fully expanded), the test compounds were dissolved in a solution of 5% acetone and 0.005% Tween 80 surfactant. An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted. The amount of the compound applied to the leaves was typically 200, 100, 50, 10, or 2 ppm, but it may vary.
  • At 24 hours after treatment, the plants were moved to a cooler chamber and inoculated by shaking well-colonized, untreated stock plants above the treated plants. This allowed producing a settling cloud of spores and resulting in uniform infection.
  • Efficacy was evaluated in 7 days later by examining leaves for colonization and growth of mildew. Table 4 lists the results of barley powdery mildew control at a compound concentration of 10 ppm or lower. Compounds having an activity designated as “AA” provided a compound having >85% control of barley powdery mildew; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of barley powdery mildew; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of barley powdery mildew; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of barley powdery mildew; and compounds having an activity designated as “D” provided a compound having <25% control of barley powdery mildew.
  • TABLE 4
    Compounds with Barley Powdery Mildew
    Control at 10 ppm or Lower
    Barley Powdery Mildew Control at a
    Cmpd. No. compound concentration of 10 ppm or lower
    I-003 A
    I-014 AA
    I-020 AA
    I-030 AA
    I-034 AA
    I-035 A
    I-064 A
    I-074 AA
    I-082 AA
    I-084 AA
    I-089 B
    I-090 A
    I-092 C
    I-094 AA
    I-095 AA
    I-096 B
    I-171 AA
    I-181 AA
    I-184 A
    I-185 AA
    I-186 A
    I-188 AA
    I-189 AA
    I-191 AA
    I-192 AA
    I-193 AA
    I-198 AA
    I-202 A
    I-205 AA
    I-206 AA
    I-208 AA
    I-210 AA
    I-211 AA
    I-212 AA
    I-213 A
    I-220 AA
    I-229 AA
    I-231 AA
    I-233 AA
    I-234 AA
    I-239 AA
    I-246 A
    I-251 AA
    I-253 A
    I-258 A
    I-259 A
    I-262 A
    I-263 A
    I-274 AA
    I-281 AA
    I-284 AA
    I-285 A
    I-287 AA
    I-289 AA
    I-292 AA
    I-307 AA
    I-308 AA
    I-310 AA
    I-316 AA
    I-323 AA
    • Example 3: Foliar Protection for Cucumber Powdery Mildew Control
  • Plants (Cucumis sativus cv. Straight Eight) were grown for 10 days in 2.5-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained in a growth chamber at conditions of 23 to 27° C., 16 hour light cycle, ambient humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Sphaerotheca fuliginea, plants were kept at conditions of 23 to 27° C., 16 hour light cycle, 60% relative humidity, and with sub-irrigation as needed to facilitate infection and disease development.
  • At 10 days after planting (1st true leaf 75% expanded and 2′ leaf not yet emerged) the test compounds were dissolved in 5% acetone and 0.05% Tween 20 surfactant. An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted. The amount of the compound applied to the leaves was typically 200, 100, 50, or 10 ppm, but it may vary.
  • At 24 hours after treatment, the plants were moved to a cooler chamber and inoculated by shaking well-colonized, untreated stock plants above the treated plants. This allowed producing a settling cloud of spores and resulting in uniform infection. Inoculated plants were kept near other sporulating stock plants to allow for infection of newly emerging leaves.
  • Efficacy was evaluated in 7 days later by examining leaves for colonization and growth of mildew. Table 5 lists the results of cucumber powdery mildew control at a compound concentration of 10 ppm or lower. Compounds having an activity designated as “AA” provided a compound having >85% control of cucumber powdery mildew; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of cucumber powdery mildew; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of cucumber powdery mildew; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of cucumber powdery mildew; and compounds having an activity designated as “D” provided a compound having <25% control of cucumber powdery mildew.
  • TABLE 5
    Compounds with Cucumber Powdery
    Mildew Control at 10 ppm or Lower
    Cucumber Powdery Mildew Control at a
    Cmpd. No. compound concentration of 10 ppm or lower
    I-003 AA
    I-014 AA
    I-020 AA
    I-030 AA
    I-034 AA
    I-035 AA
    I-064 AA
    I-074 AA
    I-082 AA
    I-089 AA
    I-090 A
    I-092 AA
    I-094 AA
    I-095 AA
    I-096 AA
    I-171 AA
    I-181 AA
    I-184 AA
    I-185 AA
    I-186 C
    I-188 AA
    I-189 AA
    I-191 AA
    I-192 AA
    I-193 AA
    I-198 AA
    I-202 AA
    I-205 AA
    I-206 AA
    I-208 AA
    I-210 AA
    I-211 AA
    I-212 AA
    I-213 AA
    I-220 AA
    I-229 AA
    I-231 AA
    I-233 A
    I-234 AA
    I-239 AA
    I-246 AA
    I-251 AA
    I-253 AA
    I-258 AA
    I-259 AA
    I-262 AA
    I-263 AA
    I-274 AA
    I-281 AA
    I-284 AA
    I-285 AA
    I-287 AA
    I-289 AA
    I-292 AA
    I-307 AA
    I-308 AA
    I-310 AA
    I-316 AA
    I-323 AA
    • Example 4: Foliar Protection Test for Wheat Septoria Leaf Blotch Control
  • Plants (Triticum aestivum cv. WinterHawk) were grown for 14 days in 2-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained at in a growth chamber at conditions of 24 to 26° C., 16 hour light cycle, 400 uM of light, 60% humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Mycosphaerella graminicola (synthetic Septoria tritici), plants were kept at conditions of 16 to 20° C., 75% relative humidity, and 200 uM of light to facilitate infection and disease development.
  • Cultures of the pathogen were maintained on oatmeal agar amended with cefotaxime (200 mg/L) at an ambient temperature, and the 14-day old cultures were used for preparing spore suspensions at a concentration of 1×107 million spores/ml in a solution of 0.01% Tween 20 in water.
  • At 14 days after planting (2 true leaves fully expanded), the test compounds were dissolved in a solution of 5% acetone and 0.01% Tween 20 surfactant. An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted. The amount of the compound applied to the leaves was typically 100, or 25 ppm, but it may vary.
  • At 1 hour after treatment, the plants were moved to a cooler chamber and inoculated by spraying the spore suspension until all leaf surfaces were wetted. The inoculated plants were then incubated for 3 days in a misting tent covered with a thin shade cloth. After misting for 3 days, they were removed from the mist tent and grown for 16 days before rating.
  • Efficacy was evaluated in 16 days later by examining the two treated leaves for diseased area. Table 6 lists the results of wheat septoria leaf blotch control at a compound concentration of 25 ppm or lower. Compounds having an activity designated as “AA” provided a compound having >85% control of wheat septoria leaf blotch; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of wheat septoria leaf blotch; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of wheat septoria leaf blotch; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of wheat septoria leaf blotch; and compounds having an activity designated as “D” provided a compound having <25% control of wheat septoria leaf blotch.
  • TABLE 6
    Compounds with Wheat Septoria Leaf
    Blotch Control at 25 ppm or Lower
    Septoria Leaf Blotch Control at a
    Cmpd. No. compound concentration of 25 ppm or lower
    I-003 C
    I-014 D
    I-020 B
    I-030 B
    I-034 B
    I-035 C
    I-064 A
    I-074 AA
    I-082 AA
    I-084 AA
    I-089 C
    I-090 A
    I-092 B
    I-094 A
    I-095 AA
    I-096 B
    I-171 AA
    I-181 B
    I-184 C
    I-185 AA
    I-186 D
    I-188 C
    I-189 A
    I-191 AA
    I-192 A
    I-193 AA
    I-198 AA
    I-202 D
    I-205 AA
    I-206 AA
    I-208 AA
    I-210 AA
    I-211 AA
    I-212 AA
    I-213 AA
    I-220 B
    I-229 D
    I-231 C
    I-233 C
    I-234 C
    I-239 D
    I-246 A
    I-251 C
    I-253 AA
    I-258 B
    I-259 C
    I-262 AA
    I-263 D
    I-274 AA
    I-281 AA
    I-284 AA
    I-285 C
    I-287 AA
    I-289 AA
    I-292 B
    I-307 B
    I-308 AA
    I-310 B
    I-316 A
    I-323 AA
    • Example 5: Foliar Protection Test for Wheat Fusarium Head Blight Control
  • Plants (Triticum aestivum cv. Samson) were grown until flowing in 4.5-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained at in a growth chamber at conditions of 20 to 21° C., 16 hour light cycle, 400 uM of light, 70% humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Fusarium graminearum, plants were kept at the same conditions to facilitate disease development.
  • Cultures of the pathogen were maintained on ¼ strength potato dextrose agar at conditions of 21° C. and 16 hour light cycle. New cultures were started at regular intervals so spores were readily available. Conidia were harvested by flooding the plates with distilled water, scraping, and then filtering through cheesecloth. Spore concentration is adjusted to 5×105 conidia per ml in water.
  • When wheat plants were flowering, the test compounds were dissolved in a solution of 5% acetone and 0.02% Tween 20 surfactant. An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted. The amount of the compound applied to the leaves was typically 100, or 25 ppm, but it may vary.
  • At 24 hours after treatment, the plants were inoculated by spraying the conidial suspension until the heads were thoroughly wetted. The inoculated plants were then placed for 3 days in a misting tent at 22° C. during the day and 17° C. during the night with 15 hours of light. After misting, they remained in these same growth conditions for further disease development
  • Efficacy was evaluated in 14 days later by examining plant heads for symptom development in terms of necrotic spikelets. Table 7 lists the results of wheat fusarium head blight control at a compound concentration of 25 ppm or lower. Compounds having an activity designated as “AA” provided a compound having >85% control of wheat fusarium head blight; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of wheat fusarium head blight; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of wheat fusarium head blight; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of wheat fusarium head blight; and compounds having an activity designated as “D” provided a compound having <25% control of wheat fusarium head blight.
  • TABLE 7
    Compounds with Wheat Fusarium Head
    Blight Control at 25 ppm or Lower
    Wheat Fusarium Head Blight Control at a
    Cmpd. No. compound concentration of 25 ppm or lower
    I-003 B
    I-014 C
    I-020 B
    I-030 B
    I-034 C
    I-035 B
    I-064 C
    I-074 C
    I-082 C
    I-089 D
    I-090 D
    I-092 C
    I-094 A
    I-095 B
    I-096 D
    I-171 C
    I-181 B
    I-184 A
    I-185 A
    I-186 B
    I-188 D
    I-189 C
    I-191 C
    I-192 D
    I-193 B
    I-198 C
    I-202 D
    I-205 C
    I-206 B
    I-208 C
    I-210 C
    I-211 C
    I-212 B
    I-213 B
    I-220 C
    I-229 C
    I-231 C
    I-233 C
    I-234 C
    I-239 C
    I-246 B
    I-251 C
    I-253 B
    I-258 C
    I-259 B
    I-262 B
    I-263 B
    I-274 C
    I-281 C
    I-284 C
    I-285 C
    I-287 C
    I-289 C
    I-292 C
    I-307 C
    I-308 C
    I-310 C
    I-316 C
    I-323 C
    • Example 6: Foliar Protection Test for Wheat Leaf Rust Control
  • Plants (Triticum aestivum cv. Winterhawk) were grown for 11 days in 2.5-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained in a growth chamber at conditions of 20 to 21° C., 16 hour light cycle, 400 uM of light, 60% humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Puccinia triticina, plants were kept at conditions of 20 to 20° C. and 80% relative humidity to facilitate infection and disease development.
  • At 11 days after planting (3rd leaf fully expanded), the test compounds were dissolved in a solution of 5% acetone and 0.02% Tween 20 surfactant. An atomizer was used for applying the solution onto both sides of the leaves until thoroughly wetted. The amount of the compound applied to the leaves was typically 25 or 10 ppm, but it may vary.
  • Spores were collected from untreated, previously inoculated plants. The spore was suspended in a solution of 0.01% Tween 20 or 0.1% water agar.
  • At three hours after treatment, plants were inoculated by spraying the spore suspension on the underside of the leaves until they are wetted. Inoculated plants were then incubated for 24 hours in a misting tent at 20° C. After misting, they were grown at the same conditions as the incubation conditions with exception of having a 85% relative humidity.
  • Efficacy was evaluated in 10 days later by examining leaves for pustule formation and sporulation. Table 8 lists the results of wheat leaf rust control at a compound concentration of 10 ppm or lower. Compounds having an activity designated as “AA” provided a compound having ≧85% control of wheat leaf rust; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of wheat leaf rust; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of wheat leaf rust; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of wheat leaf rust; and compounds having an activity designated as “D” provided a compound having <25% control of wheat leaf rust.
  • TABLE 8
    Compounds with Wheat Leaf Rust Control at 10 ppm or Lower
    Wheat Leaf Rust Control at a
    Cmpd. No. compound concentration of 10 ppm or lower
    I-003 AA
    I-014 A
    I-020 B
    I-030 AA
    I-034 AA
    I-035 AA
    I-064 AA
    I-074 A
    I-082 B
    I-084 A
    I-089 AA
    I-090 AA
    I-092 AA
    I-094 C
    I-095 AA
    I-096 A
    I-171 B
    I-181 AA
    I-184 AA
    I-185 AA
    I-186 C
    I-188 AA
    I-189 AA
    I-191 AA
    I-192 AA
    I-193 AA
    I-198 AA
    I-202 A
    I-205 AA
    I-206 AA
    I-208 AA
    I-210 A
    I-211 A
    I-212 AA
    I-213 B
    I-220 C
    I-229 B
    I-231 AA
    I-233 AA
    I-234 AA
    I-239 AA
    I-246 A
    I-251 D
    I-253 AA
    I-258 A
    I-259 C
    I-262 AA
    I-263 AA
    I-274 AA
    I-281 AA
    I-284 AA
    I-285 AA
    I-287 AA
    I-289 AA
    I-292 AA
    I-307 AA
    I-308 AA
    I-310 C
    I-316 AA
    I-323 AA
    • Example 7: Foliar Protection Test for Asian Soybean Rust Control
  • Plants (Glycine max AG4832) were grown in 2.5-inch square pots containing Fafard germination mix amended with fertilizer. For propagation, plants were maintained in a growth chamber at conditions of 21 to 26° C., 16 hour light cycle, 600 uM of light, 65% humidity, and with sub-irrigation as needed. To maintain the pathogen stocks, plants are inoculated with the pathogen of Phakopsora pachyrhizi and placed in a mist tent for 24 hours. After inoculation with the pathogen, plants were grown at conditions of 20 to 24° C., 12 hour light cycle, 400 uE of light, and 80 to 85% relative humidity to facilitate infection and disease development. At 10 to 28 days after inoculation, spores were collected and stored at 4° C. before use.
  • At 16 to 19 days after planting, the test compounds were dissolved in a solution of 5% acetone and 0.02% Tween 20 surfactant. An air brush sprayer was used for applying the solution to the plant. Because of plant stature and angle of the leaves, chemistry accumulated mainly on the top of the leaf; leaves were wet but not dripping. The amount of the compound applied to the leaves was typically 25 or 100 ppm, but it may vary.
  • At 24 hours after treatment, the left lateral leaf from the first or second trifoliate (dependent upon the purpose of the experiment) was removed and placed in a petri dish with moist filter paper and inoculated. Leaflets were inoculated by spraying the spore suspension in a solution of 0.1% water agar on the bottom/abaxial side of the leaflet until they were covered with a fine mist. Typically, approximately 1 ml/leaflet was applied.
  • Percent disease area was evaluated in 14 days later via a software program, and efficacy was calculated based on the control leaves that were treated with the formulation without a test compound. Table 9 lists the results of Asian soybean rust control at a compound concentration of 25 ppm or lower. Compounds having an activity designated as “AA” provided a compound having >85% control of Asian soybean rust; compounds having an activity designated as “A” provided a compound having from 70% to 84% control of Asian soybean rust; compounds having an activity designated as “B” provided a compound having from 50 to 69% control of Asian soybean rust; compounds having an activity designated as “C” provided a compound having from 25 to 49% control of Asian soybean rust; and compounds having an activity designated as “D” provided a compound having <25% control of Asian soybean rust.
  • TABLE 9
    Compounds with Asian Soybean Rust Control at 25 ppm or Lower
    Asian Soybean Rust Control at a
    Cmpd. No. compound concentration of 25 ppm or lower
    I-003 A
    I-014 A
    I-020 B
    I-030 A
    I-034 AA
    I-035 A
    I-064 A
    I-074 C
    I-082 B
    I-089 A
    I-090 B
    I-092 B
    I-094 C
    I-095 AA
    I-096 A
    I-171 A
    I-181 B
    I-184 B
    I-185 AA
    I-186 D
    I-188 B
    I-189 A
    I-191 A
    I-192 AA
    I-193 AA
    I-198 AA
    I-202 A
    I-205 AA
    I-206 AA
    I-208 AA
    I-210 AA
    I-211 AA
    I-212 AA
    I-213 B
    I-220 B
    I-229 C
    I-231 A
    I-233 A
    I-234 A
    I-239 AA
    I-246 AA
    I-251 C
    I-253 A
    I-258 C
    I-259 B
    I-262 AA
    I-263 AA
    I-274 A
    I-281 D
    I-284 B
    I-285 C
    I-287 AA
    I-289 AA
    I-292 B
    I-307 C
    I-308 C
    I-310 C
    I-316 A
    I-323 AA
    • Example 8: Seed Protectant for Soybean Seedling Disease
  • The pathogen of Rhizoctonia solani inoculum was grown on sterile sorghum; and the pathogen of Pythium ultimum inoculum was grown on white millet.
  • Soybean seeds (Glycine max cv.AG4832) were planted in 2.5-inch square pots containing Berger BM2 germination mix amended with fertilizer (e.g., 14-14-14). Pots with soil were inoculated with the pathogen of R. solani or P. ultimum at time of planting. A hole was pressed into the soil to a depth of about 2 to 3 cm; the inoculum was added to the hole, followed by the seed which was then covered with soil. Two seeds per pot were planted. Plants were grown in a growth chamber at conditions of 20 to 24° C., 14 hour light cycle, 500 uM of light, and 65% humidity. The pots inoculated with P. ultimum were sub-irrigated every day; and the pots inoculated with R. solani were sub-irrigated every other day.
  • Seedling emergence was captured at 7 and 14 days after seeding. At 14 days, the top of the plant was removed and fresh weight was recorded. The plant weights from the seeds treated with test compounds (e.g., in formulations) were compared to the ones either from the inoculated non-treated seeds or non-inoculated non-treated seeds. Table 10 lists the results of the R. solani control in soybean upon seed treatment with test compounds, and Table 11 lists the results of the P. ultimum control in soybean upon seed treatment with test compounds, respectively.
  • TABLE 10
    R. solani Control in Soybean from Treated Seeds
    Improvement
    Treatment Rate Plant Weight in plant weight
    Treatment (mg/seed) (g) (%)a
    Inoculated — 0.74 9.2
    non-treated seeds
    I-064 0.025 6.41 79.9
    I-074 0.025 2.06 25.7
    I-095 0.025 7.54 93.9
    I-181 0.025 3.16 39.4
    I-191 0.025 6.39 79.6
    I-193 0.025 6.83 85.0
    Non-inoculated — 8.03 100
    non-treated seeds
    aExpressed as a percentage of the maximum possible; Calculated by (weight of treated inoculated plants/weight of non-inoculated non-treated controls) × 100%.
  • TABLE 11
    P. ultimum Control in Soybean from Treated Seeds
    Improvement
    Treatment Rate Plant Weight in plant weight
    Treatment (mg/seed) (g) (%)a
    Inoculated — 3.16 48
    non-treated seeds
    I-064 0.025 5.49 88
    I-074 0.025 4.33 69
    I-095 0.025 4.65 74
    I-181 0.025 4.73 76
    I-191 0.025 5.00 80
    I-193 0.025 5.36 86
    Non-inoculated — 6.25 100
    non-treated seeds
    aExpressed as a percentage of the maximum possible; Calculated by (weight of treated inoculated plants/weight of non-inoculated non-treated controls) × 100%.
    • Example 9: Seed Protectant for Corn Seedling Disease
  • The pathogen of Fusarium graminearum was cultured aseptically on whole sorghum using standard mycological techniques and air-dried. The sorghum inoculum was then coarsely ground using a coffee mill before use.
  • Two corn seeds (Zea mays cv. DKC 36-34 or DKC 63-33) were planted in 2.5-inch square pots containing Berger BM6 15P germination mix amended with fertilizer (e.g., 19-6-12). The soil pots were pre-drenched and two two-inch holes were pressed into the soil. The sorghum inoculums ( 1/16 teaspoon) was added to each hole, followed by one corn seed (treated with or without test compounds). The two seeds were sown in opposite corners of the pot. Plants were grown in a growth chamber at conditions of 20 to 24° C., 16 hour light cycle, 500 uM of light, 65% humidity, and with sub-irrigation twice daily.
  • Seedling emergence and total plant height (cm) were recorded at 7 and 14 days after planting.
  • The plant heights from the seeds treated with test compounds (e.g., in formulations) were compared to the ones either from the inoculated non-treated seeds or non-inoculated non-treated seeds. Tables 12 and 13 list the results of the F. graminearum control in corn upon seed treatment with test compounds.
  • TABLE 12
    F. graminearum Control in Corn from Treated Seeds
    Improvement
    Treatment Rate Plant Height in plant weight
    Treatment (mg/seed) (cm) (%)a
    Inoculated 18.91 41
    non-treated seeds
    I-020 0.025 40.53 87
    I-095 0.025 39.41 85
    I-181 0.025 47.63 103
    I-185 0.025 45.66 99
    I-191 0.025 35.50 77
    Non-inoculated 46.34 100
    Non-treated seeds
    aExpressed as a percentage of the maximum possible; Calculated by (height of treated inoculated plants/height of non-inoculated non-treated controls) × 100%.
  • TABLE 13
    F. graminearum Control in Corn from Treated Seeds
    Improvement
    Treatment Rate Plant Height in plant weight
    Treatment (mg/seed) (cm) (%)a
    Inoculated 20.75 51
    non-treated seeds
    I-095 0.025 43.97 109
    I-193 0.025 40.66 101
    I-205 0.025 41.47 103
    I-206 0.025 42.72 106
    I-253 0.025 37.81 94
    Non-inoculated 40.41 100
    non-treated seeds
    aExpressed as a percentage of the maximum possible; Calculated by (height of treated inoculated plants/height of non-inoculated non-treated controls) × 100%.
    • Example 10: Early Foliar Disease Control Via Seed Treatment
  • Barley seeds (Hordeum vulgare cv. Perry or Conlon) were treated with a test compound dissolved in pure acetone, in which the acetone solution (1 mL) was used per 50 seeds in glass jars in a fume hood. The seeds were swirled in the glass jars by hand until no obvious presence of acetone remained and the seeds were mostly dry.
  • Plants were grown for 7 days in 2-inch square pots containing Metromix 200 medium amended with fertilizer. For propagation, plants were maintained in a growth chamber at conditions of 20 to 21° C., 16 hour light cycle, 400 uM of light, 50% humidity, and with sub-irrigation as needed. After inoculation with the pathogen of Blumeria graminis f sp. hordei, plants were kept at conditions of 20 to 22° C., 200 uM of light, 70% humidity to facilitate infection and disease development.
  • At 7 days after planting (1st true leaf fully expanded), the plants were moved to the cooler chamber and inoculated by shaking well-colonized, untreated stock plants above the treated material. By doing so, it produced a settling cloud of spores and resulted in uniform infection.
  • Efficacy was evaluated in 7 days later by examining leaves for colonization and growth of powdery mildew. Each side of each leaf was assigned a severity rating of 0, 1, 5, 10, 25, 50, 75, or 100 percent diseased area. Table 14 lists the results of barley powdery mildew control upon seed treatment with test compounds.
  • TABLE 14
    Barley Powdery Mildew control via Seed Treatment
    Barley Powdery
    Treatment Rate Mildew Reduction
    Treatment (mg/seed) (%)
    I-020 0.025 91
    I-181 0.025 57
    I-191 0.025 94
    I-193 0.025 96
    • Embodiments
  • For further illustration, additional non-limiting embodiments of the present disclosure are set forth below.
  • For example, embodiment 1 is a composition for agricultural use comprising an effective amount of a fungicidal compound of Formula I:
  • Figure US20170166585A1-20170615-C00352
  • or a salt thereof, wherein:
  • R1 is hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy;
  • R2 is heteroaryl, alkyl, cycloalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, oxo, or cyano; or R2 is —C(O)R21, wherein R21 is hydroxyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano;
  • R3 is —C(O)R31, —C(O)N(R32R33), or —R34SO2N(R32R33), wherein R31 is hydroxyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or 1-heterocycl-1-yl, each of which may be optionally independently substituted with one or more of hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano; R32 and R33 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C3-C6 cycloalkyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C1-C4 alkoxy, oxo, or cyano; and R34 is a bond, C1-C4 alkyl, C1-C4 haloalkyl, or C2-C4 alkenyl;
  • R4 is hydrogen or —OR6, wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of an oxygen atom, hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, cyano, —N(R61R62), —C(O)N(R61R62), or SO2R63, wherein R61 and R62 are each independently hydrogen or C1-C6 alkyl, and R63 is C1-C6 alkyl;
  • R4′ is hydrogen or C1-C4 alkyl, which may be optionally substituted with one or more of hydroxyl, C1-C4 alkoxy, or cyano;
  • R5 and R5′ are each independently hydrogen or C1-C4 alkyl; R7 is hydroxyl or C1-C4 alkyl, which may be optionally substituted with one or more of hydroxyl, C1-C4 alkoxy, oxo, or cyano; or R7 is —OR10, wherein R10 is C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkylmethyl, heterocyclyl, or aryl(C1-C4)alkyl, each of which may be optionally independently substituted with one or more of hydroxyl, an oxygen atom, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano; and
  • R8 is hydrogen, halogen, or cyano.
  • Embodiment 2 is the composition of embodiment 1 wherein R1 is C1-C4 alkyl.
  • Embodiment 3 is the composition of embodiment 2 wherein R1 is methyl.
  • Embodiment 4 is the composition of any one of embodiments 1 to 3 wherein R2 is —C(O)R21, wherein R21 is C1-C4 alkoxy.
  • Embodiment 5 is the composition of any one of embodiments 1 to 3 wherein R2 is —CH2OH.
  • Embodiment 6 is the composition of any one of embodiments 1 to 3 wherein R2 is —CH2O(C1-C4)alkyl.
  • Embodiment 7 is the composition of any one of embodiments 1 to 3 wherein R2 is cyclobutyl.
  • Embodiment 8 is the composition of any one of embodiments 1 to 3 wherein R2 is unsubstituted heteroaryl.
  • Embodiment 9 is the composition of embodiment 8 wherein R2 is a 5-membered heteroaryl.
  • Embodiment 10 is the composition of embodiment 9 wherein R2 is oxazolyl, pyrazolyl, triazolyl, isoxazolyl, or thienyl.
  • Embodiment 11 is the composition of embodiment 10 wherein R2 is oxazolyl, pyrazolyl, or triazolyl.
  • Embodiment 12 is the composition of embodiment 11 wherein R2 is 2-oxazolyl.
  • Embodiment 13 is the composition of embodiment 11 wherein R2 is 1-pyrazolyl.
  • Embodiment 14 is the composition of embodiment 11 wherein R2 is 2H-1,2,3-triazol-2-yl.
  • Embodiment 15 is the composition of any one of embodiment s 1 to 14 wherein R3 is —C(O)R31, wherein R31 is hydroxyl, alkoxy, or an optionally independently substituted 1-heterocycl-1-yl.
  • Embodiment 16 is the composition of embodiment 15 wherein R31 is hydroxyl.
  • Embodiment 17 is the composition of embodiment 15 wherein R31 is ethoxy or benzoxy.
  • Embodiment 18 is the composition of embodiment 15 wherein R31 is 2,5-dihydro-1H-pyrrolyl, 1-piperidinyl, 1-pyrrolidinyl, 1-morpholinyl, or 1-azetidinyl, each of which may be optionally independently substituted with hydroxyl, methoxy, or methyl.
  • Embodiment 19 is the composition of any one of embodiments 1 to 14 wherein R3 is —C(O)N(R32R33), wherein R32 and R33 are independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C3-C6 cycloalkyl.
  • Embodiment 20 is the composition of embodiment 19 wherein R32 is hydrogen or methyl, and R33 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, 2-propenyl, or —CH2CN.
  • Embodiment 21 is the composition of embodiment 20 wherein R32 is hydrogen, and R33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl, 2-propenyl, or —CH2CN.
  • Embodiment 22 is the composition of embodiment 20 wherein R32 is methyl, and R33 is methyl, isopropyl, or 2-propenyl.
  • Embodiment 23 is the composition of any one of embodiments 1 to 14 wherein R3 is —R34SO2N(R32R33), wherein R34 is a bond or C1-C4 alkyl, and R32 and R33 are each hydrogen.
  • Embodiment 24 is the composition of any one of embodiments 1 to 14 wherein R3 is —CH2SO2NH2.
  • Embodiment 25 is the composition of any one of embodiments 1 to 24 wherein R4 and R4′ are both hydrogen.
  • Embodiment 26 is the composition of any one of embodiments 1 to 24 wherein R4 is —OR6 and R4′ is hydrogen, wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, cyano, —N(CH3)2, —C(O)NH2, or —SO2CH3.
  • Embodiment 27 is the composition of embodiment 26 wherein R6 is hydrogen.
  • Embodiment 28 is the composition of embodiment 26 wherein R6 is C1-C6 alkyl or C2-C6 alkenyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, cyano, —N(CH3)2, —C(O)NH2, or —SO2CH3.
  • Embodiment 29 is the composition of embodiment 28 wherein R6 is ethyl, isopropyl, isobutyl, —CH2CH2OH, —CH2CH2OCH3, —(CH2)3OCH3, —CH2CH(CH3)OH, —CH2C(CH3)2OH, —CH2CH═CH2, —C(O)CH3, —C(O)CH2OH, —CH2CN, —CH2CH2CN, —CH2CH(CH3)CN, —CH2C(CH3)2CN, —CH2CH2N(CH3)2, —CH2CH2C(O)NH2, or —CH2CH2SO2CH3.
  • Embodiment 30 is the composition of embodiment 26 wherein R6 is C3-C6 cycloalkyl or C4-C10 cycloalkylalkyl, which may be optionally independently substituted with hydroxyl or oxo.
  • Embodiment 31 is the composition of embodiment 30 wherein R6 is 4-hydroxycyclohexyl, 4-oxycyclohexyl, (4-oxocyclohexyl)methyl, or (4-hydroxycyclohexyl)methyl.
  • Embodiment 32 is the composition of embodiment 26 wherein R6 is tetrahydro-2H-pyran-4-yl.
  • Embodiment 33 is the composition of any one of embodiments 1 to 24 wherein R4 is —OH or —OCH2CH2CN, and R4′ is methyl, —CH2OH, or —CH2CH2OH.
  • Embodiment 34 is the composition of embodiment 33 wherein R4 is —OH and R4 is —CH2OH.
  • Embodiment 35 is the composition of embodiment 33 wherein R4 is —OH and R4 is —CH2CH2OH.
  • Embodiment 36 is the composition of embodiment 33 wherein R4 is —OCH2CH2CN and R4′ is methyl.
  • Embodiment 37 is the composition of any one of embodiments 1 to 36 wherein R5 and R5′ are independently hydrogen or methyl.
  • Embodiment 38 is the composition of embodiment 37 wherein R5 and R5′ are both methyl.
  • Embodiment 39 is the composition of embodiment 37 wherein R5 is methyl and R5 is hydrogen.
  • Embodiment 40 is the composition of embodiment 37 wherein R5 and R5′ are both hydrogen.
  • Embodiment 41 is the composition of any one of embodiments 1 to 40 wherein R7 is hydroxyl.
  • Embodiment 42 is the composition of any one of embodiments 1 to 40 wherein R7 is C1-C4 alkyl, which may be optionally independently substituted with cyano.
  • Embodiment 43 is the composition of embodiment 42 wherein R7 is methyl, ethyl, or —(CH2)3CN.
  • Embodiment 44 is the composition of any one of embodiments 1 to 40 wherein R7 is —OR10, wherein R10 is C1-C4 alkyl, heterocyclyl, or benzyl, each of which may be optionally independently substituted with hydroxyl, methoxy, oxo, oxetanyl, or cyano.
  • Embodiment 45 is the composition of embodiment 44 wherein R10 is methyl, —CH(CH3)2, —CH2CH2OH, —CH2CH2OCH3, —C(O)CH3, —CH2(oxetan-3-yl), —CH2CN, or —CH2CH2CN.
  • Embodiment 46 is the composition of embodiment 45 wherein R10 is methyl.
  • Embodiment 47 is the composition of embodiment 44 wherein R10 is tetrahydro-2H-pyran-4-yl or benzyl.
  • Embodiment 48 is the composition of any one of embodiments 1 to 47 wherein R8 is hydrogen or fluorine.
  • Embodiment 49 is a composition for agricultural use comprising an effective amount of a fungicidal compound of Formula Ia, or Ib:
  • Figure US20170166585A1-20170615-C00353
  • or a salt thereof, wherein:
  • R1 is methyl;
  • R2 is oxazolyl, pyrazolyl, triazolyl, cyclobutyl, —CH2OH, —CH2O(C1-C4)alkyl, or —C(O)R21 wherein R21 is C1-C4 alkoxy;
  • R3 is —C(O)R31, —C(O)N(R32R33), or —R34SO2N(R32R33), wherein R31 is hydroxyl, ethoxy, benzoxy, 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 2,5-dihydro-1H-pyrrol-1-yl, or 3-hydroxyazetidin-1-yl, R32 is hydrogen or methyl, and R33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, 2-propenyl, or cyclobutyl; or R34 is a bond, or C1-C4 alkyl;
  • R5 and R5′ are each independently hydrogen or methyl;
  • R6 is hydrogen, C1-C4 alkyl, which may be substituted with one or more of hydroxyl, methoxy, oxo, cyano, or —SO2CH3; R6 is cyclohexyl or cyclohexylmethyl, which may be substituted with one or more of hydroxyl or oxo; R6 is 2-propenyl; or R6 is tetrahydropyranyl;
  • R8 is hydrogen or F;
  • R9 is hydroxyl, methyl, ethyl, or —(CH2)3CN; and
  • R10 is methyl or ethyl, each of which may be substituted with one or more of hydroxyl, methyl, methoxy, cyano, phenyl, oxo, or oxetan-3-yl; or R10 is tetrahydropyranyl.
  • Embodiment 50 is the composition of embodiment 49 wherein R2 is 1-pyrazolyl, 2H-1,2,3-triazol-2-yl, 2-oxazolyl, or —C(O)OCH2CH3.
  • Embodiment 51 is the composition of embodiment 50 wherein R2 is 1-pyrazolyl.
  • Embodiment 52 is the composition of embodiment 50 wherein R2 is 2H-1,2,3-triazol-2-yl.
  • Embodiment 53 is the composition of embodiment 50 wherein R2 is 2-oxazolyl.
  • Embodiment 54 is the composition of embodiment 50 wherein R2 is —C(O)OCH2CH3.
  • Embodiment 55 is the composition of any one of embodiment 49 to 54 wherein R3 is —C(O)R31, wherein R31 is 1-pyrrolidinyl or 1-piperidinyl.
  • Embodiment 56 is the composition of embodiment 55 wherein R3 is —C(O)R31, wherein R31 is 1-pyrrolidinyl.
  • Embodiment 57 is the composition of any one of embodiment 49 to 54 wherein R3 is —C(O)N(R32R33), R32 is hydrogen or methyl, and R33 is ethyl, isopropyl, or cyclobutyl.
  • Embodiment 58 is the composition of embodiment 57 wherein R32 is hydrogen, and R33 is ethyl.
  • Embodiment 59 is the composition of embodiment 57 wherein R32 is hydrogen, and R33 is isopropyl.
  • Embodiment 60 is the composition of embodiment 57 wherein R32 is methyl, and R33 is isopropyl.
  • Embodiment 61 is the composition of embodiment 57 wherein R32 is hydrogen, and R33 is cyclobutyl.
  • Embodiment 62 is the composition of any one of embodiments 49 to 61 wherein R5 and R5′ are each methyl.
  • Embodiment 63 is the composition of any one of embodiments 49 to 61 wherein R5 is methyl and R5′ is hydrogen.
  • Embodiment 64 is the composition of any one of embodiments 49 to 63 wherein R6 is hydrogen, isopropyl, —CH2CH2OH, —CH2CH2OCH3, —(CH2)3OCH3, —C(O)CH3, —CH2CN, —CH2CH2CN, —CH2CH(CH3)CN, —CH2C(CH3)2CN, —CH2CH2SO2CH3, or tetrahydro-2H-pyran-4-yl.
  • Embodiment 65 is the composition of any one of embodiments 49 to 64 wherein R8 is hydrogen.
  • Embodiment 66 is the composition of any one of embodiments 49 to 64 wherein R8 is F.
  • Embodiment 67 is the composition of any one of embodiments 49 to 66 wherein R9 is ethyl.
  • Embodiment 68 is the composition of any one of embodiments 49 to 66 wherein R10 is methyl.
  • Embodiment 69 is a composition for agricultural use comprising an effective amount of a fungicidal compound selected from the group consisting of:
    • (R)-ethyl-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-2,4-di xo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-isopropoxyethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-isopropoxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6-(2H-1,2,3-triazol-2-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione;
    • (R)—N-ethyl-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-2-methylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(3-methoxypropoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)—N-cyclobutyl-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)propanamide;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(3-methoxypropoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
    • (R)-ethyl 1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl 1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
    • 3-((R)-1-(5-fluoro-2-methoxyphenyl)-2-(5-methyl-2,4-dioxo-3-((R)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6-(2H-1,2,3-triazol-2-yl)-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)ethoxy)propanenitrile;
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-ethyl-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-ethyl-2-methylpropanamide;
    • (R)-2-(1-(2-(cyanomethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyano-2-methylpropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-((R)-1-(isopropylamino)-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-((R)-1-(isopropyl(methyl)amino)-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(ethylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-3-(1-(ethylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (S)-2-(1-((R)-2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
    • (R)-2-(1-(2-(2-ethyl-5-fluorophenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-ethyl-1-(2-(cyanomethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-((R)-2-(2-cyano-2-methylpropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
    • (R)-ethyl-1-(2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-ethyl-1-(2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • 2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (S)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)propyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(2-ethyl-5-fluorophenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • 2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(2-ethyl-5-fluorophenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-(methylsulfonyl)ethoxy)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
    • (R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-(methylsulfonyl)ethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-ethylpropanamide;
    • (R)—N-ethyl-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-2-methylpropanamide;
    • (R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-cyclobutyl-2-methylpropanamide;
    • (R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-cyclobutylpropanamide;
    • (R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
    • (R)-2-(1-(2-hydroxy-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide; and
    • (R)-1-(5-fluoro-2-methoxyphenyl)-2-(3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)ethyl acetate.
  • Embodiment 70 is the composition of any one of embodiments 1 to 69 further comprising a surfactant.
  • Embodiment 71 is the composition of any one of embodiments 1 to 69 further comprising a co-solvent.
  • Embodiment 72 is the composition of any one of embodiments 1 to 69 further comprising a biological control agent, microbial extract, natural product, plant growth activator or plant defense agent or mixtures thereof.
  • Embodiment 73 is the composition of embodiment 72 wherein the biological control agent comprises a bacterium, a fungus, a beneficial nematode, or a virus.
  • Embodiment 74 is the composition of embodiment 73 wherein the biological control agent comprises a bacterium of the genus Actinomycetes, Agrobacterium, Arthrobacter, Alcaligenes, Aureobacterium, Azobacter, Bacillus, Beijerinckia, Bradyrhizobium, Brevibacillus, Burkholderia, Chromobacterium, Clostridium, Clavibacter, Comamonas, Corynebacterium, Curtobacterium, Enterobacter, Flavobacterium, Gluconobacter, Hydrogenophage, Klebsiella, Metarhizium, Methylobacterium, Paenibacillus, Pasteuria, Photorhabdus, Phyllobacterium, Pseudomonas, Rhizobium, Serratia, Sphingobacterium, Stenotrophomonas, Streptomyces, Variovax, or Xenorhabdus.
  • Embodiment 75 is the composition of embodiment 73 wherein the biological control agent comprises a fungus of the genus Alternaria, Ampelomyces, Aspergillus, Aureobasidium, Beauveria, Colletotrichum, Coniothyrium, Gliocladium, Metarhizium, Muscodor, Paecilomyces, Penicillium, Trichoderma, Typhula, Ulocladium, and Verticillium.
  • Embodiment 76 is the composition of embodiment 73 wherein the biological control agent is a plant growth activator or plant defense agent selected from the group consisting of harpin, Reynoutria sachalinensis, jasmonate, lipochitooligosaccharides, salicylic acid, and isoflavones.
  • Embodiment 77 is the composition of any one of embodiments 1 to 76 further comprising one or more additional pesticides, wherein the additional pesticide comprises a fungicide, an insecticide and a herbicide or a mixture thereof.
  • Embodiment 78 is the composition of embodiment 77 wherein the additional pesticide is a fungicide selected from the group consisting of acibenzolar-S-methyl, azoxystrobin, benalaxyl, benzovindiflupyr, bixafen, boscalid, carbendazim, cyproconazole, dimethomorph, epoxiconazole, fluindapyr, fluopyram, fluoxastrobin, flutianil, flutolanil, fluxapyroxad, fosetyl-A1, ipconazole, isopyrazam, kresoxim-methyl, mefenoxam, metalaxyl, metconazole, myclobutanil, orysastrobin, oxathiapiprolin, penflufen, penthiopyrad, picoxystrobin, propiconazole, prothioconazole, pyraclostrobin, pydiflumetofen, sedaxane, silthiofam, tebuconazole, thifluzamide, thiophanate, tolclofos-methyl, trifloxystrobin, and triticonazole.
  • Embodiment 79 is the composition of embodiment 77 wherein the additional pesticide is an insecticide or nematicide selected from the group consisting of abamectin, aldicarb, aldoxycarb, bifenthrin, broflanilide, carbofuran, chlorantraniliprole, clothianidin, cyantraniliprole, cyclaniliprole, cyfluthrin, cyhalothrin, cypermethrin, deltamethrin, dinotefuran, emamectin, ethiprole, fenamiphos, fipronil, flubendiamide, fosthiazate, imidacloprid, ivermectin, lambda-cyhalothrin, milbemectin, 3-phenyl-5-(2-thienyl)-1,2,4-oxadiazole, nitenpyram, oxamyl, permethrin, spinetoram, spinosad, spirodichlofen, spirotetramat, tefluthrin, tetraniliprole, thiacloprid, thiamethoxam, thiodicarb, tioxazafen, and mixtures thereof.
  • Embodiment 80 is the composition of embodiment 77 wherein the additional pesticide is an herbicide selected from the group consisting of acetochlor, clethodim, dicamba, 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)-1,3,5-triazinane-2,4-dione (trifludimoxazin), ethyl 2-((3-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-(trifluoromethyl)-2,3-dihydropyrimidin-1(6H)-yl)phenoxy)pyridin-2-yl)oxy)acetate, flumioxazin, fomesafen, glyphosate, glufosinate, halauxifen, isoxaflutole, mesotrione, metolachlor, quizalofop, saflufenacil, sulcotrione, tembotrione, topramezone, and 2,4-D and mixtures thereof.
  • Embodiment 81 is the composition of embodiment 77 or 80 wherein the additional pesticide is an ACCase inhibitor.
  • Embodiment 82 is the composition of embodiment 81 wherein the additional pesticide is an ACCase inhibitor selected from the group consisting of chlorazifop, clodinafop, clofop, cyhalofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, kuicaoxi, metamifop, propaquizafop, quizalofop, quizalofop-P, trifop, alloxydim, butroxydim, clethodim, cloproxydim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, tralkoxydim, and pinoxaden.
  • Embodiment 83 is the composition of embodiment 77 wherein the additional pesticide is selected from the group consisting of fluoxastrobin, fluxapyroxad, ipconazole, mefenoxam, metalaxyl, penflufen, prothioconazole, pyraclostrobin, trifloxystrobin, abamectin, Bacillus firmus, clothianidin, imidacloprid, thiamethoxam and mixtures thereof.
  • Embodiment 84 is the composition of embodiment 77 wherein the treatment composition comprises tioxazafen.
  • Embodiment 85 is a treated seed comprising a composition as set forth in any one of embodiments 1 to 84.
  • Embodiment 86 is the seed of embodiment 85, wherein the treated seed comprises: a seed and a coating comprising a composition as set forth in any one of embodiments 1 to 84.
  • Embodiment 87 is the seed of embodiment 86, wherein the coating comprises the fungicidal compound of Formula I, Formula Ia, or a salt thereof in an amount of at least about 0.005 mg/seed, from about 0.005 to about 1 mg/seed, or from about 0.05 to about 0.5 mg/seed.
  • Embodiment 88 is a method of controlling agricultural fungal pathogens, the method comprising administering to a plant, a seed or soil a composition as set forth in any one of embodiments 1 to 84.
  • Embodiment 89 is the method of embodiment 88 wherein the method comprises administering the composition to a seed.
  • Embodiment 90 is a treated seed prepared according to the method of embodiment 89.
  • Embodiment 91 is the method of embodiment 88 wherein the method comprises exogenously administering the composition to a plant.
  • Embodiment 92 is the method of embodiment 91 wherein the composition is applied to the foliage of a plant.
  • Embodiment 93 is the method of embodiment 91 wherein the method comprises applying the composition to the soil surrounding the root zone of a plant.
  • Embodiment 94 is the method of embodiment 91 wherein the composition is applied directly to the base of the plant or to the soil immediately adjacent to the plant.
  • Embodiment 95 is the method of embodiment 93 or 94 wherein the composition is applied such that it drains through the soil to the root area of the plant.
  • Embodiment 96 is the method of any one of embodiments 91 to 95 wherein the composition is applied using a sprayer, a mechanical sprinkler, a drench application, drip irrigation technique, or tilled into the soil or applied in furrow.
  • When introducing elements of the present disclosure, the articles “a”, “an”, “the” and “said” are intended to mean that there are one or more of the elements. The terms “comprising”, “including” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements.
  • In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous results attained.
  • As various changes could be made in the above products and methods without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.

Claims (23)

1. A composition for agricultural use comprising an effective amount of a fungicidal compound of Formula I:
Figure US20170166585A1-20170615-C00354
or a salt thereof, wherein:
R1 is hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy;
R2 is heteroaryl, alkyl, cycloalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, oxo, or cyano; or R2 is —C(O)R21, wherein R21 is hydroxyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or heterocyclyl, each of which may be optionally independently substituted with one or more of hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano;
R3 is —C(O)R31, —C(O)N(R32R33), or —R34SO2N(R32R33), wherein R31 is hydroxyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkoxy, arylalkoxy, heteroarylalkoxy, or 1-heterocycl-1-yl, each of which may be optionally independently substituted with one or more of hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano; R32 and R33 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C3-C6 cycloalkyl, each of which may be optionally independently substituted with one or more of hydroxyl, halogen, C1-C4 alkoxy, oxo, or cyano; and R34 is a bond, C1-C4 alkyl, C1-C4 haloalkyl, or C2-C4 alkenyl;
R4 is hydrogen or —OR6, wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, or heterocyclyl, each of which may be optionally independently substituted with one or more of an oxygen atom, hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, oxo, cyano, —N(R61R62), —C(O)N(R61R62), or SO2R63, wherein R61 and R62 are each independently hydrogen or C1-C6 alkyl, and R63 is C1-C6 alkyl;
R4′ is hydrogen or C1-C4 alkyl, which may be optionally substituted with one or more of hydroxyl, C1-C4 alkoxy, or cyano;
R5 and R5′ are each independently hydrogen or C1-C4 alkyl;
R7 is hydroxyl or C1-C4 alkyl, which may be optionally substituted with one or more of hydroxyl, C1-C4 alkoxy, oxo, or cyano; or R7 is —OR10, wherein R10 is C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkylmethyl, heterocyclyl, or aryl(C1-C4)alkyl, each of which may be optionally independently substituted with one or more of hydroxyl, an oxygen atom, C1-C4 alkyl, C1-C4 alkoxy, oxo, or cyano; and
R8 is hydrogen, halogen, or cyano.
2. A composition for agricultural use comprising an effective amount of a fungicidal compound of Formula Ia, or Ib:
Figure US20170166585A1-20170615-C00355
or a salt thereof, wherein:
R1 is methyl;
R2 is oxazolyl, pyrazolyl, triazolyl, cyclobutyl, —CH2OH, —CH2O(C1-C4)alkyl, or —C(O)R21, wherein R21 is C1-C4 alkoxy;
R3 is —C(O)R31, —C(O)N(R32R33), or —R34SO2N(R32R33), wherein R31 is hydroxyl, ethoxy, benzoxy, 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 2,5-dihydro-1H-pyrrol-1-yl, or 3-hydroxyazetidin-1-yl, R32 is hydrogen or methyl, and R33 is hydrogen, methyl, ethyl, isopropyl, isobutyl, 2-propenyl, or cyclobutyl; or R34 is a bond, or C1-C4 alkyl;
R5 and R5′ are each independently hydrogen or methyl;
R6 is hydrogen, C1-C4 alkyl, which may be substituted with one or more of hydroxyl, methoxy, oxo, cyano, or —SO2CH3; R6 is cyclohexyl or cyclohexylmethyl, which may be substituted with one or more of hydroxyl or oxo; R6 is 2-propenyl; or R6 is tetrahydropyranyl;
R8 is hydrogen or F;
R9 is hydroxyl, methyl, ethyl, or —(CH2)3CN; and
R10 is methyl or ethyl, each of which may be substituted with one or more of hydroxyl, methyl, methoxy, cyano, phenyl, oxo, or oxetan-3-yl; or R10 is tetrahydropyranyl.
3. The composition of claim 2 wherein R2 is 1-pyrazolyl, 2H-1,2,3-triazol-2-yl, 2-oxazolyl, or —C(O)OCH2CH3.
4. The composition of claim 2, wherein R3 is —C(O)R31, wherein R31 is 1-pyrrolidinyl or 1-piperidinyl.
5. The composition of claim 2, wherein R3 is —C(O)N(R32R33), R32 is hydrogen or methyl, and R33 is ethyl, isopropyl, or cyclobutyl.
6. The composition of claim 2, wherein R6 is hydrogen, isopropyl, —CH2CH2OH, —CH2CH2OCH3, —(CH2)30CH3, —C(O)CH3, —CH2CN, —CH2CH2CN, —CH2CH(CH3)CN, —CH2C(CH3)2CN, —CH2CH2SO2CH3, or tetrahydro-2H-pyran-4-yl.
7. The composition of claim 2, wherein R9 is ethyl.
8. The composition of claim 2, wherein R10 is methyl.
9. A composition for agricultural use comprising an effective amount of a fungicidal compound selected from the group consisting of:
(R)-ethyl-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-isopropoxyethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-isopropoxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-3-(2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6-(2H-1,2,3-triazol-2-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione;
(R)—N-ethyl-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-2-methylpropanamide;
(R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
(R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(3-methoxypropoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
(R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
(R)—N-cyclobutyl-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)propanamide;
(R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(3-methoxypropoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
(R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
(R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
(R)-ethyl 1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-ethyl 1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-hydroxyethoxy)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
(S)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
(R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
3-((R)-1-(5-fluoro-2-methoxyphenyl)-2-(5-methyl-2,4-dioxo-3-((R)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6-(2H-1,2,3-triazol-2-yl)-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)ethoxy)propanenitrile;
(R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
(R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-ethyl-2-methylpropanamide;
(R)-2-(1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-ethyl-2-methylpropanamide;
(R)-2-(1-(2-(cyanomethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-2-(1-(2-(2-cyano-2-methylpropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-((R)-1-(isopropylamino)-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-((R)-1-(isopropyl(methyl)amino)-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-ethyl-1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(ethylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-ethyl-1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-ethyl-1-(2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-3-(1-(ethylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(S)-2-(1-((R)-2-(2-cyanoethoxy)-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-N-methylpropanamide;
(R)-2-(1-(2-(2-ethyl-5-fluorophenyl)-2-(2-hydroxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-ethyl-1-(2-(cyanomethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-2-(1-((R)-2-(2-cyano-2-methylpropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
(R)-ethyl-1-(2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-ethyl-1-(2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(S)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)propyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
2-(1-((R)-2-((S)-2-cyanopropoxy)-2-(2-ethyl-5-fluorophenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
2-(1-((R)-2-((R)-2-cyanopropoxy)-2-(2-ethyl-5-fluorophenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-ethyl-1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-(methylsulfonyl)ethoxy)ethyl)-3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate;
(R)-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-(2-(methylsulfonyl)ethoxy)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide;
(R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-ethylpropanamide;
(R)—N-ethyl-2-(1-(2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-2-methylpropanamide;
(R)-2-(1-(2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-N-cyclobutyl-2-methylpropanamide;
(R)-2-(1-((R)-2-(2-cyanoethoxy)-2-(5-fluoro-2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-cyclobutylpropanamide;
(R)-2-(1-((R)-2-(5-fluoro-2-methoxyphenyl)-2-(2-methoxyethoxy)ethyl)-5-methyl-2,4-dioxo-6-(1H-pyrazol-1-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropylpropanamide;
(R)-2-(1-(2-hydroxy-2-(2-methoxyphenyl)ethyl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-1,4-dihydrothieno[2,3-d]pyrimidin-3 (2H)-yl)-N-isopropyl-2-methylpropanamide; and
(R)-1-(5-fluoro-2-methoxyphenyl)-2-(3-(1-(isopropylamino)-2-methyl-1-oxopropan-2-yl)-5-methyl-2,4-dioxo-6-(2H-1,2,3-triazol-2-yl)-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)ethyl acetate.
10. The composition of claim 1, further comprising a surfactant.
11. The composition of claim 1, further comprising a co-solvent.
12. The composition of claim 1, further comprising a biological control agent, microbial extract, natural product, plant growth activator or plant defense agent or mixtures thereof.
13. The composition of claim 1, further comprising one or more additional pesticides, wherein the additional pesticide comprises a fungicide, an insecticide and a herbicide or a mixture thereof.
14. The composition of claim 13 wherein the additional pesticide is selected from the group consisting of fluoxastrobin, fluxapyroxad, ipconazole, mefenoxam, metalaxyl, penflufen, prothioconazole, pyraclostrobin, trifloxystrobin, abamectin, Bacillus firmus, clothianidin, imidacloprid, thiamethoxam and mixtures thereof.
15. The composition of claim 13 wherein the treatment composition comprises tioxazafen.
16. A treated seed comprising a composition as set forth in claim 1.
17. A method of controlling agricultural fungal pathogens, the method comprising administering to a plant, a seed or soil a composition as set forth in claim 1.
18. The method of claim 17 wherein the method comprises administering the composition to a seed.
19. A treated seed prepared according to the method of claim 18.
20. The method of claim 17 wherein the method comprises exogenously administering the composition to a plant.
21. The method of claim 20 wherein the composition is applied to the foliage of a plant.
22. The method of claim 20 wherein the method comprises applying the composition to the soil surrounding the root zone of a plant.
23. The method of claim 20 wherein the composition is applied directly to the base of the plant or to the soil immediately adjacent to the plant.
US15/359,531 2015-11-25 2016-11-22 Pesticidal compositions and uses thereof Abandoned US20170166585A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/359,531 US20170166585A1 (en) 2015-11-25 2016-11-22 Pesticidal compositions and uses thereof
US16/030,722 US10941157B2 (en) 2015-11-25 2018-07-09 Pesticidal compositions and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259935P 2015-11-25 2015-11-25
US15/359,531 US20170166585A1 (en) 2015-11-25 2016-11-22 Pesticidal compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/030,722 Continuation US10941157B2 (en) 2015-11-25 2018-07-09 Pesticidal compositions and uses thereof

Publications (1)

Publication Number Publication Date
US20170166585A1 true US20170166585A1 (en) 2017-06-15

Family

ID=57518013

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/359,531 Abandoned US20170166585A1 (en) 2015-11-25 2016-11-22 Pesticidal compositions and uses thereof
US16/030,722 Active US10941157B2 (en) 2015-11-25 2018-07-09 Pesticidal compositions and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/030,722 Active US10941157B2 (en) 2015-11-25 2018-07-09 Pesticidal compositions and uses thereof

Country Status (18)

Country Link
US (2) US20170166585A1 (en)
EP (1) EP3379933B1 (en)
JP (1) JP2019503338A (en)
KR (1) KR20180086191A (en)
CN (1) CN108347939B (en)
AR (1) AR106822A1 (en)
AU (1) AU2016359626A1 (en)
BR (1) BR112018009212B1 (en)
CA (1) CA3004747A1 (en)
CL (1) CL2018001231A1 (en)
CO (1) CO2018004891A2 (en)
EA (1) EA201890910A1 (en)
ES (1) ES2943235T3 (en)
MX (1) MX2018006285A (en)
PL (1) PL3379933T3 (en)
PT (1) PT3379933T (en)
SI (1) SI3379933T1 (en)
WO (1) WO2017091627A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944655B2 (en) 2011-11-11 2018-04-17 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2018161008A1 (en) 2017-03-03 2018-09-07 Gilead Apollo, Llc Processes for the preparation of fungicidal compounds
US10179793B2 (en) 2015-10-26 2019-01-15 Gilead Apollo, Llc ACC inhibitors and uses thereof
US10183951B2 (en) 2016-03-02 2019-01-22 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
WO2020092239A1 (en) 2018-10-29 2020-05-07 Gilead Apollo, Llc Processes for the preparation of fungicidal compounds
EP3669652A1 (en) * 2018-12-21 2020-06-24 Bayer AG Active compound combination
US10759812B2 (en) 2017-01-22 2020-09-01 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
US10800791B2 (en) 2015-11-25 2020-10-13 Gilead Apollo, Llc Triazole ACC inhibitors and uses thereof
US10941158B2 (en) 2015-11-25 2021-03-09 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
US10941157B2 (en) 2015-11-25 2021-03-09 Gilead Apollo, Llc Pesticidal compositions and uses thereof
US11098055B2 (en) 2015-11-25 2021-08-24 Gilead Apollo, Llc Ester ACC inhibitors and uses thereof
US11833150B2 (en) 2017-03-28 2023-12-05 Gilead Sciences, Inc. Methods of treating liver disease
US12428432B2 (en) 2019-07-02 2025-09-30 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivatives having stereo configurations and use thereof in medicine

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029653A (en) 2014-01-31 2016-10-12 达纳-法伯癌症研究所股份有限公司 Diaminopyrimidine phenyl sulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2018526421A (en) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Cyanothienotriazolodiazepines and their use
WO2017044792A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazoldiazepines and uses thereof
MX2018006499A (en) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibtors and uses thereof.
JP2021028298A (en) * 2017-11-30 2021-02-25 日本曹達株式会社 1,3,5,6-tetrasubstituted thieno[2,3-d]pyrimidine-2,4(1h,3h)dione compound, and agricultural and horticultural fungicide
CN110028521B (en) * 2019-05-27 2020-07-14 湖南科技大学 11-aryl-1, 4-benzoxazinoimidazoline compounds and preparation method and application thereof
WO2020255946A1 (en) * 2019-06-17 2020-12-24 日本曹達株式会社 2,4-dioxo-1,4-dihydrothienopyrimidine compound, agricultural and horticultural bactericide
AR119594A1 (en) 2019-08-09 2021-12-29 Gilead Sciences Inc THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF
WO2021054393A1 (en) * 2019-09-19 2021-03-25 日本曹達株式会社 2,3-dihydrothienopyrimidin-4(h)-one compound and agricultural and horticultural fungicide
CN110746439B (en) * 2019-10-18 2020-10-30 南京瑞捷医药科技有限公司 A kind of preparation method of thienopyrimidinedione compound
CN111018826B (en) * 2019-12-25 2020-11-10 西华大学 2-Cyano-5-oxopentanoic acid ethyl ester compound and its application
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
JPWO2023106175A1 (en) * 2021-12-08 2023-06-15

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4465017A (en) 1983-03-09 1984-08-14 Simmons John J Seed coating machine
US4670560A (en) 1986-04-28 1987-06-02 Ortho Pharmaceutical Corporation Thienopyrimidine-2,4-dione derivatives and intermediates thereof
DE3616010A1 (en) 1986-05-13 1987-11-19 Bayer Ag METHOD FOR SEEDING AND / OR INCRUSTING SEEDS
FR2618041B1 (en) 1987-07-16 1991-06-21 Ceres Ets DEVICE FOR TREATING SEEDS
JPH0646887B2 (en) 1988-11-08 1994-06-22 矢崎総業株式会社 Seed gel coating equipment
JPH02225485A (en) 1989-02-27 1990-09-07 Taiho Yakuhin Kogyo Kk Thienopyrimidine-3-acetic acid derivative
FI93687C (en) 1992-07-29 1995-05-26 Novasso Oy Method for coating seeds
JP3811196B2 (en) 1993-08-26 2006-08-16 武田薬品工業株式会社 Endothelin antagonist, thienopyrimidine derivative and process for producing the same
TW276256B (en) 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
JPH09110873A (en) 1995-08-17 1997-04-28 Takeda Chem Ind Ltd Thienopyrimidine derivative, its production and use
AU6670196A (en) 1995-08-17 1997-03-12 Takeda Chemical Industries Ltd. Thienopyrimidine derivatives, their production and use
WO1997040846A1 (en) 1996-04-30 1997-11-06 Takeda Chemical Industries, Ltd. COMBINED USE OF GnRH AGONIST AND ANTAGONIST
JP2007302703A (en) 1996-04-30 2007-11-22 Takeda Chem Ind Ltd Medicinal composition
JP3185133B2 (en) 1997-02-13 2001-07-09 タキイ種苗株式会社 Granulated coated seed and method for producing the same
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
SE9702001D0 (en) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US5891246A (en) 1997-08-15 1999-04-06 Gustafson, Inc. Seed coating apparatus
DE19754082A1 (en) 1997-12-05 1999-06-10 Knoll Ag Method of combating obesity
MXPA01010143A (en) 1999-04-09 2003-07-14 Cell Therapeutics Inc Xanthine derivatives and analogs as cell signaling inhibitors.
EP1370562A1 (en) 2001-02-14 2003-12-17 Warner-Lambert Company LLC Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
ES2246481T3 (en) 2002-02-27 2006-02-16 Pfizer Products Inc. ACC INHIBITORS
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
ES2324472T3 (en) 2003-01-06 2009-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem HERBICIDES THAT INHIBIT THE ACTION OF ACETIL-COA CARBOXYLASE IN VEGETABLES FOR USE AS PESTICIDES.
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
WO2006014647A2 (en) 2004-07-21 2006-02-09 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
WO2006135080A1 (en) * 2005-06-14 2006-12-21 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivative
CA2644996A1 (en) 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
EP2253630A1 (en) 2007-05-21 2010-11-24 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EA028392B1 (en) 2007-08-13 2017-11-30 Монсанто Текнолоджи Ллс Compositions and methods for controlling nematodes
EP2351743A4 (en) 2008-10-27 2012-05-09 Takeda Pharmaceutical Bicyclic compound
EP2396321B1 (en) 2009-02-10 2015-05-06 Monsanto Technology LLC Compositions and methods for controlling nematodes
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
HRP20140035T1 (en) 2009-12-29 2014-02-14 Poxel TIENO [2,3-B] PYRIDINDION AMPK ACTIVATORS AND THEIR THERAPY USES
US20130123285A1 (en) 2010-05-14 2013-05-16 University Of Rochester Compositions and Methods for Targeting A3G:RNA Complexes
UA114468C2 (en) 2010-09-02 2017-06-26 Монсанто Текнолоджи Ллс COMPOSITIONS AND METHODS OF CONTROL OF NEMATODES AS PEST OF AGRICULTURE
US9161158B2 (en) * 2011-06-27 2015-10-13 At&T Intellectual Property I, L.P. Information acquisition using a scalable wireless geocast protocol
BR112014011351B1 (en) 2011-11-11 2021-02-17 Gilead Apollo, Llc. acc inhibitors and their uses
MX2015015417A (en) 2013-05-10 2016-06-21 Nimbus Apollo Inc Acc inhibitors and uses thereof.
HK1221411A1 (en) 2013-05-10 2017-06-02 Gilead Apollo, Inc. Acc inhibitors and uses thereof
JP6417403B2 (en) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー ACC inhibitors and uses thereof
BR112015028173A2 (en) 2013-05-10 2017-07-25 Nimbus Apollo Inc acc inhibitors and uses thereof
TWI652012B (en) * 2013-05-20 2019-03-01 杜邦股份有限公司 Solid form of fungicidal pyrazole
WO2015003879A1 (en) 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicylic derivatives
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
JP2015044791A (en) * 2013-07-29 2015-03-12 クミアイ化学工業株式会社 Agricultural and horticultural pest control agents and pest control methods
AR106472A1 (en) 2015-10-26 2018-01-17 Gilead Apollo Llc ACC INHIBITORS AND USES OF THE SAME
MX2018006499A (en) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibtors and uses thereof.
MX2018006287A (en) 2015-11-25 2018-09-07 Gilead Apollo Llc Triazole acc inhibitors and uses thereof.
PL3379933T3 (en) 2015-11-25 2023-07-24 Gilead Apollo, Llc Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
SG11201804132UA (en) 2015-11-25 2018-06-28 Effector Therapeutics Inc Eif4-a-inhibiting compounds and methods related thereto
US20170166582A1 (en) 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
CN108290902B (en) 2015-11-25 2021-08-31 吉利德阿波罗公司 Ester ACC inhibitors and uses thereof
AU2017226267B2 (en) 2016-03-02 2021-06-24 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
AU2017378324B2 (en) 2016-12-16 2021-09-02 Cystic Fibrosis Foundation Bycyclic heteroaryl derivatives as CFTR potentiators

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10472374B2 (en) 2011-11-11 2019-11-12 Gilead Apollo, Llc ACC inhibitors and uses thereof
US9944655B2 (en) 2011-11-11 2018-04-17 Gilead Apollo, Llc ACC inhibitors and uses thereof
US10179793B2 (en) 2015-10-26 2019-01-15 Gilead Apollo, Llc ACC inhibitors and uses thereof
US11098055B2 (en) 2015-11-25 2021-08-24 Gilead Apollo, Llc Ester ACC inhibitors and uses thereof
US10800791B2 (en) 2015-11-25 2020-10-13 Gilead Apollo, Llc Triazole ACC inhibitors and uses thereof
US10941157B2 (en) 2015-11-25 2021-03-09 Gilead Apollo, Llc Pesticidal compositions and uses thereof
US10941158B2 (en) 2015-11-25 2021-03-09 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
US11104687B2 (en) 2016-03-02 2021-08-31 Gilead Apollo, Llc Solid forms for a thienopyrimidinedione ACC inhibitor and methods for production thereof
US10487090B2 (en) 2016-03-02 2019-11-26 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
US10183951B2 (en) 2016-03-02 2019-01-22 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
US11912718B2 (en) 2016-03-02 2024-02-27 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
US10759812B2 (en) 2017-01-22 2020-09-01 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
WO2018161008A1 (en) 2017-03-03 2018-09-07 Gilead Apollo, Llc Processes for the preparation of fungicidal compounds
US11833150B2 (en) 2017-03-28 2023-12-05 Gilead Sciences, Inc. Methods of treating liver disease
WO2020092239A1 (en) 2018-10-29 2020-05-07 Gilead Apollo, Llc Processes for the preparation of fungicidal compounds
EP3669652A1 (en) * 2018-12-21 2020-06-24 Bayer AG Active compound combination
US12428432B2 (en) 2019-07-02 2025-09-30 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivatives having stereo configurations and use thereof in medicine

Also Published As

Publication number Publication date
WO2017091627A1 (en) 2017-06-01
PL3379933T3 (en) 2023-07-24
BR112018009212A8 (en) 2019-02-26
ES2943235T3 (en) 2023-06-12
CL2018001231A1 (en) 2018-11-16
CN108347939B (en) 2021-09-28
CO2018004891A2 (en) 2018-10-22
US20190040078A1 (en) 2019-02-07
PT3379933T (en) 2023-05-08
SI3379933T1 (en) 2023-07-31
US10941157B2 (en) 2021-03-09
KR20180086191A (en) 2018-07-30
AR106822A1 (en) 2018-02-21
CN108347939A (en) 2018-07-31
MX2018006285A (en) 2018-09-07
EA201890910A1 (en) 2018-11-30
JP2019503338A (en) 2019-02-07
AU2016359626A1 (en) 2018-05-17
CA3004747A1 (en) 2017-06-01
EP3379933A1 (en) 2018-10-03
BR112018009212A2 (en) 2018-11-06
EP3379933B1 (en) 2023-02-15
BR112018009212B1 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
US10941157B2 (en) Pesticidal compositions and uses thereof
US10945434B2 (en) Azole derivative, intermediate compound, method for producing azole derivative, agricultural or horticultural chemical agent, and protective agent for industrial material
US12207654B2 (en) Bactericidal agent for agricultural or horticultural use, plant disease control method, and product for plant disease control use
US10995070B2 (en) Acetyl-CoA carboxylase modulators
ES2789582T3 (en) Fungicidal compositions
US9439427B2 (en) Pesticidal pyrazole compounds
US11375716B2 (en) Acetyl-CoA carboxylase modulators
CN110191639B (en) Substituted sulfonamides for combating animal pests
CN102318622A (en) Fungicidal mixture based on azoles and pyrimidine radicals amine
US8461077B2 (en) Combinations of active substances
EP3617196B1 (en) N-(4-pyridyl) nicotinamide compound or salt thereof
CN109982999A (en) The imidazolyl methyl-derivatives that new 5- replaces
US20240099300A1 (en) Sulfonamide apyrase inhibitors

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: MONSANTO COMPANY, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BENNETT, JENNIFER L.;REEL/FRAME:050803/0224

Effective date: 20160510

Owner name: MONSANTO COMPANY, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAAKENSON, WILLIAM P., JR.;REEL/FRAME:050803/0746

Effective date: 20160510

Owner name: NIMBUS APOLLO, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GHOSH, SHOMIR;REEL/FRAME:050803/0502

Effective date: 20160510

Owner name: MONSANTO COMPANY, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FITZSIMMONS, KAREN C.;REEL/FRAME:050803/0405

Effective date: 20160510

Owner name: NIMBUS APOLLO, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MORADEI, SILVANA MARCEL LEIT DE;REEL/FRAME:050804/0090

Effective date: 20160509

Owner name: NIMBUS APOLLO, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NIMBUS DISCOVERY, INC.;REEL/FRAME:050804/0418

Effective date: 20160509

Owner name: NIMBUS APOLLO, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MONSANTO COMPANY;REEL/FRAME:050803/0987

Effective date: 20160510

Owner name: MONSANTO COMPANY, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SLOMCZYNSKA, URSZULA J.;REEL/FRAME:050804/0718

Effective date: 20160510

Owner name: SCHROEDINGER, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREENWOOD, JEREMY ROBERT;REEL/FRAME:050804/0934

Effective date: 20160510

Owner name: MONSANTO COMPANY, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHORTT, BARRY J.;REEL/FRAME:050804/0606

Effective date: 20160510

Owner name: MONSANTO COMPANY, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STEIN, JEFFREY M.;REEL/FRAME:050804/0809

Effective date: 20160511

Owner name: NIMBUS DISCOVERY, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHROEDINGER, L.L.C.;REEL/FRAME:050805/0255

Effective date: 20160511

Owner name: SCHROEDINGER, L.L.C., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHROEDINGER, INC.;REEL/FRAME:050805/0084

Effective date: 20160511

Owner name: NIMBUS DISCOVERY, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HARRIMAN, GERALDINE C.;REEL/FRAME:050809/0396

Effective date: 20160510

Owner name: GILEAD APOLLO, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:NIMBUS APOLLO, INC.;REEL/FRAME:050809/0495

Effective date: 20160516

Owner name: GILEAD APOLLO, LLC, CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:GILEAD APOLLO, INC.;REEL/FRAME:051798/0284

Effective date: 20160805